AI assistant
UBS Group AG — Interim / Quarterly Report 2021
Jul 23, 2021
998_rns_2021-07-23_08b1e1bf-9873-477c-adda-8bfb39dfcb68.pdf
Interim / Quarterly Report
Open in viewerOpens in your device viewer
==> picture [83 x 31] intentionally omitted <==
==> picture [391 x 394] intentionally omitted <==
UBS AG
Second quarter 2021 report
Corporate calendar UBS AG
Publication of the third quarter 2021 report:
Friday, 29 October 2021
Publication dates of quarterly and annual reports and results are made available as part of the corporate calendar of UBS AG at ubs.com/investors
Contacts
Switchboards
For all general inquiries ubs.com/contact
Zurich +41-44-234 1111 London +44-207-567 8000 New York +1-212-821 3000 Hong Kong +852-2971 8888 Singapore +65-6495 8000
- 3 Introduction
1. Risk and capital management
- 8 Risk management and control 9 Capital management
Consolidated 2. financial statements
- 17 UBS AG interim consolidated financial statements (unaudited)
UBS AG standalone 3. financial information
Investor Relations
Institutional, professional and retail investors are supported by UBS’s Investor Relations team.
UBS AG, Investor Relations P.O. Box, CH-8098 Zurich, Switzerland
ubs.com/investors
Zurich +41-44-234 4100 New York +1-212-882 5734
- 71 UBS AG interim standalone financial information (unaudited)
Appendix
-
74 Alternative performance measures 77 Abbreviations frequently used in our financial reports
-
79 Information sources
Media Relations
- 80 Cautionary statement
Global media and journalists are supported by UBS’s Media Relations team.
ubs.com/media
Zurich +41-44-234 8500 [email protected]
London +44-20-7567 4714 [email protected]
New York +1-212-882 5858 [email protected]
Hong Kong +852-2971 8200 [email protected]
Imprint
Publisher: UBS AG, Zurich, Switzerland | ubs.com/media Language: English
© UBS 2021. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.
UBS AG consolidated key figures
UBS AG consolidated key figures
| As of or for thequarter ended | As of oryear-to-date 30.6.21 30.6.20 17,906 15,521 13,274 12,197 4,632 3,324 3,623 2,615 12.7 9.3 14.3 10.5 18.6 14.4 12.4 11.6 3.4 3.4 74.6 75.9 38.5 10.1 1,085,861 1,063,446 55,361 55,384 40,190 37,403 290,470 284,798 13.8 13.1 19.1 17.9 34.6 31.9 1,039,375 974,135 3.87 3.84 5.3 5.2 9.7 9.3 4,485 3,588 47,227 47,120 |
|
|---|---|---|
| USD million, except where indicated | 30.6.21 31.3.21 31.12.20 30.6.20 |
|
| Results | ||
| Operatingincome | 9,071 8,836 8,220 7,512 |
|
| Operatingexpenses | 6,589 6,684 6,324 5,987 |
|
| Operating profit /(loss)before tax | 2,481 2,151 1,896 1,525 |
|
| Netprofit /(loss)attributable to shareholders | 1,913 1,710 1,563 1,194 |
|
| Profitability andgrowth | ||
| Return on equity (%) | 13.6 11.9 10.9 8.4 |
|
| Return on tangible equity (%) | 15.3 13.4 12.2 9.5 |
|
| Return on common equitytier 1 capital(%) | 19.4 17.8 16.3 13.0 |
|
| Return on risk-weighted assets, gross(%) | 12.5 12.3 11.7 10.9 |
|
| Return on leverage ratio denominator, gross(%)1 | 3.5 3.4 3.3 3.2 |
|
| Cost / income ratio(%) | 73.3 75.9 76.3 76.9 |
|
| Netprofitgrowth(%) | 60.3 20.3 151.3 (8.7) |
|
| Resources | ||
| Total assets | 1,085,861 1,109,234 1,125,327 1,063,446 |
|
| Equityattributable to shareholders | 55,361 57,446 57,754 55,384 |
|
| Common equitytier 1 capital2 | 40,190 38,826 38,181 37,403 |
|
| Risk-weighted assets2 | 290,470 285,119 286,743 284,798 |
|
| Common equitytier 1 capital ratio(%)2 | 13.8 13.6 13.3 13.1 |
|
| Goingconcern capital ratio(%)2 | 19.1 18.7 18.3 17.9 |
|
| Total loss-absorbingcapacityratio(%)2 | 34.6 34.2 34.2 31.9 |
|
| Leverage ratio denominator1,2 | 1,039,375 1,039,736 1,036,771 974,135 |
|
| Common equitytier 1 leverage ratio(%)1,2 | 3.87 3.73 3.68 3.84 |
|
| Goingconcern leverage ratio(%)1,2 | 5.3 5.1 5.1 5.2 |
|
| Total loss-absorbingcapacityleverage ratio(%)2 | 9.7 9.4 9.5 9.3 |
|
| Other | ||
| Invested assets(USD billion)3 | 4,485 4,306 4,187 3,588 |
|
| Personnel(full-time equivalents) | 47,227 47,592 47,546 47,120 |
1 Leverage ratio denominators and leverage ratios for the respective periods in 2020 do not reflect the effects of the temporary exemption that applied from 25 March 2020 until 1 January 2021 and was granted by FINMA in connection with COVID-19. Refer to the “Regulatory and legal developments” section of our Annual Report 2020 for more information. 2 Based on the Swiss systemically relevant bank framework as of 1 January 2020. Refer to the “Capital management” section of this report for more information. 3 Consists of invested assets for Global Wealth Management, Asset Management and Personal & Corporate Banking. Refer to “Note 32 Invested assets and net new money” in the “Consolidated financial statements” section of our Annual Report 2020 for more information.
Alternative performance measures
An alternative performance measure (an APM) is a financial measure of historical or future financial performance, financial position or cash flows other than a financial measure defined or specified in the applicable recognized accounting standards or in other applicable regulations. We report a number of APMs in our external reports (annual, quarterly and other reports). We use APMs to provide a more complete picture of our operating performance and to reflect management’s view of the fundamental drivers of our business results. A definition of each APM, the method used to calculate it and the information content are presented under “Alternative performance measures” in the appendix to this report. Our APMs may qualify as non-GAAP measures as defined by US Securities and Exchange Commission (SEC) regulations.
Introduction
Overview
UBS Group AG is the holding company for the UBS Group and the parent company of UBS AG. UBS Group AG holds 100% of the issued shares in UBS AG. Financial information for UBS AG consolidated does not differ materially from that for UBS Group AG consolidated.
This report includes risk and capital management information for UBS AG consolidated and the interim consolidated financial statements, as well as UBS AG standalone financial information for the quarter ended 30 June 2021. Regulatory information for UBS AG standalone is provided in the 30 June 2021 Pillar 3 report, available under “Pillar 3 disclosures” at ubs.com/investors.
- ›[Refer to the UBS Group second quarter 2021 report, available ] under “Quarterly reporting” at ubs.com/investors , for more information
Comparison between UBS Group AG consolidated and UBS AG consolidated
The table on the following page contains a comparison of selected financial and capital information between UBS Group AG consolidated and UBS AG consolidated.
The accounting policies applied under International Financial Reporting Standards (IFRS) to both the UBS Group AG and the UBS AG consolidated financial statements are identical. However, there are certain scope and presentation differences as noted below.
-
Assets, liabilities, operating income, operating expenses and operating profit before tax relating to UBS Group AG and its directly held subsidiaries, including UBS Business Solutions AG, are reflected in the consolidated financial statements of UBS Group AG but not in those of UBS AG. UBS AG’s assets, liabilities, operating income and operating expenses related to transactions with UBS Group AG and its directly held subsidiaries, including UBS Business Solutions AG and other shared services subsidiaries, are not subject to elimination in the consolidated financial statements of UBS AG, but are eliminated in the consolidated financial statements of UBS Group AG. UBS Business Solutions AG and other shared services subsidiaries of UBS Group AG charge other legal entities within the UBS AG consolidation scope for services provided, including a markup on costs incurred.
-
The equity of UBS Group AG consolidated was USD 3.4 billion higher than the equity of UBS AG consolidated as of 30 June 2021. This difference was mainly driven by higher dividends paid by UBS AG to UBS Group AG compared with
the dividend distributions of UBS Group AG, as well as higher retained earnings in the consolidated financial statements of UBS Group AG, largely related to the aforementioned markup charged by shared services subsidiaries of UBS Group AG to other legal entities in the UBS AG scope of consolidation. In addition, UBS Group AG is the grantor of the majority of the compensation plans of the Group and recognizes share premium for equity-settled awards granted. These effects were partly offset by treasury shares acquired and canceled as part of our share repurchase programs and those held to hedge share delivery obligations associated with Group compensation plans, as well as additional share premium recognized at the UBS AG consolidated level related to the establishment of UBS Group AG and UBS Business Solutions AG, a wholly owned subsidiary of UBS Group AG.
-
The going concern capital of UBS Group AG consolidated was USD 3.8 billion higher than the going concern capital of UBS AG consolidated as of 30 June 2021, reflecting higher common equity tier 1 (CET1) capital of USD 2.4 billion and going concern loss-absorbing additional tier 1 (AT1) capital of USD 1.4 billion.
-
The CET1 capital of UBS Group AG consolidated was USD 2.4 billion higher than that of UBS AG consolidated as of 30 June 2021. The higher CET1 capital of UBS Group AG consolidated was primarily due to higher UBS Group AG consolidated IFRS equity of USD 3.4 billion, as described above, and lower UBS Group AG accruals for future capital returns to shareholders, partly offset by compensation-related regulatory capital accruals and a capital reserve for potential share repurchases at the UBS Group AG level.
-
The going concern loss-absorbing AT1 capital of UBS Group AG consolidated was USD 1.4 billion higher than that of UBS AG consolidated as of 30 June 2021, mainly reflecting deferred contingent capital plan awards granted at the Group level to eligible employees for the performance years 2016 to 2020, partly offset by two loss-absorbing AT1 capital instruments on-lent by UBS Group AG to UBS AG.
-
›[Refer to “Holding company and significant regulated ] subsidiaries and sub-groups” under “Complementary financial information” at ubs.com/investors for an illustration of the
-
consolidation scope differences between UBS AG and UBS Group AG
-
›[Refer to the “Capital management” section of this report for ] more information about differences in the loss-absorbing capacity between UBS Group AG consolidated and UBS AG consolidated
Comparison between UBS Group AG consolidated and UBS AG consolidated
| Comparison between UBS Group AG consolidated and UBS AG consolidated | |
|---|---|
| As of or for thequarter ended 30.6.21 | |
| USD million, except where indicated | UBS Group AG consolidated UBS AG consolidated Difference (absolute) |
| Income statement | |
| Operatingincome | 8,976 9,071 (94) |
| Operatingexpenses | 6,384 6,589 (206) |
| Operating profit /(loss)before tax | 2,593 2,481 111 |
| of which: Global Wealth Management | 1,294 1,273 21 |
| of which: Personal & Corporate Banking | 498 496 2 |
| of which: Asset Management | 255 254 1 |
| of which: Investment Bank | 668 655 14 |
| of which: Group Functions | (124) (197) 73 |
| Netprofit /(loss) | 2,012 1,919 93 |
| of which: netprofit /(loss) attributable to shareholders | 2,006 1,913 93 |
| of which: netprofit / (loss) attributable to non-controlling interests | 6 6 0 |
| Statement of comprehensive income | |
| Other comprehensive income | 591 592 (1) |
| of which: attributable to shareholders | 576 578 (1) |
| of which: attributable to non-controlling interests | 14 14 0 |
| Total comprehensive income | 2,602 2,510 92 |
| of which: attributable to shareholders | 2,582 2,491 92 |
| of which: attributable to non-controlling interests | 20 20 0 |
| Balance sheet | |
| Total assets | 1,086,519 1,085,861 658 |
| Total liabilities | 1,027,469 1,030,216 (2,746) |
| Total equity | 59,050 55,645 3,405 |
| of which: equity attributable to shareholders | 58,765 55,361 3,405 |
| of which: equity attributable to non-controlling interests | 284 284 0 |
| Capital information | |
| Common equitytier 1 capital | 42,583 40,190 2,393 |
| Goingconcern capital | 59,188 55,398 3,790 |
| Risk-weighted assets | 293,277 290,470 2,807 |
| Common equitytier 1 capital ratio(%) | 14.5 13.8 0.7 |
| Goingconcern capital ratio(%) | 20.2 19.1 1.1 |
| Total loss-absorbingcapacityratio(%) | 35.6 34.6 1.0 |
| Leverage ratio denominator1 | 1,039,939 1,039,375 564 |
| Common equitytier 1 leverage ratio(%)1 | 4.09 3.87 0.23 |
| Goingconcern leverage ratio(%)1 | 5.7 5.3 0.4 |
| Total loss-absorbingcapacityleverage ratio(%) | 10.0 9.7 0.4 |
1 Leverage ratio denominators and leverage ratios for 31 December 2020 do not reflect the effects of the temporary exemption that applied from 25 March 2020 until 1 January 2021 and was granted by FINMA in connection with COVID-19. Refer to the “Regulatory and legal developments” section of our Annual Report 2020 for more information.
| As of or for thequarter ended 31.3.21 | As of or for thequarter ended 31.12.20 |
|---|---|
| UBS Group AG consolidated UBS AG consolidated Difference (absolute) |
UBS Group AG consolidated UBS AG consolidated Difference (absolute) |
| 8,705 8,836 (130) |
8,117 8,220 (103) |
| 6,407 6,684 (277) |
6,132 6,324 (192) |
| 2,298 2,151 147 |
1,985 1,896 89 |
| 1,409 1,391 18 |
864 855 9 |
| 389 390 0 |
353 353 (1) |
| 227 227 0 |
401 401 0 |
| 412 394 17 |
529 528 1 |
| (139) (251) 112 |
(161) (241) 79 |
| 1,827 1,713 114 |
1,645 1,572 73 |
| 1,824 1,710 114 |
1,636 1,563 73 |
| 3 3 0 |
9 9 0 |
| (2,166) (2,032) (135) |
83 54 29 |
| (2,154) (2,019) (135) |
65 36 29 |
| (12) (12) 0 |
18 18 0 |
| (339) (319) (21) |
1,728 1,626 102 |
| (330) (309) (21) |
1,701 1,599 102 |
| (9) (9) 0 |
27 27 0 |
| 1,107,712 1,109,234 (1,522) |
1,125,765 1,125,327 438 |
| 1,049,379 1,051,481 (2,102) |
1,066,000 1,067,254 (1,254) |
| 58,333 57,753 580 |
59,765 58,073 1,691 |
| 58,026 57,446 580 |
59,445 57,754 1,691 |
| 307 307 0 |
319 319 0 |
| 40,426 38,826 1,600 |
39,890 38,181 1,709 |
| 56,288 53,255 3,033 |
56,178 52,610 3,567 |
| 287,828 285,119 2,710 |
289,101 286,743 2,358 |
| 14.0 13.6 0.4 |
13.8 13.3 0.5 |
| 19.6 18.7 0.9 |
19.4 18.3 1.1 |
| 35.0 34.2 0.7 |
35.2 34.2 1.0 |
| 1,038,225 1,039,736 (1,511) |
1,037,150 1,036,771 379 |
| 3.89 3.73 0.16 |
3.85 3.68 0.16 |
| 5.4 5.1 0.3 |
5.4 5.1 0.3 |
| 9.7 9.4 0.3 |
9.8 9.5 0.3 |
Risk and capital management
Management report
Risk management and control
UBS AG consolidated risk profile
The risk profile of UBS AG consolidated does not differ materially from that of UBS Group AG consolidated and the risk information provided in the UBS Group second quarter 2021 report is equally applicable to UBS AG consolidated.
The credit risk profile of UBS AG consolidated differs from that of UBS Group AG consolidated primarily in relation to
receivables of UBS AG and UBS Switzerland AG from UBS Group AG. The total banking products exposure of UBS AG consolidated as of 30 June 2021 was USD 1.2 billion, or 0.2%, higher than the exposure of UBS Group, compared with USD 3.3 billion, or 0.5%, as of 31 March 2021.
- ›[Refer to the “Risk management and control” section of the ]
UBS Group second quarter 2021 report for more information
Capital management
Going and gone concern requirements and information
UBS is considered a systemically relevant bank (an SRB) under Swiss banking law and, on a consolidated basis, both UBS Group AG and UBS AG are required to comply with regulations based on the Basel III framework as applicable for Swiss SRBs.
The Swiss SRB framework and requirements applicable to UBS AG consolidated are consistent with those applicable to UBS Group AG consolidated and are described in the “Capital, liquidity and funding, and balance sheet” section of our Annual Report 2020.
UBS AG is subject to going and gone concern requirements on a standalone basis. Capital and other regulatory information for UBS AG standalone is provided under “Holding company and significant regulated subsidiaries and sub-groups” at ubs.com/investors and in the 30 June 2021 Pillar 3 report, which will be available as of 20 August 2021 under “Pillar 3 disclosures” at ubs.com/investors .
The table on the next page provides the risk-weighted assets (RWA)and leverage ratio denominator (LRD)-based requirements and information as of 30 June 2021 for UBS AG consolidated.
Swiss SRB going and gone concern requirements and information
| As of 30.6.21 | RWA | LRD |
|---|---|---|
| USD million, except where indicated | in % | in % |
| Requiredgoing concern capital | ||
| Totalgoing concern capital | 13.961 40,552 |
4.881 50,670 |
| Common equity tier 1 capital | 9.66 28,062 |
3.382 35,079 |
| of which: minimum capital | 4.50 13,071 |
1.50 15,591 |
| of which: buffer capital | 5.14 14,930 |
1.88 19,488 |
| of which: countercyclical buffer | 0.02 61 |
|
| Maximum additional tier 1 capital | 4.30 12,490 |
1.50 15,591 |
| of which: additional tier 1 capital | 3.50 10,166 |
1.50 15,591 |
| of which: additional tier 1 buffer capital | 0.80 2,324 |
|
| Eligiblegoing concern capital | ||
| Totalgoing concern capital | 19.07 55,398 |
5.33 55,398 |
| Common equitytier 1 capital | 13.84 40,190 |
3.87 40,190 |
| Total loss-absorbing additional tier 1 capital | 5.24 15,208 |
1.46 15,208 |
| of which: high-trigger loss-absorbing additional tier 1 capital | 4.37 12,702 |
1.22 12,702 |
| of which: low-trigger loss-absorbing additional tier 1 capital3 | 0.86 2,506 |
0.24 2,506 |
| Requiredgone concern capital4 | ||
| Totalgone concern loss-absorbing capacity5 | 10.60 30,803 |
3.76 39,071 |
| of which: base requirement | 12.86 37,354 |
4.50 46,772 |
| of which: additional requirement for market share and LRD | 1.08 3,137 |
0.38 3,898 |
| of which: applicable reduction on requirements | (3.34) (9,688) |
(1.12) (11,598) |
| of which: rebategranted(equivalent to 47.5% of maximum rebate) 6 | (2.54) (7,368) |
(0.89) (9,257) |
| of which: reduction for usage of low-trigger tier 2 capital instruments | (0.80) (2,320) |
(0.23) (2,342) |
| Eligiblegone concern capital | ||
| Totalgone concern loss-absorbing capacity | 15.53 45,110 |
4.34 45,110 |
| Total tier 2 capital | 1.80 5,232 |
0.50 5,232 |
| of which: low-trigger loss-absorbing tier 2 capital | 1.61 4,686 |
0.45 4,686 |
| of which: non-Basel III-compliant tier 2 capital | 0.19 547 |
0.05 547 |
| TLAC-eligible senior unsecured debt | 13.73 39,878 |
3.84 39,878 |
| Total loss-absorbing capacity | ||
| Required total loss-absorbing capacity | 24.57 71,356 |
8.63 89,741 |
| Eligible total loss-absorbing capacity | 34.60 100,508 |
9.67 100,508 |
| Risk-weighted assets / leverage ratio denominator | ||
| Risk-weighted assets | 290,470 | |
| Leverage ratio denominator | 1,039,375 |
1 Includes applicable add-ons of 1.08% for RWA and 0.375% for LRD. 2 Our minimum CET1 leverage ratio requirement of 3.375% consists of a 1.5% base requirement, a 1.5% base buffer capital requirement, a 0.25% LRD add-on requirement and a 0.125% market share add-on requirement based on our Swiss credit business. 3 The relevant capital instruments were issued after the new Swiss SRB framework had been implemented and qualify as going concern capital at the UBS AG consolidated level, as agreed with FINMA. 4 A maximum of 25% of the gone concern requirements can be met with instruments that have a remaining maturity of between one and two years. Once at least 75% of the minimum gone concern requirement has been met with instruments that have a remaining maturity of greater than two years, all instruments that have a remaining maturity of between one and two years remain eligible to be included in the total gone concern capital. 5 The gone concern requirement after the application of the rebate for resolvability measures and the reduction for the use of higher quality capital instruments is floored at 8.6% and 3% for the RWA- and LRD-based requirements, respectively. This means that the combined reduction may not exceed 5.34 percentage points for the RWA-based requirement of 13.94% and 1.875 percentage points for the LRD-based requirement of 4.875%. 6 Based on the actions we completed up to December 2020 to improve resolvability, FINMA granted an increase of rebate on the gone concern requirement from 47.5% to 55.0% of the maximum rebate, effective from 1 July 2021.
Swiss SRB going and gone concern information
| USD million, except where indicated | 30.6.21 | 31.3.21 | 31.12.20 |
|---|---|---|---|
| Eligiblegoing concern capital | |||
| Totalgoing concern capital | 55,398 | 53,255 | 52,610 |
| Total tier 1 capital | 55,398 | 53,255 | 52,610 |
| Common equitytier 1 capital | 40,190 | 38,826 | 38,181 |
| Total loss-absorbing additional tier 1 capital | 15,208 | 14,429 | 14,430 |
| of which: high-trigger loss-absorbing additional tier 1 capital | 12,702 | 11,930 | 11,854 |
| of which: low-trigger loss-absorbing additional tier 1 capital1 | 2,506 | 2,499 | 2,575 |
| Eligiblegone concern capital | |||
| Totalgone concern loss-absorbing capacity | 45,110 | 44,381 | 45,545 |
| Total tier 2 capital | 5,232 | 5,253 | 7,744 |
| of which: low-trigger loss-absorbing tier 2 capital | 4,686 | 4,709 | 7,201 |
| of which: non-Basel III-compliant tier 2 capital | 547 | 544 | 543 |
| TLAC-eligible senior unsecured debt | 39,878 | 39,129 | 37,801 |
| Total loss-absorbing capacity | |||
| Total loss-absorbing capacity | 100,508 | 97,636 | 98,155 |
| Risk-weighted assets / leverage ratio denominator | |||
| Risk-weighted assets | 290,470 | 285,119 | 286,743 |
| Leverage ratio denominator2 | 1,039,375 | 1,039,736 | 1,036,771 |
| Capital and loss-absorbing capacity ratios(%) | |||
| Goingconcern capital ratio | 19.1 | 18.7 | 18.3 |
| of which: common equity tier 1 capital ratio | 13.8 | 13.6 | 13.3 |
| Gone concern loss-absorbingcapacityratio | 15.5 | 15.6 | 15.9 |
| Total loss-absorbing capacity ratio | 34.6 | 34.2 | 34.2 |
| Leverage ratios(%)2 | |||
| Goingconcern leverage ratio | 5.3 | 5.1 | 5.1 |
| of which: common equity tier 1 leverage ratio | 3.87 | 3.73 | 3.68 |
| Gone concern leverage ratio | 4.3 | 4.3 | 4.4 |
| Total loss-absorbing capacity leverage ratio | 9.7 | 9.4 | 9.5 |
1 The relevant capital instruments were issued after the new Swiss SRB framework had been implemented and qualify as going concern capital of UBS AG, as agreed with FINMA. 2 The leverage ratio denominator (LRD) and leverage ratios for 31 December 2020 do not reflect the effects of the temporary exemption that applied from 25 March 2020 until 1 January 2021 and was granted by FINMA in connection with COVID19. Refer to “UBS AG consolidated total loss-absorbing capacity and leverage ratio information” in the “Capital, liquidity and funding, and balance sheet” section of the combined UBS Group AG and UBS AG Annual Report 2020, available under “Annual reporting” at ubs.com/investors, for more information.
UBS Group AG vs UBS AG consolidated loss-absorbing capacity and leverage ratio information
Swiss SRB going and gone concern information
| Swiss SRBgoing andgone concern information | |
|---|---|
| As of 30.6.21 | |
| USD million, except where indicated | UBS Group AG (consolidated) UBS AG (consolidated) Difference |
| Eligiblegoing concern capital | |
| Totalgoing concern capital | 59,188 55,398 3,790 |
| Total tier 1 capital | 59,188 55,398 3,790 |
| Common equitytier 1 capital | 42,583 40,190 2,393 |
| Total loss-absorbing additional tier 1 capital | 16,605 15,208 1,397 |
| of which: high-trigger loss-absorbing additional tier 1 capital | 14,096 12,702 1,395 |
| of which: low-trigger loss-absorbing additional tier 1 capital | 2,509 2,506 3 |
| Eligiblegone concern capital | |
| Totalgone concern loss-absorbing capacity | 45,110 45,110 |
| Total tier 2 capital | 5,232 5,232 |
| of which: low-trigger loss-absorbing tier 2 capital | 4,686 4,686 |
| of which: non-Basel III-compliant tier 2 capital | 547 547 |
| TLAC-eligible senior unsecured debt | 39,878 39,878 |
| Total loss-absorbing capacity | |
| Total loss-absorbing capacity | 104,298 100,508 3,790 |
| Risk-weighted assets / leverage ratio denominator | |
| Risk-weighted assets | 293,277 290,470 2,807 |
| Leverage ratio denominator | 1,039,939 1,039,375 564 |
| Capital and loss-absorbing capacity ratios (%) | |
| Goingconcern capital ratio | 20.2 19.1 1.1 |
| of which: common equity tier 1 capital ratio | 14.5 13.8 0.7 |
| Gone concern loss-absorbingcapacityratio | 15.4 15.5 (0.1) |
| Total loss-absorbing capacity ratio | 35.6 34.6 1.0 |
| Leverage ratios (%) | |
| Goingconcern leverage ratio | 5.7 5.3 0.4 |
| of which: common equity tier 1 leverage ratio | 4.09 3.87 0.23 |
| Gone concern leverage ratio | 4.3 4.3 0.0 |
| Total loss-absorbing capacity leverage ratio | 10.0 9.7 0.4 |
Reconciliation of IFRS equity to Swiss SRB common equity tier 1 capital (UBS Group AG vs UBS AG consolidated)
As of 30.6.21
| As of 30.6.21 | |||
|---|---|---|---|
| UBS Group AG | UBS AG | ||
| USD million | (consolidated) | (consolidated) | Difference |
| Total IFRS equity | 59,050 | 55,645 | 3,405 |
| Equityattributable to non-controllinginterests | (284) | (284) | 0 |
| Defined benefitplans, net of tax | (144) | (144) | |
| Deferred tax assets recognized for tax loss carry-forwards | (5,183) | (5,183) | |
| Deferred tax assets on temporarydifferences, excess over threshold | (92) | 92 | |
| Goodwill, net of tax | (5,883) | (5,883) | |
| Intangible assets, net of tax | (200) | (200) | |
| Compensation-related components(not recognized in netprofit) | (1,680) | (1,680) | |
| Expected losses on advanced internal ratings-basedportfolio lessprovisions | (463) | (463) | |
| Unrealized(gains)/ losses from cash flow hedges, net of tax | (1,365) | (1,365) | 0 |
| Own credit related togains / losses on financial liabilities measured at fair value that existed at the balance sheet date | 279 | 279 | |
| Own credit related togains / losses on derivative financial instruments that existed at the balance sheet date | (50) | (50) | |
| Unrealizedgains related to debt instruments at fair value through OCI, net of tax | (89) | (89) | |
| Prudential valuation adjustments | (146) | (146) | |
| Capital reserve forpotential share repurchases | (587) | (587) | |
| Other1 | (670) | (1,834) | 1,164 |
| Total common equity tier 1 capital | 42,583 | 40,190 | 2,393 |
1 Includes accruals for dividends to shareholders for the current year and other items.
UBS Group AG vs UBS AG consolidated loss-absorbing capacity and leverage ratio information
The going concern capital of UBS AG consolidated was USD 3.8 billion lower than the going concern capital of UBS Group AG consolidated as of 30 June 2021, reflecting lower common equity tier 1 (CET1) capital of USD 2.4 billion and lower going concern loss-absorbing additional tier 1 (AT1) capital of USD 1.4 billion.
The aforementioned difference in CET1 capital was primarily due to higher UBS Group AG consolidated IFRS equity of USD 3.4 billion and lower UBS Group AG accruals for future capital returns to shareholders, partly offset by compensationrelated regulatory capital accruals and a capital reserve for potential share repurchases at the UBS Group AG level.
The going concern loss-absorbing AT1 capital of UBS AG consolidated was USD 1.4 billion lower than that of UBS Group AG consolidated as of 30 June 2021, mainly reflecting deferred contingent capital plan awards granted at the Group level to eligible employees for the performance years 2016 to 2020, partly offset by two loss-absorbing AT1 capital instruments onlent by UBS Group AG to UBS AG.
Differences in capital between UBS Group AG consolidated and UBS AG consolidated related to employee compensation plans will reverse to the extent underlying services are performed by employees of, and are consequently charged to, UBS AG and its subsidiaries. Such reversal generally occurs over the service period of the employee compensation plans.
The leverage ratio framework for UBS AG consolidated is consistent with that of UBS Group AG consolidated. As of 30 June 2021, the going concern leverage ratio of UBS AG consolidated was 0.4 percentage points lower than that of UBS Group AG consolidated, mainly because the going concern capital of UBS AG consolidated was USD 3.8 billion lower.
-
›[Refer to the “Capital management” section of the UBS Group ] second quarter 2021 report, available under “Quarterly reporting” at ubs.com/investors, for information about the developments of loss-absorbing capacity, RWA and LRD for UBS Group AG consolidated
-
›[Refer to the “Introduction” section of this report for more ] information about the differences in equity between UBS AG consolidated and UBS Group AG consolidated
Consolidated financial statements
Unaudited
Table of contents
UBS AG interim consolidated financial statements (unaudited)
17 Income statement
18 Statement of comprehensive income
20 Balance sheet
22 Statement of changes in equity
-
24 Statement of cash flows
-
26 1 Basis of accounting and other financial reporting effects
-
28 2 Segment reporting
-
29 3 Net interest income 29 4 Net fee and commission income
30 5 Other income 30 6 Personnel expenses 30 7 General and administrative expenses
-
30 8 Income taxes
-
31 9 Expected credit loss measurement
-
38 10 Fair value measurement
-
47 11 Derivative instruments
-
48 12 Other assets and liabilities
-
50 13 Debt issued designated at fair value
-
50 14 Debt issued measured at amortized cost 51 15 Interest rate benchmark reform
-
54 16 Provisions and contingent liabilities
60 17 Currency translation rates
- 61 18 Supplemental guarantor information required under SEC regulations
UBS AG interim consolidated financial statements (unaudited)
Income statement
| Income statement | |||
|---|---|---|---|
| For thequarter ended | Year-to-date | ||
| USD million | Note | 30.6.21 31.3.21 30.6.20 |
30.6.21 30.6.20 |
| Interest income from financial instruments measured at amortized cost and fair value through other comprehensive income |
3 | 2,107 2,098 2,135 |
4,205 4,591 |
| Interest expense from financial instruments measured at amortized cost | 3 | (860) (859) (1,112) |
(1,719) (2,519) |
| Net interest income from financial instruments measured at fair value throughprofit or loss | 3 | 359 351 354 |
710 616 |
| Net interest income | 3 | 1,607 1,589 1,376 |
3,196 2,689 |
| Other net income from financial instruments measured at fair value through profit or loss | 1,471 1,314 1,944 |
2,785 3,719 |
|
| Credit loss (expense) / release | 9 | 80 28 (272) |
108 (540) |
| Fee and commission income | 4 | 6,047 6,197 4,730 |
12,244 10,211 |
| Fee and commission expense | 4 | (484) (478) (419) |
(962) (875) |
| Net fee and commission income | 4 | 5,563 5,719 4,311 |
11,282 9,336 |
| Other income | 5 | 350 185 153 |
535 317 |
| Total operating income | 9,071 8,836 7,512 |
17,906 15,521 |
|
| Personnel expenses | 6 | 4,072 4,086 3,682 |
8,158 7,391 |
| General and administrative expenses | 7 | 2,070 2,141 1,879 |
4,211 3,960 |
| Depreciation and impairment of property, equipment and software | 439 449 409 |
887 814 |
|
| Amortization and impairment of goodwill and intangible assets | 9 8 17 |
17 32 |
|
| Total operating expenses | 6,589 6,684 5,987 |
13,274 12,197 |
|
| Operating profit / (loss) before tax | 2,481 2,151 1,525 |
4,632 3,324 |
|
| Tax expense / (benefit) | 8 | 563 439 328 |
1,001 703 |
| Net profit / (loss) | 1,919 1,713 1,197 |
3,631 2,621 |
|
| Net profit / (loss) attributable to non-controlling interests | 6 3 3 |
9 6 |
|
| Net profit / (loss) attributable to shareholders | 1,913 1,710 1,194 |
3,623 2,615 |
Statement of comprehensive income
| Statement of comprehensive income | ||
|---|---|---|
| For thequarter ended | Year-to-date | |
| USD million | 30.6.21 31.3.21 30.6.20 |
30.6.21 30.6.20 |
| Comprehensive income attributable to shareholders | ||
| Net profit / (loss) | 1,913 1,710 1,194 |
3,623 2,615 |
| Other comprehensive income that may be reclassified to the income statement | ||
| Foreign currency translation | ||
| Foreign currencytranslation movements related to net assets of foreign operations, before tax | 447 (1,407) 447 |
(960) 172 |
| Effectiveportion of changes in fair value of hedginginstruments designated as net investment hedges, before tax | (203) 705 (196) |
502 (61) |
| Foreign currencytranslation differences on foreign operations reclassified to the income statement | (9) 1 0 |
(8) 0 |
| Effective portion of changes in fair value of hedging instruments designated as net investment hedges reclassified to the income statement |
8 0 2 |
8 (7) |
| Income tax relatingto foreign currencytranslations, includingthe impact of net investment hedges | (4) 10 (2) |
6 (2) |
| Subtotal foreign currencytranslation, net of tax | 239 (691) 249 |
(452) 103 |
| Financial assets measured at fair value through other comprehensive income | ||
| Net unrealizedgains / (losses), before tax | 21 (131) 19 |
(110) 226 |
| Realizedgains reclassified to the income statement from equity | (3) (8) (15) |
(11) (24) |
| Realized losses reclassified to the income statement from equity | 0 2 0 |
2 0 |
| Income tax relatingto net unrealizedgains / (losses) | (4) 35 (3) |
31 (54) |
| Subtotal financial assets measured at fair value through other comprehensive income, net of tax | 14 (102) 1 |
(88) 149 |
| Cash flow hedges of interest rate risk | ||
| Effectiveportion of changes in fair value of derivative instruments designated as cash flow hedges, before tax | 542 (1,172) 291 |
(630) 2,244 |
| Net (gains) / losses reclassified to the income statement from equity | (268) (254) (171) |
(522) (274) |
| Income tax relatingto cash flow hedges | (51) 266 (25) |
215 (370) |
| Subtotal cash flow hedges, net of tax | 222 (1,160) 95 |
(937) 1,600 |
| Cost of hedging | ||
| Change in fair value of cost of hedging, before tax | (24) (13) (18) |
(37) (12) |
| Amortization of initial cost of hedgingto the income statement | 7 7 5 |
14 7 |
| Income tax relatingto cost of hedging | 0 0 0 |
0 0 |
| Subtotal cost of hedging, net of tax | (16) (6) (13) |
(23) (4) |
| Total other comprehensive income that may be reclassified to the income statement, net of tax | 459 (1,958) 333 |
(1,500) 1,847 |
| Other comprehensive income that will not be reclassified to the income statement | ||
| Defined benefit plans | ||
| Gains / (losses) on defined benefit plans, before tax | 0 (35) (417) |
(35) (314) |
| Income tax relatingto defined benefitplans | 0 3 (81) |
4 43 |
| Subtotal defined benefit plans, net of tax | 0 (32) (498) |
(31) (270) |
| Own credit on financial liabilities designated at fair value1 | ||
| Gains / (losses) from own credit on financial liabilities designated at fair value, before tax | 118 (29) (1,095) |
89 62 |
| Income tax relatingto own credit on financial liabilities designated at fair value | 0 0 223 |
0 0 |
| Subtotal own credit on financial liabilities designated at fair value, net of tax | 118 (29) (872) |
89 62 |
| Total other comprehensive income that will not be reclassified to the income statement, net of tax | 119 (61) (1,370) |
58 (208) |
| Total other comprehensive income | 578 (2,019) (1,037) |
(1,442) 1,639 |
| Total comprehensive income attributable to shareholders | 2,491 (309) 157 |
2,181 4,254 |
Statement of comprehensive income (continued)
| Statement of comprehensive income (continued) | ||
|---|---|---|
| For thequarter ended | Year-to-date | |
| USD million | 30.6.21 31.3.21 30.6.20 |
30.6.21 30.6.20 |
| Comprehensive income attributable to non-controlling interests | ||
| Net profit / (loss) | 6 3 3 |
9 6 |
| Other comprehensive income that will not be reclassified to the income statement | ||
| Foreign currency translation movements, before tax | 14 (12) 1 |
2 (4) |
| Income tax relatingto foreign currencytranslation movements | 0 0 0 |
0 0 |
| Subtotal foreign currency translation, net of tax | 14 (12) 1 |
2 (4) |
| Total other comprehensive income that will not be reclassified to the income statement, net of tax | 14 (12) 1 |
2 (4) |
| Total comprehensive income attributable to non-controlling interests | 20 (9) 4 |
10 3 |
| Total comprehensive income | ||
| Net profit / (loss) | 1,919 1,713 1,197 |
3,631 2,621 |
| Other comprehensive income | 592 (2,032) (1,035) |
(1,440) 1,635 |
| of which: other comprehensive income that may be reclassified to the income statement | 459 (1,958) 333 |
(1,500) 1,847 |
| of which: other comprehensive income that will not be reclassified to the income statement | 133 (73) (1,369) |
60 (212) |
| Total comprehensive income | 2,510 (319) 161 |
2,192 4,256 |
1 Refer to Note 10 for more information.
| Balance sheet | ||||
|---|---|---|---|---|
| USD million | Note | 30.6.21 | 31.3.21 | 31.12.20 |
| Assets | ||||
| Cash and balances at central banks | 160,672 | 158,914 | 158,231 | |
| Loans and advances to banks | 16,376 | 18,348 | 15,344 | |
| Receivables from securities financing transactions | 83,494 | 82,384 | 74,210 | |
| Cash collateral receivables on derivative instruments | 11 | 29,787 | 35,050 | 32,737 |
| Loans and advances to customers | 9 | 391,406 | 380,141 | 380,977 |
| Other financial assets measured at amortized cost | 12 | 27,201 | 26,837 | 27,219 |
| Total financial assets measured at amortized cost | 708,937 | 701,674 | 688,717 | |
| Financial assets at fair value held for trading | 10 | 122,628 | 120,717 | 125,492 |
| of which: assets pledged as collateral that may be sold or repledged by counterparties | 44,333 | 48,385 | 47,098 | |
| Derivative financial instruments | 10, 11 | 121,622 | 148,284 | 159,618 |
| Brokerage receivables | 10 | 23,010 | 24,201 | 24,659 |
| Financial assets at fair value not held for trading | 10 | 64,952 | 68,763 | 80,038 |
| Total financial assets measured at fair value through profit or loss | 332,211 | 361,964 | 389,808 | |
| Financial assets measured at fair value through other comprehensive income | 10 | 7,775 | 8,100 | 8,258 |
| Investments in associates | 1,198 | 1,542 | 1,557 | |
| Property, equipment and software | 11,732 | 11,610 | 11,958 | |
| Goodwill and intangible assets | 6,452 | 6,427 | 6,480 | |
| Deferred tax assets | 8,951 | 9,161 | 9,174 | |
| Other non-financial assets | 12 | 8,603 | 8,755 | 9,374 |
| Total assets | 1,085,861 | 1,109,234 | 1,125,327 |
| Balance sheet (continued) | ||||
|---|---|---|---|---|
| USD million | Note | 30.6.21 | 31.3.21 | 31.12.20 |
| Liabilities | ||||
| Amounts due to banks | 14,615 | 12,564 | 11,050 | |
| Payables from securities financing transactions | 5,972 | 6,651 | 6,321 | |
| Cash collateral payables on derivative instruments | 11 | 32,193 | 36,571 | 37,313 |
| Customer deposits | 517,462 | 508,903 | 527,929 | |
| Funding from UBS Group AG | 55,907 | 57,699 | 53,979 | |
| Debt issued measured at amortized cost | 14 | 84,491 | 87,495 | 85,351 |
| Other financial liabilities measured at amortized cost | 12 | 10,671 | 9,624 | 10,421 |
| Total financial liabilities measured at amortized cost | 721,311 | 719,508 | 732,364 | |
| Financial liabilities at fair value held for trading | 10 | 33,348 | 37,062 | 33,595 |
| Derivative financial instruments | 10, 11 | 121,688 | 146,041 | 161,102 |
| Brokerage payables designated at fair value | 10 | 39,129 | 45,600 | 38,742 |
| Debt issued designated at fair value | 10, 13 | 72,799 | 64,635 | 59,868 |
| Other financial liabilities designated at fair value | 10, 12 | 32,908 | 30,769 | 31,773 |
| Total financial liabilities measured at fair value through profit or loss | 299,871 | 324,108 | 325,080 | |
| Provisions | 16 | 2,792 | 2,693 | 2,791 |
| Other non-financial liabilities | 12 | 6,241 | 5,171 | 7,018 |
| Total liabilities | 1,030,216 | 1,051,481 | 1,067,254 | |
| Equity | ||||
| Share capital | 338 | 338 | 338 | |
| Share premium | 24,542 | 24,579 | 24,580 | |
| Retained earnings | 24,414 | 26,926 | 25,251 | |
| Other comprehensive income recognized directlyin equity, net of tax | 6,067 | 5,603 | 7,585 | |
| Equity attributable to shareholders | 55,361 | 57,446 | 57,754 | |
| Equityattributable to non-controllinginterests | 284 | 307 | 319 | |
| Total equity | 55,645 | 57,753 | 58,073 | |
| Total liabilities and equity | 1,085,861 | 1,109,234 | 1,125,327 |
Statement of changes in equity
| Share | Share | Retained | |
|---|---|---|---|
| USD million | capital | premium | earnings |
| Balance as of 1 January 2020 | 338 | 24,659 | 23,419 |
| Tax (expense) / benefit | (2) | ||
| Dividends | (2,550) | ||
| Translation effects recognized directly in retained earnings | (11) | ||
| Share of changes in retained earnings of associates and joint ventures | (40) | ||
| New consolidations / (deconsolidations) and other increases / (decreases) | 0 | ||
| Total comprehensive income for the period | 2,406 | ||
| of which: net profit / (loss) | 2,615 | ||
| of which: OCI that may be reclassified to the income statement, net of tax | |||
| of which: OCI that will not be reclassified to the income statement, net of tax – defined benefit plans | (270) | ||
| of which: OCI that will not be reclassified to the income statement, net of tax – own credit | 62 | ||
| of which: OCI that will not be reclassified to the income statement, net of tax – foreign currency translation | |||
| Balance as of 30 June 2020 | 338 | 24,657 | 23,225 |
| Balance as of 1 January 2021 | 338 | 24,580 | 25,251 |
| Tax (expense) / benefit | 2 | ||
| Dividends | (4,539) | ||
| Translation effects recognized directly in retained earnings | 19 | ||
| Share of changes in retained earnings of associates and joint ventures | 2 | ||
| New consolidations / (deconsolidations) and other increases / (decreases) | (39) | ||
| Total comprehensive income for the period | 3,681 | ||
| of which: net profit / (loss) | 3,623 | ||
| of which: OCI that may be reclassified to the income statement, net of tax | |||
| of which: OCI that will not be reclassified to the income statement, net of tax – defined benefit plans | (31) | ||
| of which: OCI that will not be reclassified to the income statement, net of tax – own credit | 89 | ||
| of which: OCI that will not be reclassified to the income statement, net of tax – foreign currency translation | |||
| Balance as of 30 June 2021 | 338 | 24,542 | 24,414 |
1 Excludes other comprehensive income related to defined benefit plans and own credit that is recorded directly in Retained earnings.
| Other comprehensive | of which: | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| income recognized | of which: | financial assets | Total equity | ||||||
| directly in equity, | foreign currency | measured at fair value | of which: | of which: | attributable to | Non-controlling | Total | ||
| net of tax 1 | translation | through OCI | cash flow hedges | cost of hedging | shareholders | interests | equity | ||
| 5,306 | 4,032 | 14 | 1,260 | 53,722 | 174 | 53,896 | |||
| (2) | (2) | ||||||||
| (2,550) | (4) | (2,554) | |||||||
| 11 | 0 | 11 | 0 | 0 | |||||
| (40) | (40) | ||||||||
| 0 | 0 | 0 | |||||||
| 1,847 | 103 | 149 | 1,600 | (4) | 4,254 | 3 | 4,256 | ||
| 2,615 | 6 | 2,621 | |||||||
| 1,847 | 103 | 149 | 1,600 | (4) | 1,847 | 1,847 | |||
| (270) | (270) | ||||||||
| 62 | 62 | ||||||||
| 0 | (4) | (4) | |||||||
| 7,164 | 4,134 | 163 | 2,871 | (4) | 55,384 | 173 | 55,557 | ||
| 7,585 | 5,126 | 151 | 2,321 | (13) | 57,754 | 319 | 58,073 | ||
| 2 | 2 | ||||||||
| (4,539) | (4) | (4,542) | |||||||
| (19) | 0 | (19) | 0 | 0 | 0 | ||||
| 2 | 2 | ||||||||
| (39) | (42) | (81) | |||||||
| (1,500) | (452) | (88) | (937) | (23) | 2,181 | 10 | 2,192 | ||
| 3,623 | 9 | 3,631 | |||||||
| (1,500) | (452) | (88) | (937) | (23) | (1,500) | (1,500) | |||
| (31) | (31) | ||||||||
| 89 | 89 | ||||||||
| 0 | 2 | 2 | |||||||
| 6,067 | 4,675 | 63 | 1,365 | (36) | 55,361 | 284 | 55,645 |
Statement of cash flows
| Statement of cash flows | |
|---|---|
| Year-to-date | |
| USD million | 30.6.21 30.6.20 |
| Cash flow from / (used in) operating activities | |
| Net profit / (loss) | 3,631 2,621 |
| Non-cash items included in net profit and other adjustments: | |
| Depreciation and impairment of property, equipment and software | 887 814 |
| Amortization and impairment of goodwill and intangible assets | 17 32 |
| Credit loss expense / (release) | (108) 540 |
| Share of net profits of associates / joint ventures and impairment of associates | (74) (29) |
| Deferred tax expense / (benefit) | 278 191 |
| Net loss / (gain) from investing activities | (239) 240 |
| Net loss / (gain) from financing activities | 2,070 (7,047) |
| Other net adjustments | 4,742 (595) |
| Net change in operating assets and liabilities: | |
| Loans and advances to banks / amounts due to banks | 3,872 5,585 |
| Securities financing transactions | (10,249) 3,167 |
| Cash collateral on derivative instruments | (2,183) (2,046) |
| Loans and advances to customers | (19,714) (14,143) |
| Customer deposits | 573 21,004 |
| Financial assets and liabilities at fair value held for trading and derivative financial instruments | (1,278) 38,756 |
| Brokerage receivables and payables | 2,047 1,140 |
| Financial assets at fair value not held for trading, other financial assets and liabilities | 14,416 (7,484) |
| Provisions, other non-financial assets and liabilities | 261 (1,323) |
| Income taxespaid,net of refunds | (363) (364) |
| Net cash flow from / (used in) operating activities | (1,413) 41,060 |
| Cash flow from / (used in) investing activities | |
| Purchase of subsidiaries, associates and intangible assets | (1) (1) |
| Disposal of subsidiaries, associates and intangible assets1 | 437 14 |
| Purchase of property, equipment and software | (757) (725) |
| Disposal of property, equipment and software | 264 4 |
| Purchase of financial assets measured at fair value through other comprehensive income | (1,950) (4,132) |
| Disposal and redemption of financial assets measured at fair value through other comprehensive income | 2,324 1,944 |
| Net (purchase) / redemption of debt securities measured at amortized cost | 116 (4,817) |
| Net cash flow from / (used in) investing activities | 434 (7,713) |
Statement of cash flows (continued)
| Statement of cash flows (continued) | |
|---|---|
| Year-to-date | |
| USD million | 30.6.21 30.6.20 |
| Cash flow from / (used in) financing activities | |
| Net short-term debt issued / (repaid) | (3,877) 14,912 |
| Distributions paid on UBS shares | (4,539) (2,550) |
| Repayment of lease liabilities | (274) (262) |
| Issuance of debt designated at fair value and long-term debt measured at amortized cost2 | 63,845 46,001 |
| Repayment of debt designated at fair value and long-term debt measured at amortized cost2 | (45,244) (46,137) |
| Net changes in non-controllinginterests | (4) (4) |
| Net cash flow from / (used in) financing activities | 9,908 11,960 |
| Total cash flow | |
| Cash and cash equivalents at the beginning of the period | 173,430 119,804 |
| Net cash flow from / (used in) operating, investing and financing activities | 8,929 45,308 |
| Effects of exchange rate differences on cash and cash equivalents | (5,389) 1,567 |
| Cash and cash equivalents at the end of the period3 | 176,971 166,679 |
| of which: cash and balances at central banks 4 | 160,541 149,430 |
| of which: loans and advances to banks | 15,001 14,339 |
| of which: money marketpaper | 1,428 2,911 |
| Additional information | |
| Net cash flow from / (used in) operating activities includes: | |
| Interest received in cash | 5,475 6,375 |
| Interest paid in cash | 2,703 4,249 |
| Dividends on equity investments, investment funds and associates received in cash | 1,263 1,104 |
1 Includes cash proceeds from the sale of UBS’s minority investment in Clearstream Fund Centre for the period ended 30 June 2021, and dividends received from associates in both periods. 2 Includes funding from UBS Group AG measured at amortized cost (recognized in Funding from UBS Group AG in the balance sheet) and measured at fair value (recognized in Other financial liabilities designated at fair value in the balance sheet). 3 USD 3,432 million and USD 5,393 million of cash and cash equivalents (mainly reflected in Loans and advances to banks) were restricted as of 30 June 2021 and 30 June 2020, respectively. Refer to “Note 23 Restricted and transferred financial assets” in the “Consolidated financial statements” section of the Annual Report 2020 for more information. 4 Includes only balances with an original maturity of three months or less.
Notes to the UBS AG interim consolidated financial statements (unaudited)
Note 1 Basis of accounting and other financial reporting effects
Basis of preparation
The consolidated financial statements (the financial statements) of UBS AG and its subsidiaries (together, UBS AG) are prepared in accordance with International Financial Reporting Standards (IFRS), as issued by the International Accounting Standards Board (the IASB), and are presented in US dollars (USD). These interim financial statements are prepared in accordance with IAS 34, Interim Financial Reporting .
In preparing these interim financial statements, the same accounting policies and methods of computation have been applied as in the UBS AG consolidated annual financial statements for the period ended 31 December 2020, except for the changes described in this Note. These interim financial statements are unaudited and should be read in conjunction with UBS AG’s audited consolidated financial statements included in the Annual Report 2020. In the opinion of management, all necessary adjustments were made for a fair presentation of UBS AG’s financial position, results of operations and cash flows.
Amendments to IFRS 9, IAS 39 and IFRS 7 (Interest Rate Benchmark Reform – Phase 2)
On 1 January 2021, UBS AG adopted Interest Rate Benchmark Reform – Phase 2, Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16 , addressing a number of issues in financial reporting areas that arise when interbank offered rates (IBORs) are reformed or replaced.
The amendments provide a practical expedient which permits certain changes in the contractual cash flows of debt instruments attributable to the replacement of IBORs with alternative reference rates (ARRs) to be accounted for prospectively by updating the instrument’s effective interest rate (EIR), provided (i) the change is necessary as a direct consequence of IBOR reform and (ii) the new basis for determining the contractual cash flows is economically equivalent to the previous basis.
UBS AG adopted the amendments, which provide a practical expedient with no material effect on the its financial statements.
Preparation of these interim financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, income, expenses and disclosures of contingent assets and liabilities. These estimates and assumptions are based on the best available information. Actual results in the future could differ from such estimates and differences may be material to the financial statements. Revisions to estimates, based on regular reviews, are recognized in the period in which they occur. For more information about areas of estimation uncertainty that are considered to require critical judgment, refer to “Note 1a Significant accounting policies” in the “Consolidated financial statements” section of the Annual Report 2020.
Note 1 Basis of accounting and other financial reporting effects (continued)
Furthermore, the amendments provide various hedge accounting reliefs, with the following expected to benefit UBS AG.
-
Risk components
-
The amendments permit UBS AG to designate an alternative benchmark rate as a non-contractually specified risk component, even if it is not separately identifiable at the date when it is designated, provided UBS AG can reasonably expect that it will meet the requirements within 24 months of the first designation and the risk component is reliably measurable. As of 30 June 2021, the alternative benchmark rates that UBS AG has designated as the hedged risk in fair value hedges of interest rate risk related to debt instruments and cash flow hedges of forecast transactions were the Secured Overnight Financing Rate (SOFR), the Swiss Average Rate Overnight (SARON) and the Sterling Overnight Index Average (SONIA). The designated notionals were USD 11 billion, USD 1.1 billion and USD 0.7 billion, respectively.
-
Hedge designation
Following amendments to the hedge documentation to reflect the change in designation relating to IBOR reform, UBS AG will continue its hedge relationships provided the other hedge accounting criteria and requirements of the phase 2 amendment are met. As of 30 June 2021, no such changes have been made.
- Amounts accumulated in the cash flow hedge reserve Upon changing the hedge designation as set out above, the accumulated amounts in the cash flow hedge reserve are
assumed to be based on the alternative benchmark rate. For discontinued hedging relationships, when the interest rate benchmark on which the hedged future cash flows were based is changed as required by IBOR reform, the amount accumulated in the cash flow hedge reserve is also assumed to be based on the alternative benchmark rate for the purpose of assessing whether the hedged future cash flows are still expected to occur. As of 30 June 2021, no such changes have been made.
- Retrospective effectiveness assessment as applied to hedges designated under IAS 39
Upon the end of the phase 1 relief for effectiveness assessment UBS AG may elect to reset to zero the cumulative fair value changes of the hedged item and hedging instrument for the purpose of assessing the retrospective effectiveness of a hedging relationship. As of 30 June 2021, no such election has been made.
- ›[Refer to “Note 25 Hedge accounting” in the “Consolidated ] financial statements” section of the Annual Report 2020 for details about phase 1 accounting reliefs
The amendments also introduced additional disclosure requirements regarding UBS AG’s management of the transition to alternative benchmark rates, its progress at the reporting date and the risks to which it is exposed arising from financial instruments because of the transition.
- ›[Refer to Note 15 for more information]
Note 2 Segment reporting
UBS AG’s businesses are organized globally into four business divisions: Global Wealth Management, Personal & Corporate Banking, Asset Management and the Investment Bank. All four business divisions are supported by Group Functions and qualify as reportable segments for the purpose of segment reporting. Together with Group Functions they reflect the management structure of UBS AG.
- ›[Refer to “Note 2 Segment reporting” in the “Consolidated ] financial statements” section of the Annual Report 2020 for more information about UBS AG’s reporting segments
| Personal & | ||||||
|---|---|---|---|---|---|---|
| Global Wealth | Corporate | Asset | Investment | Group | ||
| USD million | Management | Banking | Management | Bank | Functions | UBS AG |
| For the six months ended 30 June 2021 | ||||||
| Net interest income | 2,023 | 1,039 | (7) | 244 | (103) | 3,196 |
| Non-interest income | 7,582 | 1,063 | 1,310 | 4,479 | 167 | 14,603 |
| Income | 9,606 | 2,103 | 1,303 | 4,724 | 64 | 17,798 |
| Credit loss(expense)/ release | 16 | 69 | 0 | 23 | (1) | 108 |
| Total operatingincome | 9,622 | 2,172 | 1,303 | 4,747 | 63 | 17,906 |
| Total operatingexpenses | 6,958 | 1,286 | 822 | 3,698 | 511 | 13,274 |
| Operating profit /(loss) before tax | 2,664 | 886 | 481 | 1,049 | (448) | 4,632 |
| Tax expense /(benefit) | 1,001 | |||||
| Netprofit /(loss) | 3,631 | |||||
| As of 30 June 2021 | ||||||
| Total assets | 375,076 | 222,013 | 29,027 | 344,069 | 115,675 | 1,085,861 |
| Personal & | ||||||
| Global Wealth | Corporate | Asset | Investment | Group | ||
| USD million | Management | Banking | Management | Bank | Functions | UBS AG |
| For the six months ended 30 June 2020 | ||||||
| Net interest income | 2,054 | 1,029 | (9) | 3 | (387) | 2,689 |
| Non-interest income | 6,553 | 886 | 1,048 | 4,906 | (20) | 13,372 |
| Income | 8,607 | 1,914 | 1,038 | 4,909 | (407) | 16,061 |
| Credit loss(expense)/ release | (117) | (187) | 0 | (200) | (35) | (540) |
| Total operatingincome | 8,489 | 1,727 | 1,038 | 4,709 | (443) | 15,521 |
| Total operatingexpenses | 6,421 | 1,155 | 724 | 3,419 | 478 | 12,197 |
| Operating profit /(loss) before tax | 2,068 | 573 | 314 | 1,290 | (921) | 3,324 |
| Tax expense /(benefit) | 703 | |||||
| Netprofit /(loss) | 2,621 | |||||
| As of 31 December 2020 | ||||||
| Total assets | 367,714 | 231,710 | 28,266 | 369,778 | 127,858 | 1,125,327 |
Note 3 Net interest income
| Note 3 Net interest income | ||
|---|---|---|
| For thequarter ended | Year-to-date | |
| USD million | 30.6.21 31.3.21 30.6.20 |
30.6.21 30.6.20 |
| Net interest income from financial instruments measured at amortized cost and fair value through other comprehensive income | ||
| Interest income from loans and deposits1 | 1,613 1,586 1,633 |
3,198 3,504 |
| Interest income from securities financingtransactions2 | 126 135 202 |
261 569 |
| Interest income from other financial instruments measured at amortized cost | 68 73 87 |
141 176 |
| Interest income from debt instruments measured at fair value through other comprehensive income | 16 35 35 |
51 52 |
| Interest income from derivative instruments designated as cash flow hedges | 284 268 178 |
553 290 |
| Total interest income from financial instruments measured at amortized cost and fair value through other comprehensive income |
2,107 2,098 2,135 |
4,205 4,591 |
| Interest expense on loans and deposits3 | 415 439 606 |
854 1,499 |
| Interest expense on securities financingtransactions4 | 293 258 224 |
551 443 |
| Interest expense on debt issued | 126 137 256 |
263 523 |
| Interest expense on lease liabilities | 25 26 26 |
51 53 |
| Total interest expense from financial instruments measured at amortized cost | 860 859 1,112 |
1,719 2,519 |
| Total net interest income from financial instruments measured at amortized cost and fair value through other comprehensive income |
1,247 1,239 1,022 |
2,486 2,073 |
| Net interest income from financial instruments measured at fair value through profit or loss | ||
| Net interest income from financial instruments at fair value held for trading | 195 201 244 |
397 446 |
| Net interest income from brokerage balances | 216 197 182 |
412 318 |
| Net interest income from securities financingtransactions at fair value not held for trading5 | 12 12 18 |
24 51 |
| Interest income from other financial instruments at fair value not held for trading | 75 96 153 |
170 355 |
| Interest expense on other financial instruments designated at fair value | (138) (155) (244) |
(294) (555) |
| Total net interest income from financial instruments measured at fair value through profit or loss | 359 351 354 |
710 616 |
| Total net interest income | 1,607 1,589 1,376 |
3,196 2,689 |
1 Consists of interest income from cash and balances at central banks, loans and advances to banks and customers, and cash collateral receivables on derivative instruments, as well as negative interest on amounts due to banks, customer deposits, and cash collateral payables on derivative instruments. 2 Includes interest income on receivables from securities financing transactions and negative interest, including fees, on payables from securities financing transactions. 3 Consists of interest expense on amounts due to banks, cash collateral payables on derivative instruments, customer deposits, and funding from UBS Group AG, as well as negative interest on cash and balances at central banks, loans and advances to banks, and cash collateral receivables on derivative instruments. 4 Includes interest expense on payables from securities financing transactions and negative interest, including fees, on receivables from securities financing transactions. 5 Includes interest expense on securities financing transactions designated at fair value.
Note 4 Net fee and commission income
| For thequarter ended | Year-to-date | |
|---|---|---|
| USD million | 30.6.21 31.3.21 30.6.20 |
30.6.21 30.6.20 |
| Fee and commission income | ||
| Underwriting fees | 393 420 257 |
813 460 |
| of which: equity underwriting fees | 262 275 123 |
537 230 |
| of which: debt underwriting fees | 131 145 133 |
276 230 |
| M&A and corporate finance fees | 330 238 117 |
568 335 |
| Brokerage fees | 1,037 1,358 959 |
2,395 2,204 |
| Investment fund fees | 1,405 1,437 1,197 |
2,842 2,492 |
| Portfolio management and related services | 2,426 2,284 1,813 |
4,710 3,872 |
| Other | 456 461 387 |
917 848 |
| Total fee and commission income1 | 6,047 6,197 4,730 |
12,244 10,211 |
| of which: recurring | 3,823 3,621 2,980 |
7,444 6,321 |
| of which: transaction-based | 2,182 2,482 1,675 |
4,664 3,776 |
| of which: performance-based | 42 94 75 |
136 114 |
| Fee and commission expense | ||
| Brokerage fees paid | 74 68 63 |
142 149 |
| Distribution fees paid | 153 132 144 |
285 300 |
| Other | 258 277 212 |
535 426 |
| Total fee and commission expense | 484 478 419 |
962 875 |
| Net fee and commission income | 5,563 5,719 4,311 |
11,282 9,336 |
| of which: net brokerage fees | 963 1,290 896 |
2,253 2,055 |
1 Reflects third-party fee and commission income for the second quarter of 2021 of USD 3,585 million for Global Wealth Management (first quarter of 2021: USD 3,673 million; second quarter of 2020: USD 2,809 million), USD 400 million for Personal & Corporate Banking (first quarter of 2021: USD 389 million; second quarter of 2020: USD 313 million), USD 805 million for Asset Management (first quarter of 2021: USD 815 million; second quarter of 2020: USD 700 million), USD 1,248 million for the Investment Bank (first quarter of 2021: USD 1,305 million; second quarter of 2020: USD 872 million) and USD 9 million for Group Functions (first quarter of 2021: USD 15 million; second quarter of 2020: USD 36 million).
Note 5 Other income
UBS AG recognized USD 350 million of other income in the second quarter of 2021, compared with USD 153 million in the second quarter of 2020. This includes gains of USD 101 million from properties held for sale, largely driven by the sale of a
property in Basel, and other income of USD 45 million related to a legacy bankruptcy claim. In addition, the investment in Clearstream Fund Centre was sold to Deutsche Börse AG during the quarter, resulting in a USD 37 million net gain.
Note 6 Personnel expenses
| Note 6 Personnel expenses | ||
|---|---|---|
| For thequarter ended | Year-to-date | |
| USD million | 30.6.21 31.3.21 30.6.20 |
30.6.21 30.6.20 |
| Salaries and variable compensation | 2,432 2,370 2,276 |
4,802 4,408 |
| Financial advisor compensation1 | 1,183 1,170 941 |
2,353 2,035 |
| Contractors | 38 36 35 |
75 64 |
| Social security | 187 211 182 |
398 347 |
| Post-employment benefit plans | 1242 194 143 |
319 321 |
| Other personnel expenses | 108 105 104 |
212 217 |
| Total personnel expenses | 4,072 4,086 3,682 |
8,158 7,391 |
1 Financial advisor compensation consists of grid-based compensation based directly on compensable revenues generated by financial advisors and supplemental compensation calculated on the basis of financial advisor productivity, firm tenure, assets and other variables. It also includes expenses related to compensation commitments with financial advisors entered into at the time of recruitment that are subject to vesting requirements. 2 Includes curtailment gains of USD 36 million, which represent a reduction in the defined benefit obligation related to the Swiss pension plan resulting from a decrease in headcount following restructuring activities.
Note 7 General and administrative expenses
| Note 7 General and administrative expenses | ||
|---|---|---|
| For thequarter ended | Year-to-date | |
| USD million | 30.6.21 31.3.21 30.6.20 |
30.6.21 30.6.20 |
| Outsourcing costs | 95 89 99 |
184 211 |
| IT expenses | 122 125 106 |
247 222 |
| Consulting, legal and audit fees | 115 84 137 |
199 269 |
| Real estate and logistics costs | 126 127 134 |
253 271 |
| Market data services | 93 89 89 |
182 175 |
| Marketing & communication | 36 32 25 |
68 56 |
| Travel and entertainment | 12 8 10 |
20 54 |
| Litigation, regulatory & similar matters1 | 63 9 2 |
72 8 |
| Other2 | 1,408 1,578 1,278 |
2,986 2,695 |
| of which: shared services costs charged by UBS Group AG or its subsidiaries | 1,294 1,375 1,127 |
2,669 2,377 |
| of which: UK and German bank levies | (11) 41 3 |
30 17 |
| Total general and administrative expenses | 2,070 2,141 1,879 |
4,211 3,960 |
1 Reflects the net increase in / (release of) provisions for litigation, regulatory and similar matters recognized in the income statement. Refer to Note 16 for more information. 2 Includes charitable donations.
Note 8 Income taxes
Income tax expenses of USD 563 million were recognized for the second quarter of 2021, representing an effective tax rate of 22.7%, compared with USD 328 million for the second quarter of 2020 and an effective tax rate of 21.5%.
Current tax expenses were USD 346 million, compared with USD 329 million, and related to taxable profits of UBS Switzerland AG and other entities.
Deferred tax expenses were USD 217 million, compared with a net deferred tax benefit of USD 1 million, and primarily related to the amortization of deferred tax assets previously recognized in relation to tax losses carried forward and deductible temporary differences of UBS Americas Inc.
Note 9 Expected credit loss measurement
a) Credit loss expense / release
Total net credit loss releases were USD 80 million in the second quarter of 2021, reflecting an USD 88 million net release of credit losses related to stage 1 and 2 positions and USD 8 million of net credit loss expenses related to credit-impaired (stage 3) positions.
The USD 88 million stage 1 and 2 net release included the partial release of a post-model adjustment of USD 91 million (representing one-third of the USD 273 million scenario-driven
model output effects from the third quarter of 2020 to the second quarter of 2021), due to the continued positive trend in macroeconomic scenario input data.
Stage 3 net credit loss expenses were USD 8 million, including USD 3 million net expenses in the Investment Bank and USD 5 million net expenses in Personal & Corporate Banking, across various corporate lending positions.
Credit loss (expense) / release
| Credit loss(expense) / release | ||||||
|---|---|---|---|---|---|---|
| Global | Personal & | |||||
| Wealth | Corporate | Asset | Investment | Group | ||
| USD million | Management | Banking | Management | Bank | Functions | Total |
| For thequarter ended 30.6.21 | ||||||
| Stages 1 and 2 | 13 | 51 | 0 | 24 | (1) | 88 |
| Stage 3 | 0 | (5) | 0 | (3) | 0 | (8) |
| Total credit loss (expense) / release | 14 | 46 | 0 | 21 | (1) | 80 |
Note 9 Expected credit loss measurement (continued)
b) Changes to ECL models, scenarios, scenario weights and key inputs
Scenarios
The expected credit loss (ECL) scenarios, along with the related macroeconomic factors, were updated and reviewed in light of the economic and political conditions prevailing for the second quarter of 2021 through a series of governance meetings, with input and feedback from UBS risk and finance experts across the business divisions and regions. Effective from the second quarter of 2021, management has included an upside scenario and a mild downside scenario in the ECL calculation similar to the approach applied before the COVID-19 pandemic, as uncertainty regarding future economic developments and the related effects on models further decline and post-model adjustment levels decrease.
The upside scenario assumes that positive developments regarding COVID-19 enable economic activity to rebound more quickly than expected, supported by significant improvements in business and consumer activity. Structural changes from the lockdown period and accelerated technology uptake increase productivity and help to keep growth buoyant beyond the initial rebound in activity. Underlying macroeconomic conditions improve, and asset values increase substantially.
The mild downside scenario assumes a shift in sentiment caused by higher-than-expected inflation and the Federal Reserve’s intention to begin tapering its quantitative easing program. Long-term interest rates rise sharply and equities decline as market volatility ensues. Economic activity slows across the globe causing a mild recession.
The baseline and severe downside scenarios included slightly more optimistic assumptions compared with those applied in the first quarter of 2021, reflecting improvements in economic activity, greater optimism regarding the availability and effective distribution of COVID-19 vaccines, and continued government
support. The baseline scenario assumptions on a calendar-year basis are included in the table below.
Scenario weights and post-model adjustments
Management applied the following scenario weightings effective from the second quarter of 2021: upside at 5%, baseline at 55%, mild downside at 10% and severe downside at 30%. This compared with a baseline scenario weighting of 60% and a severe downside scenario weighting of 40% applied in the first quarter of 2021. The incorporation of the two new scenarios and the applied weightings did not have a material effect on allowances and provisions.
In addition, more than one year after the exceptional circumstances of the COVID-19 pandemic began, management has released one-third (USD 91 million) of the USD 273 million post-model adjustment for scenario-driven model output effects into profit or loss in the second quarter of 2021, following a portfolio level review, which supported partial overlay releases, particularly in real estate and large corporate segments. This decision was made following a continued positive trend in macroeconomic scenario input data (from the third quarter of 2020 to the second quarter of 2021), as well as positive vaccination developments and gradual lifting of lockdowns in many economies. Two-thirds of the post-model adjustment for scenario-driven model output effects (USD 183 million) was retained, given the heightened level of uncertainty that remains with regard to the ultimate effects of the crisis. This recognizes that new challenges are frequently arising in the context of the pandemic, for example, the spread of new variants of COVID19, inflationary pressure from supply chain disruption and surging demand, and the risk of potential tail effects as government and central bank support winds down.
| Baseline | |
|---|---|
| Key parameters | 2020 2021 2022 |
| Real GDPgrowth(annualpercentage change) | |
| United States | (3.6) 6.9 5.9 |
| Eurozone | (7.4) 4.3 5.3 |
| Switzerland | (4.5) 3.3 3.0 |
| Unemployment rate(%, annual average) | |
| United States | 8.1 5.4 4.4 |
| Eurozone | 8.5 8.6 8.1 |
| Switzerland | 3.2 3.3 3.1 |
| Real estate(annualpercentage change, Q4) | |
| United States | 3.4 6.5 2.9 |
| Eurozone | (0.3) 2.9 1.0 |
| Switzerland | 4.0 5.0 1.0 |
| Economic scenarios and weights applied | Economic scenarios and weights applied | Economic scenarios and weights applied | Economic scenarios and weights applied |
|---|---|---|---|
ECL scenario |
Assigned weights in % |
||
| 30.6.21 | 31.3.21 | 31.3.20 | |
| Upside | 5.0 | 0.0 | 0.0 |
| Baseline | 55.0 | 60.0 | 70.0 |
| Mild downside | 10.0 | 0.0 | 0.0 |
| Severe downside | 30.0 | 40.0 | 30.0 |
Note 9 Expected credit loss measurement (continued)
c) ECL-relevant balance sheet and off-balance sheet positions including ECL allowances and provisions
The tables below and on the following pages provide information about financial instruments and certain nonfinancial instruments that are subject to ECL requirements. For amortized-cost instruments, the carrying amount represents the maximum exposure to credit risk, taking into account the allowance for credit losses. Financial assets measured at fair value through other comprehensive income (FVOCI) are also subject to ECL; however, unlike amortized-cost instruments, the allowance for credit losses for FVOCI instruments does not
reduce the carrying amount of these financial assets. Instead, the carrying amount of financial assets measured at FVOCI represents the maximum exposure to credit risk.
In addition to on-balance sheet financial assets, certain offbalance sheet and other credit lines are also subject to ECL. The maximum exposure to credit risk for off-balance sheet financial instruments is calculated based on the maximum contractual amounts.
| USD million | 30.6.21 | 30.6.21 |
|---|---|---|
| Carrying amount¹ / Total exposure | ECL allowances /provisions | |
| Financial instruments measured at amortized cost | Total Stage 1 Stage 2 Stage 3 |
Total Stage 1 Stage 2 Stage 3 |
| Cash and balances at central banks | 160,672 160,672 0 0 |
0 0 0 0 |
| Loans and advances to banks | 16,376 16,333 42 0 |
(8) (6) (1) (1) |
| Receivables from securities financingtransactions | 83,494 83,494 0 0 |
(3) (3) 0 0 |
| Cash collateral receivables on derivative instruments | 29,787 29,787 0 0 |
0 0 0 0 |
| Loans and advances to customers | 391,406 371,090 18,403 1,913 |
(950) (124) (156) (670) |
| of which: Private clients with mortgages | 147,827 137,851 9,140 836 |
(139) (26) (76) (37) |
| of which: Real estate financing | 42,627 37,950 4,663 14 |
(49) (17) (32) 0 |
| of which: Large corporate clients | 14,294 12,671 1,229 395 |
(246) (20) (19) (207) |
| of which: SME clients | 14,116 11,753 1,814 549 |
(291) (20) (19) (253) |
| of which: Lombard | 146,167 146,135 0 32 |
(35) (6) 0 (29) |
| of which: Credit cards | 1,611 1,255 327 28 |
(34) (9) (9) (16) |
| of which: Commodity trade finance | 3,399 3,345 38 16 |
(103) (5) 0 (98) |
| Other financial assets measured at amortized cost | 27,201 26,456 436 309 |
(124) (30) (9) (86) |
| of which: Loans to financial advisors | 2,415 1,924 197 295 |
(103) (23) (6) (74) |
| Total financial assets measured at amortized cost | 708,937 687,833 18,882 2,222 |
(1,085) (163) (166) (757) |
| Financial assets measured at fair value through other comprehensive income | 7,775 7,775 0 0 |
0 0 0 0 |
| Total on-balance sheet financial assets in scope of ECL requirements | 716,713 695,609 18,882 2,222 |
(1,085) (163) (166) (757) |
| Off-balance sheet(in scope of ECL) | ||
| Guarantees | 17,457 15,719 1,580 158 |
(52) (15) (9) (27) |
| of which: Large corporate clients | 3,142 1,995 1,035 112 |
(13) (3) (3) (7) |
| of which: SME clients | 1,269 1,002 222 46 |
(13) (1) (1) (12) |
| of which: Financial intermediaries and hedge funds | 7,465 7,257 208 0 |
(16) (10) (5) 0 |
| of which: Lombard | 2,166 2,166 0 0 |
(1) 0 0 (1) |
| of which: Commodity trade finance | 2,372 2,342 30 0 |
(2) (1) 0 (1) |
| Irrevocable loan commitments | 37,751 34,505 3,064 181 |
(118) (69) (49) 0 |
| of which: Large corporate clients | 22,464 19,621 2,718 125 |
(103) (61) (42) 0 |
| Forward startingreverse repurchase and securities borrowingagreements | 8,253 8,253 0 0 |
0 0 0 0 |
| Committed unconditionallyrevocable credit lines | 40,667 37,072 3,526 68 |
(36) (28) (8) 0 |
| of which: Real estate financing | 6,542 6,135 407 0 |
(5) (4) (1) 0 |
| of which: Large corporate clients | 4,383 2,924 1,434 25 |
(7) (4) (3) 0 |
| of which: SME clients | 5,173 4,498 643 32 |
(14) (12) (2) 0 |
| of which: Lombard | 8,632 8,632 0 0 |
0 0 0 0 |
| of which: Credit cards | 9,298 8,825 464 9 |
(6) (5) (2) 0 |
| of which: Commodity trade finance | 251 251 0 0 |
0 0 0 0 |
| Irrevocable committedprolongation of existingloans | 5,281 5,260 20 1 |
(3) (2) (1) 0 |
| Total off-balance sheet financial instruments and other credit lines | 109,409 100,810 8,191 408 |
(209) (114) (67) (27) |
| Total allowances andprovisions | (1,294) (277) (233) (784) |
1 The carrying amount of financial assets measured at amortized cost represents the total gross exposure net of the respective ECL allowances.
Note 9 Expected credit loss measurement (continued)
| USD million | 31.3.21 | 31.3.21 |
|---|---|---|
| Carryingamount¹ / Total exposure | ECL allowances /provisions | |
| Financial instruments measured at amortized cost | Total Stage 1 Stage 2 Stage 3 |
Total Stage 1 Stage 2 Stage 3 |
| Cash and balances at central banks | 158,914 158,914 0 0 |
0 0 0 0 |
| Loans and advances to banks | 18,348 18,287 61 0 |
(12) (8) (3) (1) |
| Receivables from securities financingtransactions | 82,384 82,385 0 0 |
(3) (3) 0 0 |
| Cash collateral receivables on derivative instruments | 35,050 35,050 0 0 |
0 0 0 0 |
| Loans and advances to customers | 380,141 359,130 18,995 2,016 |
(993) (138) (184) (671) |
| of which: Private clients with mortgages | 142,611 132,636 9,118 857 |
(158) (37) (86) (35) |
| of which: Real estate financing | 41,092 36,099 4,979 15 |
(56) (15) (41) 0 |
| of which: Large corporate clients | 13,305 11,155 1,673 477 |
(271) (28) (28) (216) |
| of which: SME clients | 14,034 11,620 1,886 527 |
(283) (19) (19) (246) |
| of which: Lombard | 141,139 141,112 0 27 |
(34) (5) 0 (30) |
| of which: Credit cards | 1,392 1,063 301 28 |
(33) (9) (8) (16) |
| of which: Commodity trade finance | 3,695 3,663 16 15 |
(101) (5) 0 (96) |
| Other financial assets measured at amortized cost | 26,837 26,103 314 420 |
(125) (32) (7) (86) |
| of which: Loans to financial advisors | 2,473 1,961 107 405 |
(104) (26) (4) (75) |
| Total financial assets measured at amortized cost | 701,674 679,868 19,371 2,436 |
(1,133) (180) (195) (758) |
| Financial assets measured at fair value through other comprehensive income | 8,100 8,100 0 0 |
0 0 0 0 |
| Total on-balance sheet financial assets in scope of ECL requirements | 709,774 687,967 19,371 2,436 |
(1,133) (180) (195) (758) |
| Off-balance sheet(in scope of ECL) | ||
| Guarantees | 17,493 15,377 1,952 164 |
(59) (15) (15) (29) |
| of which: Large corporate clients | 3,425 2,025 1,281 119 |
(17) (3) (5) (9) |
| of which: SME clients | 1,243 936 262 45 |
(12) 0 (1) (11) |
| of which: Financial intermediaries and hedge funds | 7,579 7,304 275 0 |
(18) (9) (9) 0 |
| of which: Lombard | 2,136 2,136 0 0 |
(2) 0 0 (1) |
| of which: Commodity trade finance | 2,057 2,031 26 0 |
(4) (1) 0 (3) |
| Irrevocable loan commitments | 38,137 34,312 3,730 95 |
(138) (75) (63) 0 |
| of which: Large corporate clients | 22,943 19,600 3,278 65 |
(121) (68) (54) 0 |
| Forward startingreverse repurchase and securities borrowingagreements | 5,988 5,988 0 0 |
0 0 0 0 |
| Committed unconditionallyrevocable credit lines | 39,835 35,722 4,023 89 |
(45) (27) (18) 0 |
| of which: Real estate financing | 7,227 6,786 432 9 |
(11) (5) (6) 0 |
| of which: Large corporate clients | 4,429 2,713 1,690 25 |
(9) (3) (6) 0 |
| of which: SME clients | 5,036 4,120 878 39 |
(14) (11) (3) 0 |
| of which: Lombard | 8,566 8,566 0 0 |
(1) (1) 0 0 |
| of which: Credit cards | 9,175 8,695 469 11 |
(6) (5) (1) 0 |
| of which: Commodity trade finance | 322 322 0 0 |
0 0 0 0 |
| Irrevocable committedprolongation of existingloans | 5,824 5,785 34 5 |
(3) (3) 0 0 |
| Total off-balance sheet financial instruments and other credit lines | 107,276 97,184 9,738 354 |
(245) (121) (95) (29) |
| Total allowances andprovisions | (1,378) (301) (290) (787) |
1 The carrying amount of financial assets measured at amortized cost represents the total gross exposure net of the respective ECL allowances.
Note 9 Expected credit loss measurement (continued)
| USD million | 31.12.20 | 31.12.20 |
|---|---|---|
| Carryingamount¹ / Total exposure | ECL allowances /provisions | |
| Financial instruments measured at amortized cost | Total Stage 1 Stage 2 Stage 3 |
Total Stage 1 Stage 2 Stage 3 |
| Cash and balances at central banks | 158,231 158,231 0 0 |
0 0 0 0 |
| Loans and advances to banks | 15,344 15,160 184 0 |
(16) (9) (5) (1) |
| Receivables from securities financingtransactions | 74,210 74,210 0 0 |
(2) (2) 0 0 |
| Cash collateral receivables on derivative instruments | 32,737 32,737 0 0 |
0 0 0 0 |
| Loans and advances to customers | 380,977 358,396 20,341 2,240 |
(1,060) (142) (215) (703) |
| of which: Private clients with mortgages | 148,175 138,769 8,448 959 |
(166) (35) (93) (39) |
| of which: Real estate financing | 43,429 37,568 5,838 23 |
(63) (15) (44) (4) |
| of which: Large corporate clients | 15,161 12,658 2,029 474 |
(279) (27) (40) (212) |
| of which: SME clients | 14,872 11,990 2,254 628 |
(310) (19) (23) (268) |
| of which: Lombard | 133,850 133,795 0 55 |
(36) (5) 0 (31) |
| of which: Credit cards | 1,558 1,198 330 30 |
(38) (11) (11) (16) |
| of which: Commodity trade finance | 3,269 3,214 43 12 |
(106) (5) 0 (101) |
| Other financial assets measured at amortized cost | 27,219 26,401 348 469 |
(133) (34) (9) (90) |
| of which: Loans to financial advisors | 2,569 1,982 137 450 |
(108) (27) (5) (76) |
| Total financial assets measured at amortized cost | 688,717 665,135 20,873 2,709 |
(1,211) (187) (229) (795) |
| Financial assets measured at fair value through other comprehensive income | 8,258 8,258 0 0 |
0 0 0 0 |
| Total on-balance sheet financial assets in scope of ECL requirements | 696,976 673,394 20,873 2,709 |
(1,211) (187) (229) (795) |
| Off-balance sheet(in scope of ECL) | ||
| Guarantees | 17,081 14,687 2,225 170 |
(63) (14) (15) (34) |
| of which: Large corporate clients | 3,710 2,048 1,549 113 |
(20) (4) (5) (12) |
| of which: SME clients | 1,310 936 326 48 |
(13) (1) (1) (11) |
| of which: Financial intermediaries and hedge funds | 7,637 7,413 224 0 |
(17) (7) (9) 0 |
| of which: Lombard | 641 633 0 8 |
(2) 0 0 (2) |
| of which: Commodity trade finance | 1,441 1,416 25 0 |
(2) (1) 0 0 |
| Irrevocable loan commitments | 41,372 36,894 4,374 104 |
(142) (74) (68) 0 |
| of which: Large corporate clients | 24,209 20,195 3,950 64 |
(121) (63) (58) 0 |
| Forward startingreverse repurchase and securities borrowingagreements | 3,247 3,247 0 0 |
0 0 0 0 |
| Committed unconditionallyrevocable credit lines | 42,077 37,176 4,792 108 |
(50) (29) (21) 0 |
| of which: Real estate financing | 6,328 5,811 517 0 |
(12) (5) (7) 0 |
| of which: Large corporate clients | 4,909 2,783 2,099 27 |
(9) (2) (7) 0 |
| of which: SME clients | 5,827 4,596 1,169 63 |
(16) (12) (4) 0 |
| of which: Lombard | 9,671 9,671 0 0 |
0 (1) 0 0 |
| of which: Credit cards | 8,661 8,220 430 11 |
(8) (6) (2) 0 |
| of which: Commodity trade finance | 242 242 0 0 |
0 0 0 0 |
| Irrevocable committedprolongation of existingloans | 3,282 3,277 5 0 |
(2) (2) 0 0 |
| Total off-balance sheet financial instruments and other credit lines | 107,059 95,281 11,396 382 |
(257) (119) (104) (34) |
| Total allowances andprovisions | (1,468) (306) (333) (829) |
1 The carrying amount of financial assets measured at amortized cost represents the total gross exposure net of the respective ECL allowances.
Note 9 Expected credit loss measurement (continued)
The table below provides information about the ECL gross exposure and the ECL coverage ratio for our core loan portfolios (i.e., Loans and advances to customers and Loans to financial advisors ) and relevant off-balance sheet exposures. Cash and balances at central banks , Loans and advances to banks , Receivables from securities financing transactions , Cash collateral receivables on derivative instruments and Financial assets
measured at fair value through other comprehensive income are not included in the table below, due to their lower sensitivity to ECL.
ECL coverage ratios are calculated by taking ECL allowances and provisions divided by the gross carrying amount of the exposures.
| Coverage ratios for core loan portfolio | 30.6.21 | 30.6.21 |
|---|---|---|
| Gross carrying amount(USD million) | ECL coverage (bps) | |
| On-balance sheet | Total Stage 1 Stage 2 Stage 3 |
Total Stage 1 Stage 2 Stage 3 |
| Private clients with mortgages | 147,966 137,877 9,216 874 |
9 2 82 427 |
| Real estate financing | 42,677 37,967 4,696 14 |
12 4 69 101 |
| Large corporate clients | 14,540 12,691 1,247 602 |
169 16 151 3,446 |
| SME clients | 14,407 11,772 1,833 802 |
202 17 102 3,152 |
| Lombard | 146,202 146,141 0 61 |
2 0 0 4,698 |
| Credit cards | 1,644 1,264 336 44 |
205 72 261 3,608 |
| Commoditytrade finance | 3,503 3,350 38 114 |
295 15 2 8,605 |
| Other loans and advances to customers | 21,418 20,152 1,193 73 |
25 11 13 4,051 |
| Loans to financial advisors | 2,518 1,946 202 369 |
408 116 290 2,016 |
| Total1 | 394,875 373,161 18,762 2,952 |
27 4 86 2,521 |
| Gross exposure(USD million) | ECL coverage (bps) | |
| Off-balance sheet | Total Stage 1 Stage 2 Stage 3 |
Total Stage 1 Stage 2 Stage 3 |
| Private clients with mortgages | 8,063 7,809 251 3 |
4 4 7 349 |
| Real estate financing | 8,048 7,596 452 0 |
9 7 49 0 |
| Large corporate clients | 29,990 24,540 5,187 262 |
41 27 91 278 |
| SME clients | 8,273 7,099 1,040 134 |
43 20 91 878 |
| Lombard | 14,736 14,735 0 0 |
1 0 0 0 |
| Credit cards | 9,298 8,825 464 9 |
7 5 33 0 |
| Commoditytrade finance | 2,623 2,593 30 0 |
8 5 50 0 |
| Financial intermediaries and hedge funds | 12,447 11,981 466 0 |
14 10 120 0 |
| Other off-balance sheet commitments | 7,678 7,377 301 0 |
17 8 21 0 |
| Total2 | 101,155 92,556 8,191 408 |
21 12 82 671 |
1 Includes Loans and advances to customers of USD 392,357 million and Loans to financial advisors of USD 2,518 million, which are presented on the balance sheet line Other assets measured at amortized cost. 2 Excludes Forward starting reverse repurchase and securities borrowing agreements.
Note 9 Expected credit loss measurement (continued)
| Coverage ratios for core loan portfolio | 31.3.21 | 31.3.21 |
|---|---|---|
| Gross carryingamount(USD million) | ECL coverage(bps) | |
| On-balance sheet | Total Stage 1 Stage 2 Stage 3 |
Total Stage 1 Stage 2 Stage 3 |
| Private clients with mortgages | 142,770 132,673 9,204 893 |
11 3 93 396 |
| Real estate financing | 41,148 36,113 5,020 15 |
14 4 81 78 |
| Large corporate clients | 13,577 11,184 1,701 692 |
200 25 162 3,114 |
| SME clients | 14,317 11,639 1,905 773 |
198 16 98 3,179 |
| Lombard | 141,173 141,117 0 56 |
2 0 0 5,260 |
| Credit cards | 1,425 1,073 309 44 |
233 88 266 3,555 |
| Commoditytrade finance | 3,796 3,668 16 111 |
267 14 2 8,620 |
| Other loans and advances to customers | 22,928 21,801 1,024 103 |
24 9 26 3,211 |
| Loans to financial advisors | 2,578 1,987 111 480 |
405 131 337 1,558 |
| Total1 | 383,711 361,254 19,290 3,167 |
29 5 97 2,355 |
| Gross exposure(USD million) | ECL coverage(bps) | |
| Off-balance sheet | Total Stage 1 Stage 2 Stage 3 |
Total Stage 1 Stage 2 Stage 3 |
| Private clients with mortgages | 7,455 7,226 217 13 |
6 5 16 111 |
| Real estate financing | 8,513 8,049 455 9 |
17 7 192 53 |
| Large corporate clients | 30,796 24,339 6,249 209 |
48 31 102 422 |
| SME clients | 8,101 6,626 1,367 108 |
41 20 70 973 |
| Lombard | 14,603 14,603 0 0 |
2 1 0 0 |
| Credit cards | 9,175 8,695 469 11 |
7 6 30 0 |
| Commoditytrade finance | 2,379 2,352 26 0 |
18 5 28 0 |
| Financial intermediaries and hedge funds | 11,501 10,879 622 0 |
18 10 169 0 |
| Other off-balance sheet commitments | 8,764 8,428 332 4 |
14 7 23 0 |
| Total2 | 101,288 91,196 9,738 354 |
24 13 98 831 |
1 Includes Loans and advances to customers of USD 381,133 million and Loans to financial advisors of USD 2,578 million, which are presented on the balance sheet line Other assets measured at amortized cost. 2 Excludes Forward starting reverse repurchase and securities borrowing agreements.
Note 9 Expected credit loss measurement (continued)
| Coverage ratios for core loan portfolio | 31.12.20 | 31.12.20 |
|---|---|---|
| Gross carryingamount(USD million) | ECL coverage(bps) | |
| On-balance sheet | Total Stage 1 Stage 2 Stage 3 |
Total Stage 1 Stage 2 Stage 3 |
| Private clients with mortgages | 148,341 138,803 8,540 998 |
11 2 108 390 |
| Real estate financing | 43,492 37,583 5,883 27 |
15 4 75 1,414 |
| Large corporate clients | 15,440 12,684 2,069 686 |
181 21 192 3,089 |
| SME clients | 15,183 12,010 2,277 896 |
204 16 101 2,991 |
| Lombard | 133,886 133,800 0 86 |
3 0 0 3,592 |
| Credit cards | 1,596 1,209 342 46 |
240 91 333 3,488 |
| Commoditytrade finance | 3,375 3,219 43 113 |
315 16 2 8,939 |
| Other loans and advances to customers | 20,722 19,229 1,402 91 |
29 13 25 3,563 |
| Loans to financial advisors | 2,677 2,009 142 526 |
404 135 351 1,446 |
| Total1 | 384,714 360,547 20,697 3,470 |
30 5 106 2,247 |
| Gross exposure(USD million) | ECL coverage(bps) | |
| Off-balance sheet | Total Stage 1 Stage 2 Stage 3 |
Total Stage 1 Stage 2 Stage 3 |
| Private clients with mortgages | 6,285 6,083 198 3 |
7 6 16 197 |
| Real estate financing | 7,056 6,576 481 0 |
21 9 185 0 |
| Large corporate clients | 32,828 25,026 7,598 205 |
46 27 92 565 |
| SME clients | 9,121 7,239 1,734 148 |
40 19 63 779 |
| Lombard | 14,178 14,170 0 8 |
2 1 0 1,941 |
| Credit cards | 8,661 8,220 430 11 |
9 8 44 0 |
| Commoditytrade finance | 1,683 1,658 25 0 |
10 8 15 0 |
| Financial intermediaries and hedge funds | 7,690 7,270 448 0 |
26 13 248 166 |
| Other off-balance sheet commitments | 16,309 15,792 482 8 |
12 6 11 0 |
| Total2 | 103,812 92,034 11,396 382 |
25 13 91 894 |
1 Includes Loans and advances to customers of USD 382,036 million and Loans to financial advisors of USD 2,677 million which are presented on the balance sheet line Other assets measured at amortized cost.
2 Excludes Forward starting reverse repurchase and securities borrowing agreements.
Note 10 Fair value measurement
This Note provides fair value measurement information for both financial and non-financial instruments and should be read in conjunction with “Note 21 Fair value measurement” in the “Consolidated financial statements” section of the Annual Report 2020, which provides more information about valuation principles, valuation governance, fair value hierarchy classification, valuation adjustments, valuation techniques and inputs, sensitivity of fair value measurements, and methods applied to calculate fair values for financial instruments not measured at fair value.
- ›[Refer to the “Balance sheet and off-balance sheet” section of ] this report for more information about quarter-on-quarter balance sheet movements
All financial and non-financial assets and liabilities measured or disclosed at fair value are categorized into one of three fair value hierarchy levels. In certain cases, the inputs used to measure fair value may fall within different levels of the fair value hierarchy. For disclosure purposes, the level in the hierarchy within which the instrument is classified in its entirety is based on the lowest-level input that is significant to the position’s fair value measurement:
-
Level 1 – quoted prices (unadjusted) in active markets for identical assets and liabilities;
-
Level 2 – valuation techniques for which all significant inputs are, or are based on, observable market data; or
-
Level 3 – valuation techniques for which significant inputs are not based on observable market data.
Note 10 Fair value measurement (continued)
a) Fair value hierarchy
The fair value hierarchy classification of financial and non-financial assets and liabilities measured at fair value is summarized in the table below.
| Determination of fair values from quoted market prices or valuation techniques1 | Determination of fair values from quoted market prices or valuation techniques1 | Determination of fair values from quoted market prices or valuation techniques1 |
|---|---|---|
| 30.6.21 | 31.3.21 31.12.20 |
|
| USD million | Level 1 Level 2 Level 3 Total |
Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total |
| Financial assets measured at fair value on a recurring basis | ||
| Financial assets at fair value held for trading 103,722 16,782 2,123 122,628 |
101,907 16,630 2,179 120,717 107,526 15,630 2,337 125,492 |
|
| of which: | ||
| Equity instruments 86,760 1,336 128 88,224 |
85,251 736 137 86,124 90,327 1,101 171 91,599 |
|
| Government bills / bonds 8,123 1,776 10 9,910 |
8,384 1,890 10 10,284 9,028 2,207 10 11,245 |
|
| Investment fund units 8,048 1,707 18 9,773 |
7,400 1,602 31 9,033 7,374 1,794 23 9,192 |
|
| Corporate and municipal bonds 784 8,524 821 10,129 |
865 9,926 783 11,575 789 8,432 817 10,038 |
|
| Loans 0 3,115 1,000 4,114 |
0 2,234 1,052 3,285 0 1,860 1,134 2,995 |
|
| Asset-backed securities 7 323 147 478 |
6 242 166 415 8 236 181 425 |
|
| Derivative financial instruments 795 119,348 1,479 121,622 |
1,142 145,508 1,633 148,284 795 157,069 1,754 159,618 |
|
| of which: | ||
| Foreign exchange contracts 296 49,154 6 49,456 |
459 70,221 12 70,692 319 68,425 5 68,750 |
|
| Interest rate contracts 0 38,104 342 38,446 |
0 39,529 391 39,920 0 50,353 537 50,890 |
|
| Equity / index contracts 1 28,383 801 29,185 |
0 31,369 820 32,189 0 33,990 853 34,842 |
|
| Credit derivative contracts 0 1,739 303 2,043 |
0 1,914 395 2,309 0 2,008 350 2,358 |
|
| Commodity contracts 0 1,832 24 1,856 |
0 2,187 14 2,201 0 2,211 6 2,217 |
|
| Brokerage receivables 0 23,010 0 23,010 |
0 24,201 0 24,201 0 24,659 0 24,659 |
|
| Financial assets at fair value not held for trading 29,125 31,367 4,459 64,952 |
31,596 32,962 4,206 68,763 40,986 35,110 3,942 80,038 |
|
| of which: | ||
| Financial assets for unit-linked investment contracts 21,974 9 8 21,991 |
21,162 0 3 21,166 20,628 101 2 20,731 |
|
| Corporate and municipal bonds 88 16,009 333 16,430 |
98 15,114 334 15,547 290 16,957 372 17,619 |
|
| Government bills / bonds 6,640 3,331 0 9,971 |
9,985 3,970 0 13,956 19,704 3,593 0 23,297 |
|
| Loans 0 5,626 1,087 6,712 |
0 6,900 1,093 7,993 0 7,699 862 8,561 |
|
| Securities financing transactions 0 6,203 201 6,404 |
0 6,811 119 6,930 0 6,629 122 6,751 |
|
| Auction rate securities 0 0 1,563 1,563 |
0 0 1,587 1,587 0 0 1,527 1,527 |
|
| Investment fund units 317 172 120 610 |
263 165 99 528 278 121 105 505 |
|
| Equity instruments 105 18 594 717 |
86 0 530 616 86 0 544 631 |
|
| Other 0 0 554 554 |
0 0 441 441 0 10 408 418 |
|
| Financial assets measured at fair value through other comprehensive income on a recurring basis | ||
| Financial assets measured at fair value through other comprehensive income 2,165 5,611 0 7,775 |
2,154 5,946 0 8,100 1,144 7,114 0 8,258 |
|
| of which: | ||
| Asset-backed securities 0 5,200 0 5,200 |
0 5,480 0 5,480 0 6,624 0 6,624 |
|
| Government bills / bonds 2,121 44 0 2,165 |
2,115 43 0 2,159 1,103 47 0 1,150 |
|
| Corporate and municipal bonds 44 367 0 411 |
38 423 0 461 40 444 0 485 |
|
| Non-financial assets measured at fair value on a recurring basis | ||
| Precious metals and otherphysical commodities 5,470 0 0 5,470 |
5,709 0 0 5,709 6,264 0 0 6,264 |
|
| Non-financial assets measured at fair value on a non-recurring basis | ||
| Other non-financial assets2 0 1 67 68 |
0 1 247 248 0 1 245 246 |
|
| Total assets measured at fair value 141,277 196,119 8,129 345,525 |
142,508 225,248 8,266 376,022 156,716 239,583 8,278 404,576 |
Note 10 Fair value measurement (continued)
| Determination of fair values fromquoted marketprices or valuation techniques(continued)1 | Determination of fair values fromquoted marketprices or valuation techniques(continued)1 | Determination of fair values fromquoted marketprices or valuation techniques(continued)1 |
|---|---|---|
| USD million | 30.6.21 | 31.3.21 31.12.20 |
| Level 1 Level 2 Level 3 Total |
Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total |
|
| Financial liabilities measured at fair value on a recurring basis | ||
| Financial liabilities at fair value held for trading 27,038 6,216 94 33,348 |
30,888 6,114 61 37,062 26,889 6,652 55 33,595 |
|
| of which: | ||
| Equity instruments 20,826 387 75 21,288 |
26,191 151 50 26,392 22,519 425 40 22,985 |
|
| Corporate and municipal bonds 37 4,592 13 4,642 |
32 4,718 7 4,757 31 4,048 9 4,089 |
|
| Government bills / bonds 5,727 620 0 6,347 |
4,168 807 0 4,975 3,642 1,036 0 4,678 |
|
| Investment fund units 442 581 6 1,028 |
492 397 3 891 696 1,127 5 1,828 |
|
| Derivative financial instruments 754 117,985 2,950 121,688 |
1,405 141,522 3,114 146,041 746 156,884 3,471 161,102 |
|
| of which: | ||
| Foreign exchange contracts 280 47,050 59 47,389 |
541 67,047 54 67,642 316 70,149 61 70,527 |
|
| Interest rate contracts 0 32,177 526 32,703 |
0 33,501 546 34,046 0 43,389 527 43,916 |
|
| Equity / index contracts 9 34,431 1,902 36,342 |
0 36,614 2,070 38,684 0 38,870 2,306 41,176 |
|
| Credit derivative contracts 0 2,000 392 2,392 |
0 2,139 369 2,508 0 2,403 528 2,931 |
|
| Commodity contracts 0 2,034 51 2,085 |
0 1,907 59 1,966 0 2,003 24 2,027 |
|
| Financial liabilities designated at fair value on a recurring basis | ||
| Brokeragepayables designated at fair value 0 39,129 0 39,129 |
0 45,600 0 45,600 0 38,742 0 38,742 |
|
| Debt issued designated at fair value 0 60,321 12,478 72,799 |
0 53,900 10,736 64,635 0 50,273 9,595 59,868 |
|
| Other financial liabilities designated at fair value 0 30,032 2,876 32,908 |
0 28,317 2,452 30,769 0 29,682 2,091 31,773 |
|
| of which: | ||
| Financial liabilities related to unit-linked investment contracts 0 22,217 0 22,217 |
0 21,357 0 21,357 0 20,975 0 20,975 |
|
| Securities financing transactions 0 6,181 3 6,184 |
0 5,651 0 5,651 0 7,317 0 7,317 |
|
| Over-the-counter debt instruments 0 1,550 592 2,142 |
0 1,261 526 1,787 0 1,363 697 2,060 |
|
| Total liabilities measured at fair value 27,792 253,682 18,398 299,871 |
32,293 275,453 16,362 324,108 27,635 282,233 15,212 325,080 |
1 Bifurcated embedded derivatives are presented on the same balance sheet lines as their host contracts and are not included in this table. The fair value of these derivatives was not material for the periods presented. 2 Other non-financial assets primarily consist of properties and other non-current assets held for sale, which are measured at the lower of their net carrying amount or fair value less costs to sell.
b) Valuation adjustments and other items
The table below summarizes the valuation adjustment reserves recognized on the balance sheet. Details about each category are provided further below.
Valuation adjustment reserves on the balance sheet
| Valuation adjustment reserves on the balance sheet | |
|---|---|
| As of | |
| Life-to-dategain / (loss), USD million | 30.6.21 31.3.21 31.12.20 |
| Deferred day-1 profit or loss reserves | 405 387 269 |
| Own credit adjustments on financial liabilities designated at fair value | (278) (400) (381) |
| CVAs, FVAs, DVAs and other valuation adjustments | (956) (977) (959) |
Deferred day-1 profit or loss reserves
The table below summarizes the changes in deferred day-1 profit or loss reserves during the relevant period.
Deferred day-1 profit or loss is generally released into Other net income from financial instruments measured at fair value through profit or loss when pricing of equivalent products or the underlying parameters become observable or when the transaction is closed out.
Deferred day-1 profit or loss reserves
| Deferred day-1profit or loss reserves | ||
|---|---|---|
| For thequarter ended | Year-to-date | |
| USD million | 30.6.21 31.3.21 30.6.20 |
30.6.21 30.6.20 |
| Reserve balance at the beginning of theperiod | 387 269 194 |
269 146 |
| Profit /(loss)deferred on new transactions | 97 181 121 |
278 239 |
| (Profit)/ loss recognized in the income statement | (79) (63) (72) |
(142) (141) |
| Foreign currencytranslation | 0 (1) 0 |
(1) (1) |
| Reserve balance at the end of theperiod | 405 387 243 |
405 243 |
Note 10 Fair value measurement (continued)
Own credit
The valuation of financial liabilities designated at fair value requires consideration of the own credit component of fair value. Own credit risk is reflected in the valuation of UBS’s fair value option liabilities where this component is considered relevant for valuation purposes by UBS’s counterparties and other market participants. However, own credit risk is not reflected in the valuation of UBS’s liabilities that are fully collateralized or for other obligations for which it is established market practice to not include an own credit component.
A description of UBS’s methodology to estimate own credit and the related accounting principles is included in “Note 21 Fair value measurement” in the “Consolidated financial statements” section of the Annual Report 2020.
In the second quarter of 2021, other comprehensive income related to own credit on financial liabilities designated at fair value was positive USD 118 million, primarily due to a widening of UBS’s credit spreads.
Own credit adjustments on financial liabilities designated at fair value
| Own credit adjustments on financial liabilities designated at fair value | ||
|---|---|---|
| Included in Other comprehensive income | ||
| For thequarter ended | Year-to-date | |
| USD million | 30.6.21 31.3.21 30.6.20 |
30.6.21 30.6.20 |
| Recognized during the period: | ||
| Realized gain / (loss) | (5) (6) 8 |
(11) 9 |
| Unrealizedgain / (loss) | 123 (23) (1,103) |
100 53 |
| Total gain / (loss), before tax | 118 (29) (1,095) |
89 62 |
| As of | ||
| USD million | 30.6.21 31.3.21 30.6.20 |
|
| Recognized on the balance sheet as of the end of the period: | ||
| Unrealized life-to-date gain / (loss) | (278) (400) (31) |
Credit, funding, debit and other valuation adjustments A description of UBS’s methodology for estimating credit valuation adjustments (CVAs), funding valuation adjustments (FVAs), debit valuation adjustments (DVAs) and other valuation adjustments is included in “Note 21 Fair value measurement” in the “Consolidated financial statements” section of the Annual Report 2020.
In the second quarter of 2021, other valuation adjustments for liquidity decreased, primarily due to lower observed levels of risk across portfolios during the quarter.
Valuation adjustments on financial instruments
| Valuation adjustments on financial instruments | |
|---|---|
| As of 30.6.21 31.3.21 31.12.20 |
|
| Life-to-dategain / (loss), USD million | |
| Credit valuation adjustments1 | (51) (53) (66) |
| Funding valuation adjustments | (58) (58) (73) |
| Debit valuation adjustments | 1 1 0 |
| Other valuation adjustments | (848) (867) (820) |
| of which: liquidity | (327) (356) (340) |
| of which: model uncertainty | (521) (511) (479) |
1 Amounts do not include reserves against defaulted counterparties.
c) Transfers between Level 1 and Level 2
During the first six months of 2021, assets and liabilities transferred from Level 2 to Level 1, or from Level 1 to Level 2, that were held for the entire reporting period, were not material.
Note 10 Fair value measurement (continued)
d) Level 3 instruments: valuation techniques and inputs
The table below presents material Level 3 assets and liabilities, together with the valuation techniques used to measure fair value, the inputs used in a given valuation technique that are considered significant as of 30 June 2021 and unobservable, and a range of values for those unobservable inputs.
The range of values represents the highest- and lowest-level inputs used in the valuation techniques. Therefore the range does not reflect the level of uncertainty regarding a particular input or an assessment of the reasonableness of UBS´s estimates and assumptions, but rather the different underlying characteristics of the relevant assets and liabilities held by UBS. The ranges will therefore vary from period to period and parameter to parameter based on characteristics of the instruments held at each balance
sheet date. Furthermore, the ranges of unobservable inputs may differ across other financial institutions, reflecting the diversity of the products in each firm’s inventory.
The significant unobservable inputs disclosed in the table below are consistent with those included in “Note 21 Fair value measurement” in the “Consolidated financial statements” section of the Annual Report 2020. A description of the potential effect that a change in each unobservable input in isolation may have on a fair value measurement, including information to facilitate an understanding of factors that give rise to the input ranges shown, is also provided in “Note 21 Fair value measurement” in the “Consolidated financial statements” section of the Annual Report 2020.
Valuation techniques and inputs used in the fair value measurement of Level 3 assets and liabilities
| USD billion | Fair value Assets Liabilities 30.6.21 31.12.20 30.6.21 31.12.20 Valuation technique(s) Significant unobservable input(s)1 |
Range of inputs | Range of inputs |
|---|---|---|---|
| Assets | 30.6.21 | 31.12.20 low high weighted average2 unit1 |
|
| 30.6.21 31.12.20 |
low high weighted average2 |
||
| Financial assets and liabilities at fair value held for trading and Financial assets at fair value not held for trading | |||
| Corporate and municipal bonds 1.2 1.2 0.0 0.0 Relative value to market comparable Bondprice equivalent |
15 143 100 |
1 143 100 points |
|
| Discounted expected cash flows Discount margin |
358 358 |
268 268 basis points |
|
| Traded loans, loans measured at fair value, loan commitments and guarantees 2.6 2.4 0.0 0.0 Relative value to market comparable Loanprice equivalent |
1 101 99 |
0 101 99 points |
|
| Discounted expected cash flows Credit spread |
180 800 |
190 800 basis points |
|
| Market comparable and securitization model Credit spread |
28 1,55 8 228 |
40 1,85 8 333 basis points |
|
| Auction rate securities 1.6 1.5 Discounted expected cash flows Credit spread |
115 222 162 |
100 188 140 basis points |
|
| Investment fund units 3 0.1 0.1 0.0 0.0 Relative value to market comparable Net asset value |
|||
| Equity instruments 3 0.7 0.7 0.1 0.0 Relative value to market comparable Price |
|||
| Debt issued designated at fair value4 12.5 9.6 |
|||
| Other financial liabilities designated at fair value 2.9 2.1 Discounted expected cash flows Fundingspread |
35 175 |
42 175 basis points |
|
| Derivative financial instruments | |||
| Interest rate contracts 0.3 0.5 0.5 0.5 Option model Volatilityof interest rates |
49 73 |
29 69 basis points |
|
| Credit derivative contracts 0.3 0.3 0.4 0.5 Discounted expected cash flows Credit spreads |
2 496 |
1 489 basis points |
|
| Bondprice equivalent | 3 102 |
0 100 points |
|
| Equity / index contracts 0.8 0.9 1.9 2.3 Option model Equitydividendyields |
0 11 |
0 13 % |
|
| Volatility of equity stocks, equityand other indices |
4 99 |
4 100 % |
|
| Equity-to-FX correlation | (30) 70 |
(34) 65 % |
|
| Equity-to-equity correlation |
(25) 99 |
(16) 100 % |
1 The ranges of significant unobservable inputs are represented in points, percentages and basis points. Points are a percentage of par (e.g., 100 points would be 100% of par). 2 Weighted averages are provided for non-derivative financial instruments and were calculated by weighting inputs based on the fair values of the respective instruments. Weighted averages are not provided for inputs related to derivative contracts, as this would not be meaningful. 3 The range of inputs is not disclosed, as there is a dispersion of values given the diverse nature of the investments. 4 Debt issued designated at fair value is composed primarily of UBS structured notes, which include variable maturity notes with various equity and foreign exchange underlying risks, rates-linked and credit-linked notes, all of which have embedded derivative parameters that are considered to be unobservable. The equivalent derivative instrument parameters are presented in the respective derivative financial instruments lines in this table.
Note 10 Fair value measurement (continued)
e) Level 3 instruments: sensitivity to changes in unobservable input assumptions
The table below summarizes those financial assets and liabilities classified as Level 3 for which a change in one or more of the unobservable inputs to reflect reasonably possible alternative assumptions would change fair value significantly, and the estimated effect thereof. The table presents the favorable and unfavorable effects for each class of financial assets and liabilities for which the potential change in fair value is considered significant. The sensitivity of fair value measurements for debt issued designated at fair value and over-the-counter debt instruments designated at fair value is reported together with the equivalent derivative or securities financing instrument.
The sensitivity data shown below presents an estimation of valuation uncertainty based on reasonably possible alternative values for Level 3 inputs at the balance sheet date and does not represent the estimated effect of stress scenarios. Typically, these financial assets and liabilities are sensitive to a combination of inputs from Levels 1–3. Although well-defined interdependencies may exist between Levels 1–2 and Level 3 parameters (e.g., between interest rates, which are generally Level 1 or Level 2, and prepayments, which are generally Level 3), these have not been incorporated in the table. Furthermore, direct interrelationships between the Level 3 parameters are not a significant element of the valuation uncertainty.
Sensitivity of fair value measurements to changes in unobservable input assumptions
| 30.6.21 | 31.3.21 | 31.12.20 | |
|---|---|---|---|
| USD million | Favorable changes Unfavorable changes |
Favorable changes Unfavorable changes |
Favorable changes Unfavorable changes |
| Traded loans, loans designated at fair value, loan commitments and guarantees | 22 (13) |
26 (21) |
29 (28) |
| Securities financing transactions | 69 (68) |
71 (51) |
40 (52) |
| Auction rate securities | 114 (114) |
88 (88) |
105 (105) |
| Asset-backed securities | 48 (34) |
50 (40) |
41 (41) |
| Equity instruments | 150 (120) |
127 (99) |
129 (96) |
| Interest rate derivative contracts, net | 25 (14) |
38 (23) |
11 (16) |
| Credit derivative contracts, net | 8 (10) |
10 (10) |
10 (14) |
| Foreign exchange derivative contracts, net | 15 (9) |
17 (11) |
20 (15) |
| Equity / index derivative contracts, net | 344 (324) |
358 (344) |
318 (294) |
| Other | 58 (77) |
77 (92) |
91 (107) |
| Total | 852 (782) |
861 (779) |
794 (768) |
f) Level 3 instruments: movements during the period
Significant changes in Level 3 instruments
The table on the following pages presents additional information about material Level 3 assets and liabilities measured at fair value on a recurring basis. Level 3 assets and liabilities may be hedged with instruments classified as Level 1 or Level 2 in the fair value hierarchy and, as a result, realized and unrealized gains and losses included in the table may not include the effect of related hedging activity. Furthermore, the realized and
unrealized gains and losses presented in the table are not limited solely to those arising from Level 3 inputs, as valuations are generally derived from both observable and unobservable parameters.
Assets and liabilities transferred into or out of Level 3 are presented as if those assets or liabilities had been transferred at the beginning of the year.
Note 10 Fair value measurement (continued)
Movements of Level 3 instruments
| Total gains / losses | Total gains / losses | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| included in | |||||||||||
| comprehensive income | |||||||||||
| of which: | |||||||||||
| related to | |||||||||||
| Level 3 | |||||||||||
| instruments | |||||||||||
| Balance | Net gains / | held at the | Balance | ||||||||
| as of | losses | end of the | Transfers | Transfers | Foreign | as of | |||||
| 31 December | included in | reporting | into | out of | currency | 30 June | |||||
| USD billion | 2019 | income1 | period | Purchases | Sales | Issuances | Settlements | Level 3 | Level 3 | translation | 2020 |
| Financial assets at fair value held for | |||||||||||
| trading | 1.8 | (0.1) | 0.0 | 0.3 | (1.0) | 1.4 | 0.0 | 0.3 | 0.0 | 0.0 | 2.7 |
| of which: | |||||||||||
| Investment fund units | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Corporate and municipal bonds | 0.5 | 0.0 | 0.0 | 0.2 | (0.2) | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.8 |
| Loans | 0.8 | 0.0 | 0.0 | 0.0 | (0.6) | 1.4 | 0.0 | 0.0 | 0.0 | 0.0 | 1.6 |
| Other | 0.4 | 0.0 | 0.0 | 0.0 | (0.2) | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.3 |
| Derivative financial instruments – | |||||||||||
| assets | 1.3 | 0.3 | 0.4 | 0.0 | 0.0 | 0.5 | (0.5) | 0.0 | (0.1) | 0.0 | 1.5 |
| of which: | |||||||||||
| Interest rate contracts | 0.3 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | (0.2) | 0.0 | 0.0 | 0.0 | 0.3 |
| Equity / index contracts | 0.6 | 0.0 | 0.1 | 0.0 | 0.0 | 0.5 | (0.2) | 0.0 | (0.1) | 0.0 | 0.8 |
| Credit derivative contracts | 0.4 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | (0.2) | 0.0 | 0.0 | 0.0 | 0.4 |
| Other | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Financial assets at fair value not held | |||||||||||
| for trading | 4.0 | (0.1) | (0.1) | 0.5 | (0.6) | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 3.7 |
| of which: | |||||||||||
| Loans | 1.2 | 0.0 | 0.0 | 0.4 | (0.5) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.0 |
| Auction rate securities | 1.5 | (0.1) | (0.1) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.4 |
| Equity instruments | 0.5 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.5 |
| Other | 0.7 | 0.0 | 0.0 | 0.1 | (0.1) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.8 |
| Derivative financial instruments – | |||||||||||
| liabilities | 2.0 | 1.2 | 1.1 | 0.0 | 0.0 | 0.5 | (0.8) | 0.6 | (0.3) | 0.0 | 3.3 |
| of which: | |||||||||||
| Interest rate contracts | 0.1 | 0.7 | 0.7 | 0.0 | 0.0 | 0.0 | (0.3) | 0.3 | 0.0 | 0.0 | 0.8 |
| Equity / index contracts | 1.3 | 0.2 | 0.2 | 0.0 | 0.0 | 0.5 | (0.4) | 0.0 | (0.2) | 0.0 | 1.4 |
| Credit derivative contracts | 0.5 | 0.3 | 0.3 | 0.0 | 0.0 | 0.1 | (0.1) | 0.3 | (0.1) | 0.0 | 0.9 |
| Other | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 |
| Debt issued designated at fair value | 9.6 | 0.1 | 0.2 | 0.0 | 0.0 | 2.9 | (3.5) | 0.4 | (1.0) | 0.0 | 8.5 |
| Other financial liabilities designated | |||||||||||
| at fair value | 1.0 | 0.1 | 0.1 | 0.0 | 0.0 | 1.5 | (0.3) | 0.0 | 0.0 | 0.0 | 2.4 |
1 Net gains / losses included in comprehensive income are composed of Net interest income, Other net income from financial instruments measured at fair value through profit or loss and Other income. 2 Total Level 3 assets as of 30 June 2021 were USD 8.1 billion (31 December 2020: USD 8.3 billion). Total Level 3 liabilities as of 30 June 2021 were USD 18.4 billion (31 December 2020: USD 15.2 billion).
Note 10 Fair value measurement (continued)
| Total gains / losses | Total gains / losses | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| included in | |||||||||||
| comprehensive income | |||||||||||
| of which: | |||||||||||
| related to | |||||||||||
| Level 3 | |||||||||||
| instruments | |||||||||||
| Balance | Net gains / | held at the | Balance | ||||||||
| as of | losses | end of the | Transfers | Transfers | Foreign | as of | |||||
| 31 | December | included in | reporting | into | out of | currency | 30 June | ||||
| 20202 | income1 | period | Purchases | Sales | Issuances | Settlements | Level 3 | Level 3 | translation | 20212 | |
| 2.3 | 0.0 | 0.0 | 0.3 | (0.8) | 0.4 | 0.0 | 0.2 | (0.2) | 0.0 | 2.1 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| 0.8 | 0.0 | 0.0 | 0.1 | (0.1) | 0.0 | 0.0 | 0.0 | (0.1) | 0.0 | 0.8 | |
| 1.1 | 0.0 | 0.0 | 0.1 | (0.5) | 0.4 | 0.0 | 0.0 | (0.2) | 0.0 | 1.0 | |
| 0.4 | (0.1) | (0.1) | 0.0 | (0.2) | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.3 | |
| 1.8 | (0.2) | (0.1) | 0.0 | 0.0 | 0.5 | (0.4) | 0.0 | (0.1) | 0.0 | 1.5 | |
| 0.5 | (0.1) | (0.1) | 0.0 | 0.0 | 0.0 | (0.1) | 0.0 | 0.0 | 0.0 | 0.3 | |
| 0.9 | 0.1 | 0.1 | 0.0 | 0.0 | 0.3 | (0.4) | 0.0 | (0.1) | 0.0 | 0.8 | |
| 0.3 | (0.1) | (0.1) | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| 3.9 | 0.1 | 0.1 | 0.7 | (0.3) | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 4.5 | |
| 0.9 | 0.0 | 0.0 | 0.4 | (0.1) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.1 | |
| 1.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.6 | |
| 0.5 | 0.1 | 0.1 | 0.1 | (0.1) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.6 | |
| 1.0 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.2 | |
| 3.5 | 0.2 | 0.0 | 0.0 | 0.0 | 0.7 | (1.2) | 0.0 | (0.2) | 0.0 | 2.9 | |
| 0.5 | (0.1) | (0.1) | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.5 | |
| 2.3 | 0.4 | 0.2 | 0.0 | 0.0 | 0.5 | (1.1) | 0.0 | (0.2) | 0.0 | 1.9 | |
| 0.5 | (0.2) | (0.2) | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.4 | |
| 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | (0.1) | 0.0 | 0.0 | 0.0 | 0.1 | |
| 9.6 | 0.3 | 0.2 | 0.0 | 0.0 | 6.3 | (2.9) | 0.1 | (0.8) | (0.2) | 12.5 | |
| 2.1 | 0.0 | 0.0 | 0.0 | 0.0 | 1.0 | (0.2) | 0.0 | 0.0 | 0.0 | 2.9 |
Note 10 Fair value measurement (continued)
g) Financial instruments not measured at fair value
The table below reflects the estimated fair values of financial instruments not measured at fair value.
Financial instruments not measured at fair value
| Financial instruments not measured at fair value | ||
|---|---|---|
| 30.6.21 | 31.3.21 31.12.20 |
|
| USD billion | Carrying amount Fair value |
Carrying amount Fair value Carrying amount Fair value |
| Assets | ||
| Cash and balances at central banks | 160.7 160.7 |
158.9 158.9 158.2 158.2 |
| Loans and advances to banks | 16.4 16.4 |
18.3 18.3 15.3 15.3 |
| Receivables from securities financing transactions | 83.5 83.5 |
82.4 82.4 74.2 74.2 |
| Cash collateral receivables on derivative instruments | 29.8 29.8 |
35.0 35.0 32.7 32.7 |
| Loans and advances to customers | 391.4 391.0 |
380.1 380.1 381.0 382.3 |
| Other financial assets measured at amortized cost | 27.2 27.7 |
26.8 27.3 27.2 28.0 |
| Liabilities | ||
| Amounts due to banks | 14.6 14.6 |
12.6 12.6 11.0 11.1 |
| Payables from securities financing transactions | 6.0 6.0 |
6.7 6.7 6.3 6.3 |
| Cash collateral payables on derivative instruments | 32.2 32.2 |
36.6 36.6 37.3 37.3 |
| Customer deposits | 517.5 517.5 |
508.9 509.0 527.9 528.0 |
| Funding from UBS Group AG | 55.9 57.5 |
57.7 59.2 54.0 55.6 |
| Debt issued measured at amortized cost | 84.5 85.4 |
87.5 88.3 85.4 86.3 |
| Other financial liabilities measured at amortized cost1 | 7.0 7.0 |
6.0 6.0 6.6 6.7 |
1 Excludes lease liabilities.
The fair values included in the table above have been calculated for disclosure purposes only. The valuation techniques and assumptions relate only to UBS’s financial instruments not otherwise measured at fair value. Other institutions may use
different methods and assumptions for their fair value estimation, and therefore such fair value disclosures cannot necessarily be compared from one financial institution to another.
Note 11 Derivative instruments
a) Derivative instruments
| a) Derivative instruments | |||||
|---|---|---|---|---|---|
| Derivative | Notional values | Derivative | Notional values | Other | |
| financial | related to derivative | financial | related to derivative | notional | |
| As of 30.6.21, USD billion | assets | financial assets1 | liabilities | financial liabilities1 | values2 |
| Derivative financial instruments | |||||
| Interest rate contracts | 38.4 | 995 | 32.7 | 912 | 9,918 |
| Credit derivative contracts | 2.0 | 54 | 2.4 | 54 | 0 |
| Foreign exchange contracts | 49.5 | 3,074 | 47.4 | 2,869 | 2 |
| Equity/ index contracts | 29.2 | 458 | 36.3 | 615 | 90 |
| Commoditycontracts | 1.9 | 59 | 2.1 | 58 | 15 |
| Loan commitments measured at FVTPL | 0.0 | 1 | 0.0 | 11 | |
| Unsettledpurchases of non-derivative financial instruments3 | 0.3 | 29 | 0.3 | 26 | |
| Unsettled sales of non-derivative financial instruments3 | 0.3 | 39 | 0.4 | 23 | |
| Total derivative financial instruments, based on IFRS netting4 | 121.6 | 4,708 | 121.7 | 4,569 | 10,024 |
| Further netting potential not recognized on the balance sheet5 | (107.5) | (106.8) | |||
| of which: netting of recognized financial liabilities / assets | (86.8) | (86.8) | |||
| of which: netting with collateral received /pledged | (20.6) | (20.0) | |||
| Total derivative financial instruments, after consideration of further | |||||
| netting potential | 14.2 | 14.9 | |||
| As of 31.3.21, USD billion | |||||
| Derivative financial instruments | |||||
| Interest rate contracts | 39.9 | 991 | 34.0 | 901 | 11,707 |
| Credit derivative contracts | 2.3 | 65 | 2.5 | 62 | 0 |
| Foreign exchange contracts | 70.7 | 3,283 | 67.6 | 3,067 | 2 |
| Equity/ index contracts | 32.2 | 468 | 38.7 | 599 | 97 |
| Commoditycontracts | 2.2 | 62 | 2.0 | 54 | 12 |
| Loan commitments measured at FVTPL | 0.0 | 1 | 0.0 | 9 | |
| Unsettledpurchases of non-derivative financial instruments3 | 0.6 | 26 | 0.3 | 32 | |
| Unsettled sales of non-derivative financial instruments3 | 0.4 | 42 | 0.8 | 21 | |
| Total derivative financial instruments, based on IFRS netting4 | 148.3 | 4,938 | 146.0 | 4,745 | 11,817 |
| Further netting potential not recognized on the balance sheet5 | (130.1) | (127.5) | |||
| of which: netting of recognized financial liabilities / assets | (105.1) | (105.1) | |||
| of which: netting with collateral received /pledged | (25.0) | (22.5) | |||
| Total derivative financial instruments, after consideration of further | |||||
| netting potential | 18.2 | 18.5 | |||
| As of 31.12.20, USD billion | |||||
| Derivative financial instruments | |||||
| Interest rate contracts | 50.9 | 928 | 43.9 | 880 | 11,292 |
| Credit derivative contracts | 2.4 | 58 | 2.9 | 65 | 0 |
| Foreign exchange contracts | 68.7 | 2,951 | 70.5 | 2,820 | 1 |
| Equity/ index contracts | 34.8 | 450 | 41.2 | 581 | 91 |
| Commoditycontracts | 2.2 | 58 | 2.0 | 50 | 10 |
| Loan commitments measured at FVTPL | 0.0 | 10 | |||
| Unsettledpurchases of non-derivative financial instruments3 | 0.3 | 18 | 0.2 | 10 | |
| Unsettled sales of non-derivative financial instruments3 | 0.2 | 17 | 0.3 | 13 | |
| Total derivative financial instruments, based on IFRS netting4 | 159.6 | 4,480 | 161.1 | 4,430 | 11,394 |
| Further netting potential not recognized on the balance sheet5 | (144.4) | (141.2) | |||
| of which: netting of recognized financial liabilities / assets | (117.2) | (117.2) | |||
| of which: netting with collateral received /pledged | (27.2) | (23.9) | |||
| Total derivative financial instruments, after consideration of further | |||||
| netting potential | 15.2 | 19.9 |
1 In cases where derivative financial instruments are presented on a net basis on the balance sheet, the respective notional values of the netted derivative financial instruments are still presented on a gross basis. Notional amounts of exchange-traded agency transactions and OTC-cleared transactions entered into on behalf of clients are not disclosed, as they have a significantly different risk profile. 2 Other notional values relate to derivatives that are cleared through either a central counterparty or an exchange. The fair value of these derivatives is presented on the balance sheet net of the corresponding cash margin under Cash collateral receivables on derivative instruments and Cash collateral payables on derivative instruments and was not material for all periods presented. 3 Changes in the fair value of purchased and sold nonderivative financial instruments between trade date and settlement date are recognized as derivative financial instruments. 4 Financial assets and liabilities are presented net on the balance sheet if UBS AG has the unconditional and legally enforceable right to offset the recognized amounts, both in the normal course of business and in the event of default, bankruptcy or insolvency of UBS AG or its counterparties, and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously. 5 Reflects the netting potential in accordance with enforceable master netting and similar arrangements where not all criteria for a net presentation on the balance sheet have been met. Refer to “Note 22 Offsetting financial assets and financial liabilities” in the “Consolidated financial statements” section of the Annual Report 2020 for more information.
Note 11 Derivative instruments (continued)
b) Cash collateral on derivative instruments
| Receivables | Payables | Receivables | Payables | Receivables | Payables | |
|---|---|---|---|---|---|---|
| USD billion | 30.6.21 | 30.6.21 | 31.3.21 | 31.3.21 | 31.12.20 | 31.12.20 |
| Cash collateral on derivative instruments, based on IFRS netting1 | 29.8 | 32.2 | 35.0 | 36.6 | 32.7 | 37.3 |
| Further netting potential not recognized on the balance sheet2 | (18.3) | (16.9) | (21.1) | (20.7) | (21.1) | (21.6) |
| of which: netting of recognized financial liabilities / assets | (15.9) | (14.4) | (18.2) | (18.3) | (19.6) | (19.6) |
| of which: netting with collateral received /pledged | (2.4) | (2.5) | (2.9) | (2.3) | (1.5) | (2.1) |
| Cash collateral on derivative instruments, after consideration of further netting potential | 11.5 | 15.3 | 14.0 | 15.9 | 11.6 | 15.7 |
1 Financial assets and liabilities are presented net on the balance sheet if UBS AG has the unconditional and legally enforceable right to offset the recognized amounts, both in the normal course of business and in the event of default, bankruptcy or insolvency of UBS AG or its counterparties, and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously. 2 Reflects the netting potential in accordance with enforceable master netting and similar arrangements where not all criteria for a net presentation on the balance sheet have been met. Refer to “Note 22 Offsetting financial assets and financial liabilities” in the “Consolidated financial statements” section of the Annual Report 2020 for more information.
Note 12 Other assets and liabilities
a) Other financial assets measured at amortized cost
| a) Other financial assets measured at amortized cost | |||
|---|---|---|---|
| USD million | 30.6.21 | 31.3.21 | 31.12.20 |
| Debt securities | 18,484 | 18,533 | 18,801 |
| of which:government bills / bonds | 9,531 | 9,664 | 9,789 |
| Loans to financial advisors | 2,415 | 2,473 | 2,569 |
| Fee- and commission-related receivables | 1,980 | 2,069 | 2,014 |
| Finance lease receivables | 1,363 | 1,344 | 1,447 |
| Settlement and clearingaccounts | 1,225 | 564 | 614 |
| Accrued interest income | 532 | 522 | 592 |
| Other | 1,202 | 1,333 | 1,182 |
| Total other financial assets measured at amortized cost | 27,201 | 26,837 | 27,219 |
b) Other non-financial assets
| b) Other non-financial assets | |||
|---|---|---|---|
| USD million | 30.6.21 | 31.3.21 | 31.12.20 |
| Precious metals and otherphysical commodities | 5,470 | 5,709 | 6,264 |
| Bail deposit1 | 1,382 | 1,364 | 1,418 |
| Prepaid expenses | 746 | 743 | 731 |
| VAT and other tax receivables | 395 | 317 | 392 |
| Properties and other non-current assets held for sale | 68 | 248 | 246 |
| Other | 542 | 372 | 323 |
| Total other non-financial assets | 8,603 | 8,755 | 9,374 |
1 Refer to item 1 in Note 16b for more information.
Note 12 Other assets and liabilities (continued)
c) Other financial liabilities measured at amortized cost
| c) Other financial liabilities measured at amortized cost | |||
|---|---|---|---|
| USD million | 30.6.21 | 31.3.21 | 31.12.20 |
| Other accrued expenses | 1,549 | 1,544 | 1,508 |
| Accrued interest expenses | 1,050 | 946 | 1,382 |
| Settlement and clearingaccounts | 2,151 | 1,268 | 1,181 |
| Lease liabilities | 3,634 | 3,667 | 3,821 |
| Other | 2,288 | 2,200 | 2,530 |
| Total other financial liabilities measured at amortized cost | 10,671 | 9,624 | 10,421 |
d) Other financial liabilities designated at fair value
| d) Other financial liabilities designated at fair value | |||
|---|---|---|---|
| USD million | 30.6.21 | 31.3.21 | 31.12.20 |
| Financial liabilities related to unit-linked investment contracts | 22,217 | 21,357 | 20,975 |
| Securities financingtransactions | 6,184 | 5,651 | 7,317 |
| Over-the-counter debt instruments | 2,142 | 1,787 | 2,060 |
| Funding from UBS Group AG | 2,266 | 1,907 | 1,375 |
| Other | 99 | 68 | 46 |
| Total other financial liabilities designated at fair value | 32,908 | 30,769 | 31,773 |
| of which: life-to-date own credit (gain) / loss | 115 | 208 | 148 |
e) Other non-financial liabilities
| e) Other non-financial liabilities | |||
|---|---|---|---|
| USD million | 30.6.21 | 31.3.21 | 31.12.20 |
| Compensation-related liabilities | 3,771 | 2,969 | 4,776 |
| of which: financial advisor compensationplans | 1,313 | 1,200 | 1,497 |
| of which: other compensationplans | 1,287 | 704 | 2,034 |
| of which: net defined benefit liability | 652 | 642 | 711 |
| of which: other compensation-related liabilities1 | 518 | 422 | 534 |
| Deferred tax liabilities | 382 | 321 | 558 |
| Current tax liabilities | 1,186 | 1,058 | 943 |
| VAT and other taxpayables | 540 | 504 | 470 |
| Deferred income | 246 | 209 | 212 |
| Other | 116 | 111 | 61 |
| Total other non-financial liabilities | 6,241 | 5,171 | 7,018 |
1 Includes liabilities for payroll taxes and untaken vacation.
Note 13 Debt issued designated at fair value
| USD million | 30.6.21 | 31.3.21 | 31.12.20 |
|---|---|---|---|
| Issued debt instruments | |||
| Equity-linked1 | 49,157 | 44,615 | 41,069 |
| Rates-linked | 16,397 | 12,668 | 11,038 |
| Credit-linked | 1,826 | 1,804 | 1,933 |
| Fixed-rate | 2,883 | 3,343 | 3,604 |
| Commodity-linked | 1,961 | 1,564 | 1,497 |
| Other | 575 | 640 | 726 |
| Total debt issued designated at fair value | 72,799 | 64,635 | 59,868 |
| of which: issued by UBS AG with original maturity greater than oneyear2 | 51,830 | 47,348 | 46,427 |
| of which: life-to-date own credit (gain) / loss | 164 | 193 | 233 |
1 Includes investment fund unit-linked instruments issued. 2 Issued by the legal entity UBS AG. Based on original contractual maturity without considering any early redemption features. As of 30 June 2021, more than 99% of the balance was unsecured (31 March 2021: 100%; 31 December 2020: 100%).
Note 14 Debt issued measured at amortized cost
| USD million | 30.6.21 | 31.3.21 | 31.12.20 |
|---|---|---|---|
| Certificates of deposit | 12,193 | 14,723 | 15,680 |
| Commercial paper | 25,304 | 26,591 | 25,472 |
| Other short-term debt | 5,219 | 6,080 | 5,515 |
| Short-term debt1 | 42,716 | 47,394 | 46,666 |
| Senior unsecured debt | 26,130 | 23,330 | 18,483 |
| of which: issued by UBS AG with original maturity greater than oneyear2 | 26,109 | 23,309 | 18,464 |
| Covered bonds | 1,449 | 2,606 | 2,796 |
| Subordinated debt | 5,232 | 5,253 | 7,744 |
| of which: low-trigger loss-absorbing tier 2 capital instruments | 4,686 | 4,709 | 7,201 |
| of which: non-Basel III-compliant tier 2 capital instruments | 547 | 544 | 543 |
| Debt issued through the Swiss central mortgage institutions | 8,963 | 8,911 | 9,660 |
| Other long-term debt | 0 | 2 | 3 |
| Long-term debt3 | 41,775 | 40,101 | 38,685 |
| Total debt issued measured at amortized cost4 | 84,491 | 87,495 | 85,351 |
1 Debt with an original contractual maturity of less than one year. 2 Issued by the legal entity UBS AG. Based on original contractual maturity without considering any early redemption features. As of 30 June 2021, 100% of the balance was unsecured (31 March 2021: 100%; 31 December 2020: 100%). 3 Debt with an original contractual maturity greater than or equal to one year. The classification of debt issued into short-term and long-term does not consider any early redemption features. 4 Net of bifurcated embedded derivatives, the fair value of which was not material for the periods presented.
Note 15 Interest rate benchmark reform
Background
A market-wide reform of major interest rate benchmarks is being undertaken globally, with the Financial Conduct Authority (the FCA) announcing in March 2021 that the publication of London Interbank Offered Rates (LIBORs) will cease for all nonUS dollar LIBORs, as well as for one-week and two-month USD LIBOR, after 31 December 2021. Publication of the remaining USD LIBOR tenors will cease immediately after 30 June 2023.
The majority of UBS AG’s Interbank Offered Rate (IBOR) exposure is to CHF LIBOR and USD LIBOR. The alternative reference rate (ARR) for CHF LIBOR is the Swiss Average Rate Overnight (SARON). The ARR for USD LIBOR is the Secured Overnight Financing Rate (SOFR); in addition, there are recommended ARRs for GBP LIBOR, JPY LIBOR and EUR LIBOR. For certain products in the US, UBS AG is considering the use of credit-sensitive rates as an alternative to SOFR.
As of 30 June 2021, transition uncertainty with respect to significant interest rate benchmarks remains, with the exception of the Euro Interbank Offered Rate (Euribor). The reform of Euribor is now complete and consisted of a change in the underlying calculation method.
The transition to ARRs includes a number of active steps that will also benefit from the support of associated regulatory activities. There may be some contracts, known as “tough legacy contracts,” that cannot be practically transitioned or amended from IBORs to ARRs. The FCA continues to consult market participants about requiring the ICE Benchmark Administration to continue publishing certain LIBOR settings (i.e., one-, threeand six-month settings for the GBP, JPY and USD LIBORs) on a “synthetic” basis, which are not representative of the underlying financial markets, for a certain duration after 31 December 2021. However, these synthetic LIBORs will not be available for use in new contracts, given that they are non-representative, and are instead intended to help reduce disruption where resolution has not been agreed for certain tough legacy contracts. Furthermore, in February 2021, the EU Benchmarks Regulation was amended to enable the European Commission to designate a statutory replacement rate for tough legacy LIBOR contracts that are governed by the laws of EU Member States and remain outstanding after LIBOR cessation. On 6 April 2021, New York State LIBOR legislation was enacted with the intention of minimizing legal uncertainty and adverse economic effects associated with USD LIBOR transition for tough legacy contracts governed by New York law. For USD LIBOR contracts not governed by New York law, a bill has been introduced in Congress with similar objectives.
In October 2020, the International Swaps and Derivatives Association (ISDA) released the IBOR Fallbacks Supplement and IBOR Fallbacks Protocol, amending ISDA standard definitions for interest-rate derivatives to incorporate fallbacks for derivatives linked to certain IBORs. The changes came into effect on 25 January 2021 and, from that date, all newly cleared and noncleared derivatives between adhering parties that reference ISDA standard definitions now include these fallbacks. UBS AG adhered to the protocol in November 2020.
UBS AG is focused on transitioning existing contracts via bilateral and multi-lateral agreements, leveraging industry solutions (e.g., the use of fallback provisions) and through thirdparty actions (clearing houses, agents, etc.). Furthermore, in line with regulatory guidance UBS AG has implemented a framework to limit entry into new contracts referencing IBORs.
Governance over the transition to alternative benchmark rates
UBS AG has established a global cross-divisional, cross-functional governance structure and change program to address the scale and complexity of the transition. This global program is sponsored by the Group CFO and led by senior representatives from the business divisions and UBS AG’s control and support functions. The program includes governance and execution structures within each business division, together with crossdivisional teams from each control and support function. Progress is overseen centrally via a monthly operating committee and a monthly steering committee, as well as quarterly updates to the joint Audit and Risk committees.
Risks
A core part of UBS AG’s change program is the identification, management and monitoring of the risks associated with IBOR reform and transition. These risks include, but are not limited to, the following:
-
economic risks to UBS AG and its clients, through the repricing of existing contracts, reduced transparency and / or liquidity of pricing information, market uncertainty or disruption;
-
accounting risks, where the transition affects the accounting treatment, including hedge accounting and consequential income statement volatility;
-
valuation risks arising from the variation between benchmarks that will cease and ARRs, affecting the risk profile of financial instruments;
-
operational risks arising from changes to UBS AG’s front-toback processes and systems to accommodate the transition, as well as the revision of operational controls related to the reform; and
-
legal and conduct risks relating to UBS AG’s engagement with clients and market counterparties around new benchmark products and amendments required for existing contracts referencing benchmarks that will cease.
Note 15 Interest rate benchmark reform (continued)
In some cases, contracts may contain provisions intended to provide a fallback interest rate in the event of a brief unavailability of the relevant IBOR. These provisions may not be effective or may produce arbitrary results in the event of a permanent cessation of the relevant IBOR. While efforts to transition outstanding transactions from IBORs to ARRs have made substantial progress, including through industry-wide protocols, such as the ISDA IBOR Fallbacks Supplement and IBOR Fallbacks Protocol, there are still substantial volumes of transactions that require modification to effectively transition to ARRs.
UBS AG remains confident that it has the transparency, oversight and operational preparedness to progress with the IBOR transition consistent with market timelines. UBS AG does not expect changes to its risk management approach and strategy as a result of interest rate benchmark reform.
Progress made during 2020 and the first half of 2021
Approaches to transition vary by product type. During 2020, UBS AG transitioned most of its CHF LIBOR-linked deposits to SARON and launched SARON-based mortgages and corporate loans based on all major ARRs in the Swiss market, as well as SOFR-based mortgages in the US market. By the end of the second quarter of 2021, UBS AG had successfully transitioned its GBP LIBOR- and EUR LIBOR-based private and commercial real estate mortgages in the UK and Monaco to the Sterling Overnight Index Average (SONIA) and Euribor, respectively. UBS AG has detailed plans in place to deliver the required changes for all other IBOR exposures, predominantly during 2021.
Financial instruments yet to transition to alternative benchmarks The amounts included in the table below relate to financial instrument contracts across UBS AG’s business divisions where
UBS AG has material exposures subject to IBOR reform that have not yet transitioned to ARRs, and that:
-
contractually reference an interest rate benchmark that will transition to an alternative benchmark; and
-
have a contractual maturity date (including open-ended contracts) after the agreed cessation dates.
Contracts where penalty terms reference IBORs, or where exposure to an IBOR is not the primary purpose of the contract, have not been included, as these contracts do not have a material impact on the transition process. In addition, contracts that have been changed to incorporate ARR-based interest rates before the relevant cessation date have been excluded from the table below, because UBS AG expects no further transition work to implement the reform.
In line with information provided to management and external parties monitoring UBS AG’s transition progress, the table below includes the following financial metrics for instruments subject to interest rate benchmark reform:
-
gross carrying value / exposure for non-derivative financial instruments; and
-
total trade count for derivative financial instruments.
The exposures included in the table below represent the maximum IBOR exposure, with the actual IBOR exposure being dependent upon client preferences and investment decisions. Overall, the effort required to transition is affected by multiple factors, including whether negotiations need to take place with multiple stakeholders (as is the case for syndicated loans or certain listed securities), market readiness – such as liquidity in ARR equivalent products – and a client’s technical readiness to handle ARR market conventions.
As significant IBOR exposures transition to ARRs during 2021, the values and trade count disclosed are expected to decrease.
| instrument contracts across UBS AG’s business divisions wh | ere As significant IBOR exposures transition to ARRs during 2021, the values and trade count disclosed are expected to decrease. |
|---|---|
| 30.6.21 | |
| **LIBOR benchmark rates1 ** | |
| Measure | CHF USD GBP EUR2 JPY XCCY |
| Carrying value of non-derivative financial instruments | |
| Total non-derivative financial assets USD million |
31,423 77,502 1,829 6,587 3,070 **3,7963 ** |
| Total non-derivative financial liabilities USD million |
2,029 9,834 566 1,919 1,060 0 |
| Trade count of derivative financial instruments | |
| Total derivative financial instruments Trade count |
9,519 42,566 12,513 9,626 4,247 **5,9484 ** |
| Off-balance sheet exposures | |
| Total irrevocable loan commitments USD million |
1 4,433 0 0 0 **15,7675 ** |
| 31.3.21 | |
| LIBOR benchmark rates1 | |
| Measure | CHF USD GBP EUR2 JPY XCCY |
| Carrying value of non-derivative financial instruments | |
| Total non-derivative financial assets USD million |
36,046 72,185 5,399 8,253 3,060 4,4693 |
| Total non-derivative financial liabilities USD million |
2,612 13,142 1,429 2,252 1,460 0 |
| Trade count of derivative financial instruments | |
| Total derivative financial instruments Trade count |
9,749 40,080 13,006 9,613 3,961 5,2064 |
| Off-balance sheet exposures | |
| Total irrevocable loan commitments USD million |
106 4,656 167 0 0 15,1885 |
1 Contracts have been disclosed without regard to early termination rights. Instead, it is assumed that such contracts will transition away from IBORs without such rights being exercised. 2 Includes primarily EUR LIBOR positions. 3 Includes loans related to revolving multi-currency credit lines. 4 Includes cross-currency swaps where either leg or both legs are indexed to an IBOR. 5 Includes loan commitments that can be drawn in different currencies at the client‘s discretion.
Note 15 Interest rate benchmark reform (continued)
Non-derivative instruments
UBS AG’s significant non-derivative IBOR exposures primarily relate to brokerage receivable and payable balances, corporate and private loans, and mortgages, linked to CHF and USD LIBORs.
In March 2021, following the FCA announcement regarding the cessation timelines for IBORs, UBS AG started a centralized communication initiative for private mortgages linked to CHF LIBOR, with the objective of transitioning these exposures either through the activation of existing fallbacks or the amendment of contractual terms, where such fallbacks do not exist. During the second quarter of 2021, mortgages that were linked to CHF LIBOR have been reduced by approximately USD 2 billion and the remaining USD 3 billion of mortgages linked to GBP LIBOR as of 31 March 2021 have successfully transitioned. US mortgages linked to USD LIBOR are planned to transition to SOFR from 2022–2023. US securities-based lending increased by approximately USD 4 billion in the second quarter of 2021, with agreements expected to switch to an alternative benchmark from the fourth quarter of 2021.
UBS AG is also proactively discussing transition mechanisms with many of its brokerage and corporate clients in order to transition their exposures throughout 2021 from CHF LIBOR, EUR LIBOR and GBP LIBOR. During the second quarter of 2021, the gross carrying amount of IBOR-indexed non-derivative financial assets and liabilities related to brokerage accounts, predominantly linked to GBP and USD LIBOR, was reduced by approximately USD 8 billion in aggregate as a result of successful transitions.
For certain non-derivative financial assets and financial liabilities, in particular bonds issued by third parties, UBS AG is dependent on the participation and engagement of others in effecting the transition from IBORs. UBS AG is actively monitoring such exposures and is in discussions with clients.
As presented in the table on the previous page, UBS AG had approximately USD 16 billion (31 March 2021, USD 15 billion) of irrevocable commitments as of 30 June 2021 that can be drawn down in different currencies with IBOR-based interest rates, primarily USD LIBOR and Euribor, and that expire after the relevant benchmark cessation dates. Related drawn-down amounts under these commitments were USD 4 billion (31 March 2021, USD 4 billion).
In addition, UBS AG had approximately USD 10 billion (31 March 2021, USD 16 billion) of committed revocable credit lines outstanding that allow clients to draw down a number of IBOR-linked products. UBS AG is in discussions with impacted clients, with plans in place to have all contracts amended by the relevant cessation dates.
Derivative instruments
UBS AG holds derivatives for trading and hedging purposes, including those designated in hedge accounting relationships. A significant number of interest rate and cross-currency swaps have floating legs that reference various benchmarks that will cease.
The majority of derivatives are transacted with clearing houses where UBS AG is dependent upon industry-wide compression activities to reduce exposure and clearing house actions to convert any remaining derivatives nearer the cessation dates. London Clearing House (LCH), which is the clearing house for a significant number of UBS AG’s IRS derivatives, has confirmed that a standardized transition will be undertaken in December 2021 to transition IBOR-based derivatives to respective ARRs. UBS AG expects derivative volumes to fluctuate in line with business activity until such clearing house actions are taken.
For derivatives not transacted with clearing houses, as previously noted, UBS AG adhered to the ISDA IBOR Fallback Protocol in November 2020, although its preferred approach, in line with regulatory expectations, is to actively switch to ARRs before the relevant cessation dates or to bilaterally compress where feasible. UBS AG has begun a series of outreach activities to understand counterparties’ intentions regarding whether they seek to adhere to the protocol or will actively switch.
In order to minimize the operational risk of converting high volumes of transactions at the time of cessation, UBS AG is making progress with its preparations to convert derivative instruments in bulk to ARR equivalents.
Note 16 Provisions and contingent liabilities
a) Provisions
The table below presents an overview of total provisions.
| The table below presents an overview of total provisions. | |||
|---|---|---|---|
| USD million | 30.6.21 | 31.3.21 | 31.12.20 |
| Provisions other thanprovisions for expected credit losses | 2,583 | 2,448 | 2,534 |
| Provisions for expected credit losses | 209 | 245 | 257 |
| Totalprovisions | 2,792 | 2,693 | 2,791 |
The following table presents additional information for provisions other than provisions for expected credit losses.
| Litigation, | ||||
|---|---|---|---|---|
| regulatory and | ||||
| USD million | similar matters1 | Restructuring2 | Other3 | Total |
| Balance as of 31 December 2020 | 2,135 | 67 | 332 | 2,534 |
| Balance as of 31 March 2021 | 2,072 | 58 | 318 | 2,448 |
| Increase inprovisions recognized in the income statement | 87 | 114 | 31 | 233 |
| Release ofprovisions recognized in the income statement | (24) | (5) | (4) | (33) |
| Provisions used in conformitywith designatedpurpose | (27) | (20) | (31) | (78) |
| Capitalized reinstatement costs | 0 | 0 | (1) | (1) |
| Reclassifications | 0 | 1 | (1) | 0 |
| Foreign currencytranslation / unwind of discount | 11 | (1) | 4 | 13 |
| Balance as of 30 June 2021 | 2,119 | 148 | 317 | 2,583 |
1 Comprises provisions for losses resulting from legal, liability and compliance risks. 2 Includes personnel-related restructuring provisions of USD 104 million as of 30 June 2021 (31 March 2021: USD 9 million; 31 December 2020: USD 13 million) and provisions for onerous contracts of USD 40 million as of 30 June 2021 (31 March 2021: USD 44 million; 31 December 2020: USD 49 million). 3 Mainly includes provisions related to real estate, employee benefits and operational risks.
Restructuring provisions primarily relate to personnel-related provisions and onerous contracts. Personnel-related restructuring provisions are used within a short time period but potential changes in amount may be triggered when natural staff attrition reduces the number of people affected by a restructuring event and therefore the estimated costs. Onerous contracts for property are recognized when UBS AG is committed to pay for
non-lease components, such as utilities, service charges, taxes and maintenance, when a property is vacated or not fully recovered from sub-tenants.
Information about provisions and contingent liabilities in respect of litigation, regulatory and similar matters, as a class, is included in Note 16b. There are no material contingent liabilities associated with the other classes of provisions.
b) Litigation, regulatory and similar matters
UBS operates in a legal and regulatory environment that exposes it to significant litigation and similar risks arising from disputes and regulatory proceedings. As a result, UBS (which for purposes of this Note may refer to UBS AG and/or one or more of its subsidiaries, as applicable) is involved in various disputes and legal proceedings, including litigation, arbitration, and regulatory and criminal investigations.
Such matters are subject to many uncertainties, and the outcome and the timing of resolution are often difficult to predict, particularly in the earlier stages of a case. There are also situations where UBS may enter into a settlement agreement. This may occur in order to avoid the expense, management distraction or reputational implications of continuing to contest liability, even for those matters for which UBS believes it should be exonerated. The uncertainties inherent in all such matters affect the amount and timing of any potential outflows for both matters with respect to which provisions have been established and other contingent liabilities. UBS makes provisions for such matters brought against it when, in the opinion of management after seeking legal advice, it is more likely than not that UBS has a present legal or constructive obligation as a result of past
events, it is probable that an outflow of resources will be required, and the amount can be reliably estimated. Where these factors are otherwise satisfied, a provision may be established for claims that have not yet been asserted against UBS, but are nevertheless expected to be, based on UBS’s experience with similar asserted claims. If any of those conditions is not met, such matters result in contingent liabilities. If the amount of an obligation cannot be reliably estimated, a liability exists that is not recognized even if an outflow of resources is probable. Accordingly, no provision is established even if the potential outflow of resources with respect to such matters could be significant. Developments relating to a matter that occur after the relevant reporting period, but prior to the issuance of financial statements, which affect management’s assessment of the provision for such matter (because, for example, the developments provide evidence of conditions that existed at the end of the reporting period), are adjusting events after the reporting period under IAS 10 and must be recognized in the financial statements for the reporting period.
Note 16 Provisions and contingent liabilities (continued)
Specific litigation, regulatory and other matters are described below, including all such matters that management considers to be material and others that management believes to be of significance due to potential financial, reputational and other effects. The amount of damages claimed, the size of a transaction or other information is provided where available and appropriate in order to assist users in considering the magnitude of potential exposures.
In the case of certain matters below, we state that we have established a provision, and for the other matters, we make no such statement. When we make this statement and we expect disclosure of the amount of a provision to prejudice seriously our position with other parties in the matter because it would reveal what UBS believes to be the probable and reliably estimable outflow, we do not disclose that amount. In some cases we are subject to confidentiality obligations that preclude such disclosure. With respect to the matters for which we do not state whether we have established a provision, either: (a) we have not established a provision, in which case the matter is treated as a contingent liability under the applicable accounting standard; or (b) we have established a provision but expect disclosure of that fact to prejudice seriously our position with other parties in the matter because it would reveal the fact that UBS believes an outflow of resources to be probable and reliably estimable.
With respect to certain litigation, regulatory and similar matters for which we have established provisions, we are able to estimate the expected timing of outflows. However, the aggregate amount of the expected outflows for those matters for which we are able to estimate expected timing is immaterial relative to our current and expected levels of liquidity over the relevant time periods.
The aggregate amount provisioned for litigation, regulatory and similar matters as a class is disclosed in the “Provisions” table in Note 16a above. It is not practicable to provide an aggregate estimate of liability for our litigation, regulatory and similar matters as a class of contingent liabilities. Doing so would require UBS to provide speculative legal assessments as to claims and proceedings that involve unique fact patterns or novel legal theories, that have not yet been initiated or are at early stages of adjudication, or as to which alleged damages have not been quantified by the claimants. Although UBS therefore cannot provide a numerical estimate of the future losses that could arise from litigation, regulatory and similar matters, UBS believes that the aggregate amount of possible future losses from this class that are more than remote substantially exceeds the level of current provisions.
Litigation, regulatory and similar matters may also result in non-monetary penalties and consequences. For example, the non-prosecution agreement UBS entered into with the US Department of Justice (DOJ), Criminal Division, Fraud Section in connection with submissions of benchmark interest rates, including, among others, the British Bankers’ Association London Interbank Offered Rate (LIBOR), was terminated by the DOJ based on its determination that UBS had committed a US crime in relation to foreign exchange matters. As a consequence, UBS AG pleaded guilty to one count of wire fraud for conduct in the LIBOR matter, paid a fine and was subject to probation, which ended in January 2020.
A guilty plea to, or conviction of, a crime could have material consequences for UBS. Resolution of regulatory proceedings may require UBS to obtain waivers of regulatory disqualifications to maintain certain operations, may entitle regulatory authorities to limit, suspend or terminate licenses and regulatory authorizations, and may permit financial market utilities to limit, suspend or terminate UBS’s participation in such utilities. Failure to obtain such waivers, or any limitation, suspension or termination of licenses, authorizations or participations, could have material consequences for UBS.
The risk of loss associated with litigation, regulatory and similar matters is a component of operational risk for purposes of determining capital requirements. Information concerning our capital requirements and the calculation of operational risk for this purpose is included in the “Capital management” section of the UBS Group second quarter 2021 report.
Provisions for litigation, regulatory and similar matters by business division and in Group Functions[1]
| Global Wealth | Personal & | Asset | ||||
|---|---|---|---|---|---|---|
| Manage- | Corporate | Manage- | Investment | Group | ||
| USD million | ment | Banking | ment | Bank | Functions | Total |
| Balance as of 31 December 2020 | 861 | 115 | 0 | 227 | 932 | 2,135 |
| Balance as of 31 March 2021 | 810 | 109 | 1 | 217 | 935 | 2,072 |
| Increase inprovisions recognized in the income statement | 20 | 0 | 0 | 66 | 1 | 87 |
| Release ofprovisions recognized in the income statement | (11) | (11) | 0 | (2) | 0 | (24) |
| Provisions used in conformity with designated purpose | (27) | 0 | 0 | 0 | 0 | (27) |
| Foreign currency translation / unwind of discount | 8 | 2 | 0 | 1 | 0 | 11 |
| Balance as of 30 June 2021 | 800 | 100 | 1 | 282 | 936 | 2,119 |
1 Provisions, if any, for matters described in this Note are recorded in Global Wealth Management (item 3 and item 4) and Group Functions (item 2). Provisions, if any, for the matters described in items 1 and 6 of this Note are allocated between Global Wealth Management and Personal & Corporate Banking, and provisions, if any, for the matters described in this Note in item 5 are allocated between the Investment Bank and Group Functions.
Note 16 Provisions and contingent liabilities (continued)
- Inquiries regarding cross-border wealth management businesses
Tax and regulatory authorities in a number of countries have made inquiries, served requests for information or examined employees located in their respective jurisdictions relating to the cross-border wealth management services provided by UBS and other financial institutions. It is possible that the implementation of automatic tax information exchange and other measures relating to cross-border provision of financial services could give rise to further inquiries in the future. UBS has received disclosure orders from the Swiss Federal Tax Administration (FTA) to transfer information based on requests for international administrative assistance in tax matters. The requests concern a number of UBS account numbers pertaining to current and former clients and are based on data from 2006 and 2008. UBS has taken steps to inform affected clients about the administrative assistance proceedings and their procedural rights, including the right to appeal. The requests are based on data received from the German authorities, who seized certain data related to UBS clients booked in Switzerland during their investigations and have apparently shared this data with other European countries. UBS expects additional countries to file similar requests.
Since 2013, UBS (France) S.A., UBS AG and certain former employees have been under investigation in France for alleged complicity in unlawful solicitation of clients on French territory, regarding the laundering of proceeds of tax fraud, and banking and financial solicitation by unauthorized persons. In connection with this investigation, the investigating judges ordered UBS AG to provide bail (“ caution ”) of EUR 1.1 billion and UBS (France) S.A. to post bail of EUR 40 million, which was reduced on appeal to EUR 10 million.
A trial in the court of first instance took place from 8 October 2018 until 15 November 2018. On 20 February 2019, the court announced a verdict finding UBS AG guilty of unlawful solicitation of clients on French territory and aggravated laundering of the proceeds of tax fraud, and UBS (France) S.A. guilty of aiding and abetting unlawful solicitation and laundering the proceeds of tax fraud. The court imposed fines aggregating EUR 3.7 billion on UBS AG and UBS (France) S.A. and awarded EUR 800 million of civil damages to the French state. UBS has appealed the decision. Under French law, the judgment is suspended while the appeal is pending. The trial in the Court of
Appeal took place between 8-24 March 2021. At the conclusion of the trial, the prosecutor asserted that the maximum penalty was EUR 2.2 billion and requested the court to award a penalty of at least EUR 2 billion. The French state asked for civil damages of EUR 1 billion. The judgment on the merits of the case is currently set for 27 September 2021. A subsequent appeal to the Cour de Cassation, France’s highest court, is possible with respect to questions of law.
UBS believes that based on both the law and the facts the judgment of the court of first instance should be reversed. UBS believes it followed its obligations under Swiss and French law as well as the European Savings Tax Directive. Even assuming liability, which it contests, UBS believes the penalties and damage amounts awarded greatly exceed the amounts that could be supported by the law and the facts. In particular, UBS believes the court incorrectly based the penalty on the total regularized assets rather than on any unpaid taxes on those assets for which a fraud has been characterized and further incorrectly awarded damages based on costs that were not proven by the civil party. Notwithstanding that UBS believes it should be acquitted, our balance sheet at 30 June 2021 reflected provisions with respect to this matter in an amount of EUR 450 million (USD 534 million at 30 June 2021). The wide range of possible outcomes in this case contributes to a high degree of estimation uncertainty. The provision reflected on our balance sheet at 30 June 2021 reflects our best estimate of possible financial implications, although it is reasonably possible that actual penalties and civil damages could exceed the provision amount.
In 2016, UBS was notified by the Belgian investigating judge that it is under formal investigation (“ inculpé ”) regarding the laundering of proceeds of tax fraud, of banking and financial solicitation by unauthorized persons, and of serious tax fraud.
Our balance sheet at 30 June 2021 reflected provisions with respect to matters described in this item 1 in an amount that UBS believes to be appropriate under the applicable accounting standard. As in the case of other matters for which we have established provisions, the future outflow of resources in respect of such matters cannot be determined with certainty based on currently available information and accordingly may ultimately prove to be substantially greater (or may be less) than the provision that we have recognized.
Note 16 Provisions and contingent liabilities (continued)
2. Claims related to sales of residential mortgage-backed securities and mortgages
From 2002 through 2007, prior to the crisis in the US residential loan market, UBS was a substantial issuer and underwriter of US residential mortgage-backed securities (RMBS) and was a purchaser and seller of US residential mortgages.
In November 2018, the DOJ filed a civil complaint in the District Court for the Eastern District of New York. The complaint seeks unspecified civil monetary penalties under the Financial Institutions Reform, Recovery and Enforcement Act of 1989 related to UBS’s issuance, underwriting and sale of 40 RMBS transactions in 2006 and 2007. UBS moved to dismiss the civil complaint on 6 February 2019. On 10 December 2019, the district court denied UBS’s motion to dismiss.
Our balance sheet at 30 June 2021 reflected a provision with respect to matters described in this item 2 in an amount that UBS believes to be appropriate under the applicable accounting standard. As in the case of other matters for which we have established provisions, the future outflow of resources in respect of this matter cannot be determined with certainty based on currently available information and accordingly may ultimately prove to be substantially greater (or may be less) than the provision that we have recognized.
3. Madoff
In relation to the Bernard L. Madoff Investment Securities LLC (BMIS) investment fraud, UBS AG, UBS (Luxembourg) S.A. (now UBS Europe SE, Luxembourg branch) and certain other UBS subsidiaries have been subject to inquiries by a number of regulators, including the Swiss Financial Market Supervisory Authority (FINMA) and the Luxembourg Commission de Surveillance du Secteur Financier. Those inquiries concerned two third-party funds established under Luxembourg law, substantially all assets of which were with BMIS, as well as certain funds established in offshore jurisdictions with either direct or indirect exposure to BMIS. These funds faced severe losses, and the Luxembourg funds are in liquidation. The documentation establishing both funds identifies UBS entities in various roles, including custodian, administrator, manager, distributor and promoter, and indicates that UBS employees serve as board members.
In 2009 and 2010, the liquidators of the two Luxembourg funds filed claims against UBS entities, non-UBS entities and certain individuals, including current and former UBS employees, seeking amounts totaling approximately EUR 2.1 billion, which includes amounts that the funds may be held liable to pay the trustee for the liquidation of BMIS (BMIS Trustee).
A large number of alleged beneficiaries have filed claims against UBS entities (and non-UBS entities) for purported losses relating to the Madoff fraud. The majority of these cases have been filed in Luxembourg, where decisions that the claims in eight test cases were inadmissible have been affirmed by the Luxembourg Court of Appeal, and the Luxembourg Supreme Court has dismissed a further appeal in one of the test cases.
In the US, the BMIS Trustee filed claims against UBS entities, among others, in relation to the two Luxembourg funds and one of the offshore funds. The total amount claimed against all defendants in these actions was not less than USD 2 billion. In 2014, the US Supreme Court rejected the BMIS Trustee’s motion for leave to appeal decisions dismissing all claims except those for the recovery of approximately USD 125 million of payments alleged to be fraudulent conveyances and preference payments. In 2016, the bankruptcy court dismissed these claims against the UBS entities. In February 2019, the Court of Appeals reversed the dismissal of the BMIS Trustee’s remaining claims, and the US Supreme Court subsequently denied a petition seeking review of the Court of Appeals’ decision. The case has been remanded to the Bankruptcy Court for further proceedings.
4. Puerto Rico
Declines since 2013 in the market prices of Puerto Rico municipal bonds and of closed-end funds (funds) that are solemanaged and co-managed by UBS Trust Company of Puerto Rico and distributed by UBS Financial Services Incorporated of Puerto Rico (UBS PR) led to multiple regulatory inquiries, which in 2014 and 2015, led to settlements with the Office of the Commissioner of Financial Institutions for the Commonwealth of Puerto Rico, the US Securities and Exchange Commission (SEC) and the Financial Industry Regulatory Authority.
Since then UBS clients in Puerto Rico who own the funds or Puerto Rico municipal bonds and/or who used their UBS account assets as collateral for UBS non-purpose loans filed customer complaints and arbitration demands. Allegations include fraud, misrepresentation and unsuitability of the funds and of the loans seeking aggregate damages of USD 3.4 billion, of which USD 2.9 billion have been resolved through settlements, arbitration or withdrawal of claims.
A shareholder derivative action was filed in 2014 against various UBS entities and current and certain former directors of the funds, alleging hundreds of millions of US dollars in losses in the funds. In 2015, defendants’ motion to dismiss was denied.
In 2011, a purported derivative action was filed on behalf of the Employee Retirement System of the Commonwealth of Puerto Rico (System) against over 40 defendants, including UBS PR, which was named in connection with its underwriting and consulting services. Plaintiffs alleged that defendants violated their purported fiduciary duties and contractual obligations in connection with the issuance and underwriting of USD 3 billion of bonds by the System in 2008 and sought damages of over USD 800 million. In 2016, the court granted the System’s request to join the action as a plaintiff. In 2017, the court denied defendants’ motion to dismiss the complaint. In 2020, the court denied plaintiffs’ motion for summary judgment.
Note 16 Provisions and contingent liabilities (continued)
Beginning in 2015, certain agencies and public corporations of the Commonwealth of Puerto Rico (Commonwealth) defaulted on certain interest payments on Puerto Rico bonds. In 2016, US federal legislation created an oversight board with power to oversee Puerto Rico’s finances and to restructure its debt. The oversight board has imposed a stay on the exercise of certain creditors’ rights. In 2017, the oversight board placed certain of the bonds into a bankruptcy-like proceeding under the supervision of a Federal District Judge.
In May 2019, the oversight board filed complaints in Puerto Rico federal district court bringing claims against financial, legal and accounting firms that had participated in Puerto Rico municipal bond offerings, including UBS, seeking a return of underwriting and swap fees paid in connection with those offerings. UBS estimates that it received approximately USD 125 million in fees in the relevant offerings.
In August 2019, and February and November 2020, four US insurance companies that insured issues of Puerto Rico municipal bonds sued UBS and several other underwriters of Puerto Rico municipal bonds in three separate cases. The actions collectively seek recovery of an aggregate of USD 955 million in damages from the defendants. The plaintiffs in these cases claim that defendants failed to reasonably investigate financial statements in the offering materials for the insured Puerto Rico bonds issued between 2002 and 2007, which plaintiffs argue they relied upon in agreeing to insure the bonds notwithstanding that they had no contractual relationship with the underwriters. In June 2021 the court in the first of the three cases denied defendants’ motion to dismiss; defendants are seeking leave to appeal that decision. In July 2021, the court in another of these cases granted defendants’ motion to dismiss. A motion to dismiss is pending in the remaining case.
Our balance sheet at 30 June 2021 reflected provisions with respect to matters described in this item 4 in amounts that UBS believes to be appropriate under the applicable accounting standard. As in the case of other matters for which we have established provisions, the future outflow of resources in respect of such matters cannot be determined with certainty based on currently available information and accordingly may ultimately prove to be substantially greater (or may be less) than the provisions that we have recognized.
5. Foreign exchange, LIBOR and benchmark rates, and other trading practices
Foreign exchange-related regulatory matters: Beginning in 2013, numerous authorities commenced investigations concerning possible manipulation of foreign exchange markets and precious metals prices. As a result of these investigations, UBS entered into resolutions with the UK Financial Conduct Authority (FCA), the US Commodity Futures Trading Commission (CFTC), FINMA, the Board of Governors of the Federal Reserve System (Federal Reserve Board) and the Connecticut Department of Banking, the DOJ’s Criminal Division and the European Commission. UBS has ongoing obligations under the Cease and Desist Order of the Federal Reserve Board and the Office of the Comptroller of the
Currency (as successor to the Connecticut Department of Banking), and to cooperate with relevant authorities and to undertake certain remediation measures. UBS has also been granted conditional immunity by the Antitrust Division of the DOJ and by authorities in other jurisdictions in connection with potential competition law violations relating to foreign exchange and precious metals businesses. Investigations relating to foreign exchange matters by certain authorities remain ongoing notwithstanding these resolutions.
Foreign exchange-related civil litigation: Putative class actions have been filed since 2013 in US federal courts and in other jurisdictions against UBS and other banks on behalf of putative classes of persons who engaged in foreign currency transactions with any of the defendant banks. UBS has resolved US federal court class actions relating to foreign currency transactions with the defendant banks and persons who transacted in foreign exchange futures contracts and options on such futures under a settlement agreement that provides for UBS to pay an aggregate of USD 141 million and provide cooperation to the settlement classes. Certain class members have excluded themselves from that settlement and have filed individual actions in US and English courts against UBS and other banks, alleging violations of US and European competition laws and unjust enrichment.
In 2015, a putative class action was filed in federal court against UBS and numerous other banks on behalf of persons and businesses in the US who directly purchased foreign currency from the defendants and alleged co-conspirators for their own end use. In March 2017, the court granted UBS’s (and the other banks’) motions to dismiss the complaint. The plaintiffs filed an amended complaint in August 2017. In March 2018, the court denied the defendants’ motions to dismiss the amended complaint.
LIBOR and other benchmark-related regulatory matters: Numerous government agencies, including the SEC, the CFTC, the DOJ, the FCA, the UK Serious Fraud Office, the Monetary Authority of Singapore, the Hong Kong Monetary Authority, FINMA, various state attorneys general in the US and competition authorities in various jurisdictions, have conducted investigations regarding potential improper attempts by UBS, among others, to manipulate LIBOR and other benchmark rates at certain times. UBS reached settlements or otherwise concluded investigations relating to benchmark interest rates with the investigating authorities. UBS has ongoing obligations to cooperate with the authorities with whom we have reached resolutions and to undertake certain remediation measures with respect to benchmark interest rate submissions. UBS has been granted conditional leniency or conditional immunity from authorities in certain jurisdictions, including the Antitrust Division of the DOJ and the Swiss Competition Commission (WEKO), in connection with potential antitrust or competition law violations related to certain rates. However, UBS has not reached a final settlement with WEKO, as the Secretariat of WEKO has asserted that UBS does not qualify for full immunity.
Note 16 Provisions and contingent liabilities (continued)
LIBOR and other benchmark-related civil litigation: A number of putative class actions and other actions are pending in the federal courts in New York against UBS and numerous other banks on behalf of parties who transacted in certain interest rate benchmark-based derivatives. Also pending in the US and in other jurisdictions are a number of other actions asserting losses related to various products whose interest rates were linked to LIBOR and other benchmarks, including adjustable rate mortgages, preferred and debt securities, bonds pledged as collateral, loans, depository accounts, investments and other interest-bearing instruments. The complaints allege manipulation, through various means, of certain benchmark interest rates, including USD LIBOR, Euroyen TIBOR, Yen LIBOR, EURIBOR, CHF LIBOR, GBP LIBOR, SGD SIBOR and SOR and Australian BBSW, and seek unspecified compensatory and other damages under varying legal theories.
USD LIBOR class and individual actions in the US: In 2013 and 2015, the district court in the USD LIBOR actions dismissed, in whole or in part, certain plaintiffs’ antitrust claims, federal racketeering claims, CEA claims, and state common law claims. Although the Second Circuit vacated the district court’s judgment dismissing antitrust claims, the district court again dismissed antitrust claims against UBS in 2016. Certain plaintiffs have appealed that decision to the Second Circuit. Separately, in 2018, the Second Circuit reversed in part the district court’s 2015 decision dismissing certain individual plaintiffs’ claims and certain of these actions are now proceeding. UBS entered into an agreement in 2016 with representatives of a class of bondholders to settle their USD LIBOR class action. The agreement has received final court approval. In 2018, the district court denied plaintiffs’ motions for class certification in the USD class actions for claims pending against UBS, and plaintiffs sought permission to appeal that ruling to the Second Circuit. In July 2018, the Second Circuit denied the petition to appeal of the class of USD lenders and in November 2018 denied the petition of the USD exchange class. In December 2019, UBS entered into an agreement with representatives of the class of USD lenders to settle their USD LIBOR class action. The agreement has received final court approval. In January 2019, a putative class action was filed in the District Court for the Southern District of New York against UBS and numerous other banks on behalf of US residents who, since 1 February 2014, directly transacted with a defendant bank in USD LIBOR instruments. The complaint asserts antitrust claims. The defendants moved to dismiss the complaint in August 2019. On 26 March 2020 the court granted defendants’ motion to dismiss the complaint in its entirety. Plaintiffs have appealed the dismissal. In August 2020, an individual action was filed in the Northern District of California against UBS and numerous other banks alleging that the defendants conspired to fix the interest rate used as the basis for loans to consumers by jointly setting the USD LIBOR rate and monopolized the market for LIBORbased consumer loans and credit cards.
Other benchmark class actions in the US: In 2014, 2015 and 2017, the court in one of the Euroyen TIBOR lawsuits dismissed certain of the plaintiffs’ claims, including plaintiffs’ federal antitrust and racketeering claims. In August 2020, the court granted defendants’ motion for judgment on the pleadings and dismissed the lone remaining claim in the action as impermissibly
extraterritorial. Plaintiffs have appealed. In 2017, the court dismissed the other Yen LIBOR / Euroyen TIBOR action in its entirety on standing grounds. In April 2020, the appeals court reversed the dismissal and in August 2020 plaintiffs in that action filed an amended complaint. Defendants moved to dismiss the amended complaint in October 2020. In 2017, the court dismissed the CHF LIBOR action on standing grounds and failure to state a claim. Plaintiffs filed an amended complaint following the dismissal, and the court granted a renewed motion to dismiss in September 2019. Plaintiffs have appealed. Also in 2017, the court in the EURIBOR lawsuit dismissed the case as to UBS and certain other foreign defendants for lack of personal jurisdiction. Plaintiffs have appealed. In October 2018, the court in the SIBOR / SOR action dismissed all but one of plaintiffs’ claims against UBS. Plaintiffs filed an amended complaint following the dismissal, and the court granted a renewed motion to dismiss in July 2019. Plaintiffs appealed. In March 2021, the Second Circuit reversed the dismissal. In November 2018, the court in the BBSW lawsuit dismissed the case as to UBS and certain other foreign defendants for lack of personal jurisdiction. Following that dismissal, plaintiffs filed an amended complaint in April 2019, which UBS and other defendants named in the amended complaint moved to dismiss. In February 2020, the court in the BBSW action granted in part and denied in part defendants’ motions to dismiss the amended complaint. In August 2020, UBS and other BBSW defendants joined a motion for judgment on the pleadings. The court dismissed the GBP LIBOR action in August 2019. Plaintiffs have appealed.
Government bonds: Putative class actions have been filed since 2015 in US federal courts against UBS and other banks on behalf of persons who participated in markets for US Treasury securities since 2007. A consolidated complaint was filed in 2017 in the US District Court for the Southern District of New York alleging that the banks colluded with respect to, and manipulated prices of, US Treasury securities sold at auction and in the secondary market and asserting claims under the antitrust laws and for unjust enrichment. Defendants’ motions to dismiss the consolidated complaint was granted on 31 March 2021. Plaintiffs filed an amended complaint, which defendants moved to dismiss in June 2021. Similar class actions have been filed concerning European government bonds and other government bonds.
In May 2021, the European Commission issued a decision finding that UBS and six other banks breached European Union antitrust rules in 2007-2011 relating to European government bonds. The European Commission fined UBS EUR 172 million. UBS is appealing the amount of the fine.
With respect to additional matters and jurisdictions not encompassed by the settlements and orders referred to above, our balance sheet at 30 June 2021 reflected a provision in an amount that UBS believes to be appropriate under the applicable accounting standard. As in the case of other matters for which we have established provisions, the future outflow of resources in respect of such matters cannot be determined with certainty based on currently available information and accordingly may ultimately prove to be substantially greater (or may be less) than the provision that we have recognized.
Note 16 Provisions and contingent liabilities (continued)
6. Swiss retrocessions
The Federal Supreme Court of Switzerland ruled in 2012, in a test case against UBS, that distribution fees paid to a firm for distributing third-party and intra-group investment funds and structured products must be disclosed and surrendered to clients who have entered into a discretionary mandate agreement with the firm, absent a valid waiver. FINMA issued a supervisory note to all Swiss banks in response to the Supreme Court decision. UBS has met the FINMA requirements and has notified all potentially affected clients.
The Supreme Court decision has resulted, and may continue to result, in a number of client requests for UBS to disclose and potentially surrender retrocessions. Client requests are assessed on a case-by-case basis. Considerations taken into account when assessing these cases include, among other things, the existence
of a discretionary mandate and whether or not the client documentation contained a valid waiver with respect to distribution fees.
Our balance sheet at 30 June 2021 reflected a provision with respect to matters described in this item 6 in an amount that UBS believes to be appropriate under the applicable accounting standard. The ultimate exposure will depend on client requests and the resolution thereof, factors that are difficult to predict and assess. Hence, as in the case of other matters for which we have established provisions, the future outflow of resources in respect of such matters cannot be determined with certainty based on currently available information and accordingly may ultimately prove to be substantially greater (or may be less) than the provision that we have recognized.
Note 17 Currency translation rates
The following table shows the rates of the main currencies used to translate the financial information of UBS AG’s operations with a functional currency other than the US dollar into US dollars.
| Closing exchange rate | Average rate1 | Average rate1 | |
|---|---|---|---|
| As of | For thequarter ended | Year-to-date | |
| 30.6.21 31.3.21 31.12.20 30.6.20 |
30.6.21 31.3.21 30.6.20 |
30.6.21 30.6.20 |
|
| 1 CHF | 1.08 1.06 1.13 1.06 |
1.10 1.09 1.04 |
1.09 1.04 |
| 1 EUR | 1.19 1.17 1.22 1.12 |
1.20 1.20 1.11 |
1.20 1.11 |
| 1 GBP | 1.38 1.38 1.37 1.24 |
1.39 1.38 1.24 |
1.39 1.26 |
| 100 JPY | 0.90 0.90 0.97 0.93 |
0.91 0.93 0.93 |
0.92 0.93 |
1 Monthly income statement items of operations with a functional currency other than the US dollar are translated into US dollars using month-end rates. Disclosed average rates for a quarter represent an average of three month-end rates, weighted according to the income and expense volumes of all operations of UBS AG with the same functional currency for each month. Weighted average rates for individual business divisions may deviate from the weighted average rates for UBS AG.
Note 18 Supplemental guarantor information required under SEC regulations
Joint liability of UBS Switzerland AG
In 2015, the Personal & Corporate Banking and Wealth Management businesses booked in Switzerland were transferred from UBS AG to UBS Switzerland AG through an asset transfer in accordance with the Swiss Merger Act. Under the terms of the asset transfer agreement, UBS Switzerland AG assumed joint liability for contractual obligations of UBS AG existing on the asset transfer date, including the full and unconditional
guarantee of certain registered debt securities issued by UBS AG. To reflect this joint liability, UBS Switzerland AG is presented in a separate column as a subsidiary co-guarantor.
The joint liability of UBS Switzerland AG for contractual obligations of UBS AG decreased by USD 2.5 billion in the first half of 2021 to USD 7.6 billion as of 30 June 2021, mainly related to derivative financial instruments.
Supplemental guarantor consolidated income statement
| Supplemental guarantor consolidated income statement | |||||
|---|---|---|---|---|---|
| USD million | UBS | ||||
| UBS AG | Switzerland AG | Other | Elimination | UBS AG | |
| For the six months ended 30 June 2021 | (standalone)1 | (standalone)1 | subsidiaries2 | entries | (consolidated) |
| Operating income | |||||
| Interest income from financial instruments measured at amortized cost and | |||||
| fair value through other comprehensive income | 1,521 | 1,812 | 1,228 | (356) | 4,205 |
| Interest expense from financial instruments measured at amortized cost | (1,441) | (276) | (517) | 515 | (1,719) |
| Net interest income from financial instruments measured at fair value through | |||||
| profit or loss | 619 | 114 | 110 | (133) | 710 |
| Net interest income | 699 | 1,650 | 820 | 26 | 3,196 |
| Other net income from financial instruments measured at fair value through | |||||
| profit or loss | 1,757 | 417 | 720 | (109) | 2,785 |
| Credit loss (expense) / release | 47 | 80 | 3 | (23) | 108 |
| Fee and commission income | 2,064 | 2,571 | 7,996 | (387) | 12,244 |
| Fee and commission expense | (412) | (239) | (690) | 380 | (962) |
| Net fee and commission income | 1,652 | 2,331 | 7,306 | (7) | 11,282 |
| Other income | 3,231 | 118 | 519 | (3,333) | 535 |
| Total operating income | 7,387 | 4,596 | 9,367 | (3,445) | 17,906 |
| Operating expenses | |||||
| Personnel expenses | 1,915 | 1,116 | 5,125 | 1 | 8,158 |
| General and administrative expenses | 1,722 | 1,710 | 2,152 | (1,373) | 4,211 |
| Depreciation and impairment of property, equipment and software | 453 | 141 | 351 | (58) | 887 |
| Amortization and impairment ofgoodwill and intangible assets | 4 | 0 | 13 | 0 | 17 |
| Total operating expenses | 4,095 | 2,967 | 7,641 | (1,429) | 13,274 |
| Operating profit / (loss) before tax | 3,293 | 1,629 | 1,726 | (2,016) | 4,632 |
| Tax expense / (benefit) | 222 | 299 | 493 | (13) | 1,001 |
| Net profit / (loss) | 3,070 | 1,331 | 1,233 | (2,003) | 3,631 |
| Netprofit / (loss) attributable to non-controllinginterests | 0 | 0 | 9 | 0 | 9 |
| Net profit / (loss) attributable to shareholders | 3,070 | 1,331 | 1,224 | (2,003) | 3,623 |
1 Amounts presented for UBS AG standalone and UBS Switzerland AG standalone represent IFRS standalone information. Refer to the UBS AG standalone and UBS Switzerland AG standalone financial statements, available under “Complementary financial information” at ubs.com/investors, for information prepared in accordance with Swiss GAAP. 2 The ”Other subsidiaries“ column includes consolidated information for the UBS Americas Holding LLC, UBS Europe SE and UBS Asset Management AG significant sub-groups, as well as standalone information for other subsidiaries.
Note 18 Supplemental guarantor information required under SEC regulations (continued)
| Supplemental guarantor consolidated statement of comprehensive income | |||||
|---|---|---|---|---|---|
| USD million | UBS | ||||
| UBS AG | Switzerland AG | Other | Elimination | UBS AG | |
| For the six months ended 30 June 2021 | (standalone)1 | (standalone)1 | subsidiaries2 | entries | (consolidated) |
| Comprehensive income attributable to shareholders | |||||
| Net profit / (loss) | 3,070 | 1,331 | 1,224 | (2,003) | 3,623 |
| Other comprehensive income | |||||
| Other comprehensive income that may be reclassified to the income statement | |||||
| Foreign currency translation, net of tax | (38) | (641) | (287) | 515 | (452) |
| Financial assets measured at fair value through other comprehensive income, net of tax | 0 | 0 | (88) | 0 | (88) |
| Cash flow hedges, net of tax | (662) | (159) | (110) | (5) | (937) |
| Cost of hedging, net of tax | (23) | (23) | |||
| Total other comprehensive income that may be reclassified to the income statement, net of tax | (723) | (801) | (485) | 509 | (1,500) |
| Other comprehensive income that will not be reclassified to the income statement | |||||
| Defined benefit plans, net of tax | 41 | (123) | 50 | 0 | (31) |
| Own credit on financial liabilities designated at fair value, net of tax | 89 | 89 | |||
| Total other comprehensive income that will not be reclassified to the income statement, net of tax | 131 | (123) | 50 | 0 | 58 |
| Total other comprehensive income | (592) | (924) | (435) | 509 | (1,442) |
| Total comprehensive income attributable to shareholders | 2,478 | 407 | 790 | (1,494) | 2,181 |
| Total comprehensive income attributable to non-controllinginterests | 10 | 10 | |||
| Total comprehensive income | 2,478 | 407 | 800 | (1,494) | 2,192 |
1 Amounts presented for UBS AG standalone and UBS Switzerland AG standalone represent IFRS standalone information. Refer to the UBS AG standalone and UBS Switzerland AG standalone financial statements, available under “Complementary financial information” at ubs.com/investors, for information prepared in accordance with Swiss GAAP. 2 The ”Other subsidiaries“ column includes consolidated information for the UBS Americas Holding LLC, UBS Europe SE and UBS Asset Management AG significant sub-groups, as well as standalone information for other subsidiaries.
Note 18 Supplemental guarantor information required under SEC regulations (continued)
| Supplemental guarantor consolidated balance sheet | |||||
|---|---|---|---|---|---|
| USD million | UBS | ||||
| UBS AG | Switzerland AG | Other | Elimination | UBS AG | |
| As of 30 June 2021 | (standalone)1 | (standalone)1 | subsidiaries2 | entries | (consolidated) |
| Assets | |||||
| Cash and balances at central banks | 42,807 | 88,250 | 29,616 | 160,672 | |
| Loans and advances to banks | 38,654 | 6,427 | 20,083 | (48,788) | 16,376 |
| Receivables from securities financingtransactions | 60,265 | 8,701 | 50,113 | (35,584) | 83,494 |
| Cash collateral receivables on derivative instruments | 30,817 | 886 | 12,064 | (13,980) | 29,787 |
| Loans and advances to customers | 105,202 | 225,329 | 85,489 | (24,613) | 391,406 |
| Other financial assets measured at amortized cost | 8,767 | 7,428 | 12,979 | (1,974) | 27,201 |
| Total financial assets measured at amortized cost | 286,512 | 337,020 | 210,343 | (124,938) | 708,937 |
| Financial assets at fair value held for trading | 107,827 | 56 | 17,728 | (2,983) | 122,628 |
| of which: assets pledged as collateral that may be | |||||
| sold or repledged by counterparties | 52,493 | 0 | 6,835 | (14,995) | 44,333 |
| Derivative financial instruments | 117,032 | 5,172 | 36,950 | (37,532) | 121,622 |
| Brokerage receivables | 14,497 | 8,516 | (3) | 23,010 | |
| Financial assets at fair value not held for trading | 39,698 | 7,741 | 35,237 | (17,724) | 64,952 |
| Total financial assets measured at fair value through profit or loss | 279,053 | 12,970 | 98,431 | (58,242) | 332,211 |
| Financial assets measured at fair value | |||||
| through other comprehensive income | 135 | 7,641 | 7,775 | ||
| Investments in subsidiaries and associates | 53,492 | 37 | 54 | (52,384) | 1,198 |
| Property, equipment and software | 6,703 | 1,378 | 3,963 | (312) | 11,732 |
| Goodwill and intangible assets | 214 | 6,211 | 28 | 6,452 | |
| Deferred tax assets | 835 | 8,116 | 8,951 | ||
| Other non-financial assets | 5,813 | 1,935 | 858 | (3) | 8,603 |
| Total assets | 632,757 | 353,339 | 335,616 | (235,852) | 1,085,861 |
| Liabilities | |||||
| Amounts due to banks | 33,193 | 32,461 | 47,086 | (98,126) | 14,615 |
| Payables from securities financingtransactions | 17,503 | 849 | 23,265 | (35,645) | 5,972 |
| Cash collateralpayables on derivative instruments | 31,481 | 536 | 14,095 | (13,919) | 32,193 |
| Customer deposits | 99,713 | 286,370 | 119,737 | 11,642 | 517,462 |
| Fundingfrom UBS GroupAG | 55,907 | 55,907 | |||
| Debt issued measured at amortized cost | 75,543 | 8,976 | 1 | (29) | 84,491 |
| Other financial liabilities measured at amortized cost | 4,915 | 3,019 | 5,012 | (2,274) | 10,671 |
| Total financial liabilities measured at amortized cost | 318,256 | 332,211 | 209,195 | (138,351) | 721,311 |
| Financial liabilities at fair value held for trading | 28,822 | 482 | 6,850 | (2,806) | 33,348 |
| Derivative financial instruments | 117,636 | 4,460 | 37,131 | (37,539) | 121,688 |
| Brokeragepayables designated at fair value | 26,521 | 12,613 | (5) | 39,129 | |
| Debt issued designated at fair value | 72,034 | 860 | (95) | 72,799 | |
| Other financial liabilities designated at fair value | 11,054 | 26,164 | (4,311) | 32,908 | |
| Total financial liabilities measured at fair value through profit or loss | 256,068 | 4,942 | 83,618 | (44,756) | 299,871 |
| Provisions | 1,337 | 289 | 1,170 | (3) | 2,792 |
| Other non-financial liabilities | 1,858 | 1,076 | 3,370 | (63) | 6,241 |
| Total liabilities | 577,518 | 338,517 | 297,354 | (183,174) | 1,030,216 |
| Equity attributable to shareholders | 55,239 | 14,822 | 37,978 | (52,678) | 55,361 |
| Equityattributable to non-controllinginterests | 284 | 284 | |||
| Total equity | 55,239 | 14,822 | 38,262 | (52,678) | 55,645 |
| Total liabilities and equity | 632,757 | 353,339 | 335,616 | (235,852) | 1,085,861 |
1 Amounts presented for UBS AG standalone and UBS Switzerland AG standalone represent IFRS standalone information. Refer to the UBS AG standalone and UBS Switzerland AG standalone financial statements, available under “Complementary financial information” at ubs.com/investors, for information prepared in accordance with Swiss GAAP. 2 The ”Other subsidiaries“ column includes consolidated information for the UBS Americas Holding LLC, UBS Europe SE and UBS Asset Management AG significant sub-groups, as well as standalone information for other subsidiaries.
Note 18 Supplemental guarantor information required under SEC regulations (continued)
| Supplemental guarantor consolidated statement of cash flows | ||||
|---|---|---|---|---|
| USD million | UBS | Other | UBS AG | |
| For the six months ended 30 June 2021 | UBS AG1 | Switzerland AG1 | subsidiaries1 | (consolidated) |
| Net cash flow from / (used in) operating activities | (3,264) | 1,407 | 445 | (1,413) |
| Cash flow from / (used in) investing activities | ||||
| Purchase of subsidiaries, associates and intangible assets | 0 | (1) | 0 | (1) |
| Disposal of subsidiaries, associates and intangible assets2 | 16 | 0 | 421 | 437 |
| Purchase of property, equipment and software | (313) | (134) | (310) | (757) |
| Disposal of property, equipment and software | 264 | 0 | 1 | 264 |
| Purchase of financial assets measured at fair value through other comprehensive income | (11) | 0 | (1,939) | (1,950) |
| Disposal and redemption of financial assets measured at fair value through other comprehensive income | 11 | 0 | 2,313 | 2,324 |
| Net (purchase) / redemption of debt securities measured at amortized cost | 273 | 293 | (449) | 116 |
| Net cash flow from / (used in) investing activities | 239 | 158 | 36 | 434 |
| Cash flow from / (used in) financing activities | ||||
| Net short-term debt issued / (repaid) | (3,863) | (14) | 0 | (3,877) |
| Distributions paid on UBS shares | (4,539) | 0 | 0 | (4,539) |
| Repayment of lease liabilities | (143) | 0 | (130) | (274) |
| Issuance of debt designated at fair value and long-term debt measured at amortized cost3 | 63,422 | 289 | 134 | 63,845 |
| Repayment of debt designated at fair value and long-term debt measured at amortized cost3 | (44,428) | (570) | (246) | (45,244) |
| Net changes in non-controlling interests | 0 | 0 | (4) | (4) |
| Net activityrelated togroupinternal capital transactions and dividends | 2,224 | (537) | (1,687) | 0 |
| Net cash flow from / (used in) financing activities | 12,673 | (833) | (1,932) | 9,908 |
| Total cash flow | ||||
| Cash and cash equivalents at the beginning of the year | 39,400 | 93,342 | 40,689 | 173,430 |
| Net cash flow from / (used in) operating, investing and financing activities | 9,648 | 732 | (1,451) | 8,929 |
| Effects of exchange rate differences on cash and cash equivalents | (945) | (3,926) | (518) | (5,389) |
| Cash and cash equivalents at the end of the period4 | 48,103 | 90,148 | 38,721 | 176,971 |
| of which: cash and balances at central banks | 42,676 | 88,250 | 29,616 | 160,541 |
| of which: loans and advances to banks | 4,655 | 1,610 | 8,735 | 15,001 |
| of which: money market paper | 772 | 288 | 369 | 1,428 |
1 Cash flows generally represent a third-party view from a UBS AG consolidated perspective, except for Net activity related to group internal capital transactions and dividends. 2 Includes cash proceeds from the sale of UBS’s minority investment in Clearstream Fund Centre and dividends received from associates. 3 Includes funding from UBS Group AG to UBS AG. 4 Comprises balances with an original maturity of three months or less. USD 3,432 million of cash and cash equivalents were restricted.
Note 18 Supplemental guarantor information required under SEC regulations (continued)
Supplemental guarantor consolidated income statement
| Supplemental guarantor consolidated income statement | |||||
|---|---|---|---|---|---|
| USD million | UBS | ||||
| UBS AG | Switzerland AG | Other | Elimination | UBS AG | |
| For the six months ended 30 June 2020 | (standalone)1 | (standalone)1 | subsidiaries2 | entries | (consolidated) |
| Operating income | |||||
| Interest income from financial instruments measured at amortized cost and | |||||
| fair value through other comprehensive income | 1,813 | 1,821 | 1,439 | (481) | 4,591 |
| Interest expense from financial instruments measured at amortized cost | (2,152) | (258) | (759) | 651 | (2,519) |
| Net interest income from financial instruments measured at fair value through profit or loss |
507 | 83 | 175 | (149) | 616 |
| Net interest income | 169 | 1,645 | 854 | 20 | 2,689 |
| Other net income from financial instruments measured at fair value through | |||||
| profit or loss | 2,570 | 435 | 386 | 329 | 3,719 |
| Credit loss (expense) / release | (239) | (218) | (83) | 0 | (540) |
| Fee and commission income | 1,855 | 2,293 | 6,581 | (518) | 10,211 |
| Fee and commission expense | (307) | (454) | (623) | 509 | (875) |
| Net fee and commission income | 1,548 | 1,839 | 5,958 | (8) | 9,336 |
| Other income | 2,207 | 135 | 831 | (2,857) | 317 |
| Total operating income | 6,255 | 3,836 | 7,947 | (2,517) | 15,521 |
| Operating expenses | |||||
| Personnel expenses | 1,713 | 1,027 | 4,651 | 0 | 7,391 |
| General and administrative expenses | 1,619 | 1,568 | 1,983 | (1,210) | 3,960 |
| Depreciation and impairment of property, equipment and software | 430 | 122 | 320 | (57) | 814 |
| Amortization and impairment ofgoodwill and intangible assets | 2 | 0 | 30 | 0 | 32 |
| Total operating expenses | 3,764 | 2,716 | 6,983 | (1,267) | 12,197 |
| Operating profit / (loss) before tax | 2,490 | 1,120 | 964 | (1,250) | 3,324 |
| Tax expense / (benefit) | 138 | 215 | 266 | 83 | 703 |
| Net profit / (loss) | 2,352 | 904 | 698 | (1,333) | 2,621 |
| Netprofit / (loss) attributable to non-controllinginterests | 0 | 0 | 6 | 0 | 6 |
| Net profit / (loss) attributable to shareholders | 2,352 | 904 | 691 | (1,333) | 2,615 |
1 Amounts presented for UBS AG standalone and UBS Switzerland AG standalone represent IFRS standalone information. Refer to the UBS AG standalone and UBS Switzerland AG standalone financial statements, available under “Complementary financial information” at ubs.com/investors, for information prepared in accordance with Swiss GAAP. 2 The ”Other subsidiaries“ column includes consolidated information for the UBS Americas Holding LLC, UBS Europe SE and UBS Asset Management AG significant sub-groups, as well as standalone information for other subsidiaries.
Note 18 Supplemental guarantor information required under SEC regulations (continued)
Supplemental guarantor consolidated statement of comprehensive income
| Supplemental guarantor consolidated statement of comprehensive income | |||||
|---|---|---|---|---|---|
| USD million | UBS | ||||
| UBS AG | Switzerland AG | Other | Elimination | UBS AG | |
| For the six months ended 30 June 2020 | (standalone)1 | (standalone)1 | subsidiaries2 | entries | (consolidated) |
| Comprehensive income attributable to shareholders | |||||
| Net profit / (loss) | 2,352 | 904 | 691 | (1,333) | 2,615 |
| Other comprehensive income | |||||
| Other comprehensive income that may be reclassified to the income statement | |||||
| Foreign currency translation, net of tax | 7 | 278 | (111) | (72) | 103 |
| Financial assets measured at fair value through other comprehensive income, net of tax | 0 | 0 | 149 | 0 | 149 |
| Cash flow hedges, net of tax | 1,348 | 84 | 176 | (8) | 1,600 |
| Cost of hedging, net of tax | 9 | 0 | (13) | 0 | (4) |
| Total other comprehensive income that may be reclassified to the income statement, net of tax | 1,364 | 362 | 201 | (80) | 1,847 |
| Other comprehensive income that will not be reclassified to the income statement | |||||
| Defined benefit plans, net of tax | (131) | (97) | (42) | 0 | (270) |
| Own credit on financial liabilities designated at fair value, net of tax | 62 | 62 | |||
| Total other comprehensive income that will not be reclassified to the income statement, net of tax | (69) | (97) | (42) | 0 | (208) |
| Total other comprehensive income | 1,295 | 265 | 160 | (80) | 1,639 |
| Total comprehensive income attributable to shareholders | 3,647 | 1,169 | 851 | (1,413) | 4,254 |
| Total comprehensive income attributable to non-controllinginterests | 3 | 3 | |||
| Total comprehensive income | 3,647 | 1,169 | 854 | (1,413) | 4,256 |
1 Amounts presented for UBS AG standalone and UBS Switzerland AG standalone represent IFRS standalone information. Refer to the UBS AG standalone and UBS Switzerland AG standalone financial statements, available under “Complementary financial information” at ubs.com/investors, for information prepared in accordance with Swiss GAAP. 2 The ”Other subsidiaries“ column includes consolidated information for the UBS Americas Holding LLC, UBS Europe SE and UBS Asset Management AG significant sub-groups, as well as standalone information for other subsidiaries.
Note 18 Supplemental guarantor information required under SEC regulations (continued)
| Supplemental guarantor consolidated balance sheet | |||||
|---|---|---|---|---|---|
| USD million | UBS | ||||
| UBS AG | Switzerland AG | Other | Elimination | UBS AG | |
| As of 31 December 2020 | (standalone)1 | (standalone)1 | subsidiaries2 | entries | (consolidated) |
| Assets | |||||
| Cash and balances at central banks | 34,426 | 91,638 | 32,167 | 158,231 | |
| Loans and advances to banks | 40,171 | 6,385 | 19,465 | (50,678) | 15,344 |
| Receivables from securities financingtransactions | 56,568 | 4,026 | 43,350 | (29,735) | 74,210 |
| Cash collateral receivables on derivative instruments | 32,771 | 1,543 | 10,093 | (11,671) | 32,737 |
| Loans and advances to customers | 99,952 | 228,279 | 73,513 | (20,767) | 380,977 |
| Other financial assets measured at amortized cost | 8,411 | 8,084 | 13,368 | (2,644) | 27,219 |
| Total financial assets measured at amortized cost | 272,299 | 339,956 | 191,957 | (115,495) | 688,717 |
| Financial assets at fair value held for trading | 110,812 | 55 | 16,260 | (1,634) | 125,492 |
| of which: assets pledged as collateral that | |||||
| may be sold or repledged by counterparties | 54,468 | 1 | 6,247 | (13,617) | 47,098 |
| Derivative financial instruments | 154,313 | 6,342 | 44,005 | (45,041) | 159,618 |
| Brokerage receivables | 16,898 | 7,763 | (2) | 24,659 | |
| Financial assets at fair value not held for trading | 46,198 | 13,068 | 36,444 | (15,672) | 80,038 |
| Total financial assets measured at fair value through profit or loss | 328,221 | 19,464 | 104,473 | (62,350) | 389,808 |
| Financial assets measured at fair value | |||||
| through other comprehensive income | 187 | 8,072 | 8,258 | ||
| Investments in subsidiaries and associates | 53,606 | 38 | 439 | (52,526) | 1,557 |
| Property, equipment and software | 6,999 | 1,335 | 3,975 | (350) | 11,958 |
| Goodwill and intangible assets | 217 | 6,234 | 28 | 6,480 | |
| Deferred tax assets | 840 | 1 | 8,334 | (1) | 9,174 |
| Other non-financial assets | 6,641 | 2,063 | 854 | (183) | 9,374 |
| Total assets | 669,010 | 362,857 | 324,337 | (230,878) | 1,125,327 |
| Liabilities | |||||
| Amounts due to banks | 41,414 | 34,096 | 43,066 | (107,527) | 11,050 |
| Payables from securities financingtransactions | 17,247 | 566 | 18,407 | (29,899) | 6,321 |
| Cash collateralpayables on derivative instruments | 35,875 | 561 | 12,495 | (11,618) | 37,313 |
| Customer deposits | 98,441 | 293,371 | 112,372 | 23,745 | 527,929 |
| Fundingfrom UBS GroupAG | 53,979 | 53,979 | |||
| Debt issued measured at amortized cost | 75,658 | 9,687 | 3 | 3 | 85,351 |
| Other financial liabilities measured at amortized cost | 5,285 | 2,567 | 5,745 | (3,175) | 10,421 |
| Total financial liabilities measured at amortized cost | 327,898 | 340,848 | 192,088 | (128,470) | 732,364 |
| Financial liabilities at fair value held for trading | 28,800 | 335 | 5,989 | (1,529) | 33,595 |
| Derivative financial instruments | 156,192 | 5,593 | 44,359 | (45,043) | 161,102 |
| Brokeragepayables designated at fair value | 25,045 | 13,704 | (7) | 38,742 | |
| Debt issued designated at fair value | 58,986 | 935 | (54) | 59,868 | |
| Other financial liabilities designated at fair value | 11,255 | 23,445 | (2,927) | 31,773 | |
| Total financial liabilities measured at fair value through profit or loss | 280,279 | 5,927 | 88,433 | (49,559) | 325,080 |
| Provisions | 1,293 | 301 | 1,197 | 2,791 | |
| Other non-financial liabilities | 2,173 | 987 | 3,907 | (49) | 7,018 |
| Total liabilities | 611,643 | 348,063 | 285,625 | (178,078) | 1,067,254 |
| Equity attributable to shareholders | 57,367 | 14,794 | 38,393 | (52,800) | 57,754 |
| Equityattributable to non-controllinginterests | 319 | 319 | |||
| Total equity | 57,367 | 14,794 | 38,712 | (52,800) | 58,073 |
| Total liabilities and equity | 669,010 | 362,857 | 324,337 | (230,878) | 1,125,327 |
1 Amounts presented for UBS AG standalone and UBS Switzerland AG standalone represent IFRS standalone information. Refer to the UBS AG standalone and UBS Switzerland AG standalone financial statements, available under “Complementary financial information” at ubs.com/investors, for information prepared in accordance with Swiss GAAP. 2 The ”Other subsidiaries“ column includes consolidated information for the UBS Americas Holding LLC, UBS Europe SE and UBS Asset Management AG significant sub-groups, as well as standalone information for other subsidiaries.
Note 18 Supplemental guarantor information required under SEC regulations (continued)
| Supplemental guarantor consolidated statement of cash flows | ||||
|---|---|---|---|---|
| USD million | UBS | Other | UBS AG | |
| For the six months ended 30 June 2020 | UBS AG1 | Switzerland AG1 | subsidiaries1 | (consolidated) |
| Net cash flow from / (used in) operating activities | 7,484 | 16,765 | 16,811 | 41,060 |
| Cash flow from / (used in) investing activities | ||||
| Purchase of subsidiaries, associates and intangible assets | 0 | (1) | 0 | (1) |
| Disposal of subsidiaries, associates and intangible assets | 14 | 0 | 0 | 14 |
| Purchase of property, equipment and software | (277) | (139) | (309) | (725) |
| Disposal of property, equipment and software | 1 | 0 | 3 | 4 |
| Purchase of financial assets measured at fair value through other comprehensive income | (77) | 0 | (4,055) | (4,132) |
| Disposal and redemption of financial assets measured at fair value through other comprehensive income | 27 | 0 | 1,917 | 1,944 |
| Net (purchase) / redemption of debt securities measured at amortized cost | (3,126) | (373) | (1,318) | (4,817) |
| Net cash flow from / (used in) investing activities | (3,437) | (513) | (3,762) | (7,713) |
| Cash flow from / (used in) financing activities | ||||
| Net short-term debt issued / (repaid) | 14,916 | (3) | (1) | 14,912 |
| Distributions paid on UBS shares | (2,550) | 0 | 0 | (2,550) |
| Repayment of lease liabilities | (133) | 0 | (129) | (262) |
| Issuance of debt designated at fair value and long-term debt measured at amortized cost2 | 45,597 | 336 | 68 | 46,001 |
| Repayment of debt designated at fair value and long-term debt measured at amortized cost2 | (45,770) | (306) | (62) | (46,137) |
| Net changes in non-controlling interests | 0 | 0 | (4) | (4) |
| Net activityrelated togroupinternal capital transactions and dividends | 1,513 | (749) | (763) | 0 |
| Net cash flow from / (used in) financing activities | 13,573 | (723) | (890) | 11,960 |
| Total cash flow | ||||
| Cash and cash equivalents at the beginning of the year | 39,598 | 62,551 | 17,655 | 119,804 |
| Net cash flow from / (used in) operating, investing and financing activities | 17,620 | 15,529 | 12,160 | 45,308 |
| Effects of exchange rate differences on cash and cash equivalents | 48 | 1,549 | (30) | 1,567 |
| Cash and cash equivalents at the end of the period3 | 57,266 | 79,629 | 29,784 | 166,679 |
| of which: cash and balances at central banks | 51,139 | 77,212 | 21,078 | 149,430 |
| of which: loans and advances to banks | 4,492 | 1,979 | 7,867 | 14,339 |
| of which: money market paper | 1,635 | 437 | 839 | 2,911 |
1 Cash flows generally represent a third-party view from a UBS AG consolidated perspective, except for Net activity related to group internal capital transactions and dividends. 2 Incudes funding from UBS Group AG to UBS AG. 3 Comprises balances with an original maturity of three months or less. USD 5,393 million of cash and cash equivalents were restricted.
UBS AG standalone financial information
Unaudited
Table of contents
UBS AG interim standalone financial information (unaudited)
-
71 Income statement
-
72 Balance sheet
-
73 Basis of accounting and items impacting comparability
UBS AG interim standalone financial information (unaudited)
Income statement
| Income statement | ||
|---|---|---|
| USD million | CHF million | |
| Year-to-date | Year-to-date | |
| 30.6.21 30.6.20 |
30.6.21 30.6.20 |
|
| Interest and discount income1 | 2,039 2,619 |
1,865 2,518 |
| Interest and dividend income from trading portfolio | 1,332 1,192 |
1,221 1,145 |
| Interest and dividend income from financial investments | 51 169 |
46 162 |
| Interest expense2 | (2,582) (3,478) |
(2,361) (3,344) |
| Gross interest income | 839 501 |
772 481 |
| Credit loss (expense) / release | 60 (121) |
55 (116) |
| Net interest income | 898 381 |
828 365 |
| Fee and commission income from securities and investment business and other fee and commission income | 1,985 1,791 |
1,814 1,720 |
| Credit-related fees and commissions | 64 122 |
59 118 |
| Fee and commission expense | (412) (307) |
(376) (295) |
| Net fee and commission income | 1,637 1,606 |
1,497 1,542 |
| Net trading income | 1,544 2,439 |
1,383 2,343 |
| Net income from disposal of financial investments | 54 74 |
50 71 |
| Dividend income from investments in subsidiaries and other participations | 2,358 1,602 |
2,181 1,541 |
| Income from real estate holdings | 259 256 |
237 246 |
| Sundry ordinary income | 701 607 |
642 583 |
| Sundryordinaryexpenses | (167) (193) |
(150) (185) |
| Other income from ordinary activities | 3,205 2,346 |
2,959 2,256 |
| Total operating income | 7,284 6,771 |
6,667 6,506 |
| Personnel expenses | 1,881 1,862 |
1,713 1,789 |
| General and administrative expenses | 1,788 1,726 |
1,634 1,659 |
| Subtotal operatingexpenses | 3,669 3,588 |
3,347 3,448 |
| Impairment of investments in subsidiaries and other participations | 39 86 |
37 84 |
| Depreciation, amortization and impairment of property, equipment, software, goodwill and intangible assets | 391 350 |
358 336 |
| Changes inprovisions and other allowances and losses | 74 15 |
68 15 |
| Total operating expenses | 4,173 4,040 |
3,811 3,883 |
| Operating profit | 3,111 2,731 |
2,856 2,623 |
| Extraordinary income | 136 98 |
126 94 |
| Extraordinary expenses | 1 0 |
1 0 |
| Tax expense / (benefit) | 202 182 |
183 174 |
| Net profit / (loss) for the period | 3,045 2,647 |
2,797 2,542 |
1 Interest and discount income includes negative interest income on financial assets of approximately USD 0.2 billion (CHF 0.2 billion) and approximately USD 0.2 billion (CHF 0.2 billion) for the periods ended 30 June 2021 and 30 June 2020, respectively. 2 Includes negative interest expense on financial liabilities of approximately USD 0.2 billion (CHF 0.2 billion) and approximately USD 0.1 billion (CHF 0.1 billion) for the periods ended 30 June 2021 and 30 June 2020, respectively.
Balance sheet
| Balance sheet | ||
|---|---|---|
| USD million | CHF million | |
| 30.6.21 31.12.20 |
30.6.21 31.12.20 |
|
| Assets | ||
| Cash and balances at central banks | 42,734 34,148 |
39,529 30,239 |
| Due from banks | 36,114 38,357 |
33,405 33,966 |
| Receivables from securities financingtransactions | 67,067 63,305 |
62,038 56,058 |
| Due from customers | 126,688 124,596 |
117,188 110,334 |
| Funding provided to significant regulated subsidiaries eligible as total loss-absorbingcapacity1 | 26,995 26,354 |
24,972 23,337 |
| Mortgage loans | 5,389 5,406 |
4,985 4,787 |
| Trading portfolio assets | 111,525 115,164 |
103,163 101,981 |
| Derivative financial instruments | 16,160 17,203 |
14,949 15,234 |
| Financial investments | 17,932 23,852 |
16,588 21,122 |
| Accrued income andprepaid expenses | 1,388 1,414 |
1,284 1,253 |
| Investments in subsidiaries and otherparticipations | 50,801 50,444 |
46,992 44,670 |
| Property,equipment and software | 5,693 6,091 |
5,266 5,394 |
| Other assets | 3,488 2,690 |
3,225 2,381 |
| Total assets | 511,973 509,024 |
473,583 450,756 |
| of which: subordinated assets | 19,308 19,999 |
17,860 17,710 |
| of which: subject to mandatory conversion and / or debt waiver | 17,576 18,067 |
16,259 15,998 |
| Liabilities | ||
| Due to banks | 41,083 49,655 |
38,003 43,971 |
| Payables from securities financingtransactions | 23,635 24,407 |
21,863 21,613 |
| Due to customers | 136,036 132,747 |
125,835 117,553 |
| Funding received from UBS Group AG eligible as total loss-absorbing capacity at UBS AG level measured at amortized cost1 |
55,011 53,585 |
50,887 47,451 |
| Trading portfolio liabilities | 28,822 28,806 |
26,660 25,509 |
| Derivative financial instruments | 17,343 21,918 |
16,043 19,409 |
| Financial liabilities designated at fair value | 74,331 58,737 |
68,758 52,014 |
| of which: funding received from UBS Group AG eligible as total loss-absorbing capacity at UBS AG level1 | 2,112 0 |
1,954 0 |
| Bonds issued | 76,266 76,490 |
70,547 67,734 |
| of which: total loss-absorbing capacity eligible at UBS AG level1 | 5,044 7,480 |
4,666 6,624 |
| Accrued expenses and deferred income | 2,692 3,282 |
2,490 2,906 |
| Other liabilities | 4,391 5,591 |
4,061 4,951 |
| Provisions | 1,461 1,411 |
1,351 1,250 |
| Total liabilities | 461,071 456,628 |
426,498 404,359 |
| Equity | ||
| Share capital | 393 393 |
386 386 |
| General reserve | 36,326 36,326 |
35,649 35,649 |
| of which: statutory capital reserve | 36,326 36,326 |
35,649 35,649 |
| of which: capital contribution reserve | 36,326 36,326 |
35,649 35,649 |
| Voluntaryearnings reserve | 11,138 11,138 |
8,253 6,098 |
| Netprofit /(loss)for theperiod | 3,045 4,539 |
2,797 4,265 |
| Total equity | 50,902 52,396 |
47,085 46,397 |
| Total liabilities and equity | 511,973 509,024 |
473,583 450,756 |
| of which: subordinated liabilities | 63,019 62,053 |
58,294 54,950 |
| of which: subject to mandatory conversion and / or debt waiver | 62,448 61,486 |
57,766 54,448 |
1 Represents the Swiss GAAP carrying amount of instruments qualifying as total loss-absorbing capital.
Basis of accounting and items impacting comparability
UBS AG standalone financial statements are prepared in accordance with Swiss GAAP (the FINMA Accounting Ordinance, FINMA Circular 2020/1 “Accounting – banks” and the Banking Ordinance).
The accounting policies are principally the same as the IFRSbased accounting policies for the consolidated financial statements outlined in Note 1 to the consolidated financial statements of UBS AG included in the UBS Group AG and UBS AG Annual Report 2020. Major differences between the Swiss GAAP requirements and International Financial Reporting Standards are described in Note 35 to the consolidated financial statements of UBS AG. Further information on the accounting policies applied for the standalone financial statements of UBS AG is provided in Note 2 to the UBS AG standalone financial statements as of 31 December 2020.
In preparing the interim financial information for UBS AG, the same accounting policies and methods of computation have
been applied as in the annual standalone financial statements as of 31 December 2020.
This interim financial information is unaudited and should be read in conjunction with the audited 2020 standalone financial statements of UBS AG, available under “Holding company and significant regulated subsidiaries and sub-groups” under complementary financial information at ubs.com/investors.
In the fourth quarter of 2020, UBS decided not to proceed with the transfer of a portion of the Global Wealth Management business booked in Switzerland from UBS Switzerland AG to UBS AG. As a result of this decision, the beneficial ownership of that business was re-transferred from UBS AG to UBS Switzerland AG with effective date 31 December 2020. UBS AG’s share of the profits for the first six months of 2020 of USD 221 million (CHF 213 million) is reflected in Fee and commission income from securities and investment business and other fee and commission income .
Alternative performance measures
Alternative performance measures
An alternative performance measure (an APM) is a financial measure of historical or future financial performance, financial position or cash flows other than a financial measure defined or specified in the applicable recognized accounting standards or in other applicable regulations. We report a number of APMs in our external reports (annual, quarterly and other reports). We use APMs to provide a more complete picture of our operating performance and to reflect management’s view of the fundamental drivers of our business results. A definition of each APM, the method used to calculate it and the information content are presented in the table below. Our APMs may qualify as non-GAAP measures as defined by US Securities and Exchange Commission (SEC) regulations.
| APM label | Calculation | Information content |
|---|---|---|
| Invested assets (USD and CHF) – GWM, P&C, AM |
Calculated as the sum of managed fund assets, managed institutional assets, discretionary and advisory wealth management portfolios, fiduciary deposits, time deposits, savings accounts, and wealth management securities or brokerage accounts. |
This measure provides information about the volume of client assets managed by or deposited with UBS for investment purposes. |
| Client assets (USD and CHF) – GWM, P&C |
Calculated as the sum of invested assets and other assets held purely for transactional purposes or custody only. |
This measure provides information about the volume of client assets managed by or deposited with UBS for investment purposes, including other assets held purely for transactional purposes or custody only. |
| Recurring net fee income (USD and CHF) – GWM, P&C |
Calculated as the total of fees for services provided on an ongoing basis, such as portfolio management fees, asset-based investment fund fees and custody fees, which are generated on client assets, and administrative fees for accounts (as well as credit card fees for GWM). |
This measure provides information about the amount of recurring net fee income. |
| Transaction-based income (USD and CHF) – GWM, P&C |
Calculated as the total of the non-recurring portion of net fee and commission income, mainly composed of brokerage and transaction-based investment fund fees, as well as fees for payment and foreign exchange transactions (and credit card fees for P&C), together with other net income from financial instruments measured at fair value through profit or loss. |
This measure provides information about the amount of the non-recurring portion of net fee and commission income. |
| Cost / income ratio (%) | Calculated as operating expenses divided by operating income before credit loss expense or release. |
This measure provides information about the efficiency of the business by comparing operating expenses with gross income. |
| Gross margin on invested assets (bps) – AM |
Calculated as operating income before credit loss expense or release (annualized as applicable) divided by average invested assets. |
This measure provides information about the operating income before credit loss expense or release of the business in relation to invested assets. |
| Net interest margin (bps) – P&C |
Calculated as net interest income (annualized as applicable) divided by average loans. |
This measure provides information about the profitability of the business by calculating the difference between the price charged for lending and the cost of funding, relative to loan value. |
| Net margin on invested assets (bps) – AM |
Calculated as operating profit before tax (annualized as applicable) divided by average invested assets. |
This measure provides information about the operating profit before tax of the business in relation to invested assets. |
| Business volume for Personal Banking (CHF and USD) – P&C |
Calculated as the sum of client assets and loans. | This measure provides information about the volume of client assets and loans. |
| Net new business volume for Personal Banking (CHF and USD) – P&C |
Calculated as the sum of net inflows and outflows of client assets and loans during a specific period (annualized as applicable). |
This measure provides information about the business volume as a result of net new business volume flows during a specific period. |
| Net new business volume growth for Personal Banking (%) – P&C |
Calculated as the sum of net inflows and outflows of client assets and loans during a specific period (annualized as applicable) divided by total business volume / client assets at the beginning of the period. |
This measure provides information about the growth of the business volume as a result of net new business volume flows during a specific period. |
| APM label | Calculation | Information content |
|---|---|---|
| Net profit growth (%) | Calculated as the change in net profit attributable to shareholders from continuing operations between current and comparison periods divided by net profit attributable to shareholders from continuing operations of the comparison period. |
This measure provides information about profit growth in comparison with the prior period. |
| Pre-tax profit growth (%) | Calculated as the change in net profit before tax attributable to shareholders from continuing operations between current and comparison periods divided by net profit before tax attributable to shareholders from continuing operations of the comparison period. |
This measure provides information about pre-tax profit growth in comparison with the prior period. |
| Return on common equity tier 1 capital (%) |
Calculated as annualized net profit attributable to shareholders divided by average common equity tier 1 capital. |
This measure provides information about the profitability of the business in relation to common equity tier 1 capital. |
| Return on equity (%) | Calculated as annualized net profit attributable to shareholders divided by average equity attributable to shareholders. |
This measure provides information about the profitability of the business in relation to equity. |
| Return on attributed equity (%) | Calculated as annualized business division operating profit before tax divided by average attributed equity. |
This measure provides information about the profitability of the business divisions in relation to attributed equity. |
| Return on leverage ratio denominator, gross (%) |
Calculated as annualized operating income before credit loss expense or release divided by average leverage ratio denominator. |
This measure provides information about the revenues of the business in relation to leverage ratio denominator. |
| Return on risk-weighted assets, gross (%) |
Calculated as annualized operating income before credit loss expense or release divided by average risk- weighted assets. |
This measure provides information about the revenues of the business in relation to risk-weighted assets. |
| Return on tangible equity (%) | Calculated as annualized net profit attributable to shareholders divided by average equity attributable to shareholders less average goodwill and intangible assets. |
This measure provides information about the profitability of the business in relation to tangible equity. |
| Total book value per share (USD and CHF1) |
Calculated as equity attributable to shareholders divided by the number of shares outstanding. |
This measure provides information about net assets on a per-share basis. |
| Tangible book value per share (USD and CHF1) |
Calculated as equity attributable to shareholders less goodwill and intangible assets divided by the number of shares outstanding. |
This measure provides information about tangible net assets on a per-share basis. |
| Loan penetration (%) – GWM |
Calculated as loans divided by invested assets. | This measure provides information about the loan volume in relation to invested assets. |
| Net new money (USD) – AM |
Calculated as the sum of the net amount of inflows and outflows of invested assets (as defined in UBS policy) recorded during a specific period. |
This measure provides information about the development of invested assets during a specific period as a result of net new money flows and excludes movements due to market performance, foreign exchange translation, dividends, interest and fees. |
| Impaired loan portfolio as a percentage of total loan portfolio, gross (%) – GWM, P&C |
Calculated as impaired loan portfolio divided by total gross loan portfolio. |
This measure provides information about the proportion of impaired loan portfolio in the total gross loan portfolio. |
| Secured loan portfolio as a percentage of total loan portfolio, gross (%) – P&C |
Calculated as secured loan portfolio divided by total gross loan portfolio. |
This measure provides information about the proportion of secured loan portfolio in the total gross loan portfolio. |
| Active Digital Banking clients in Personal Banking (%) – P&C |
Calculated as the number of clients (within the meaning of numbers of unique business relationships operated by Personal Banking), excluding persons under the age of 15, clients who do not have a private account, clients domiciled outside Switzerland, and clients who have defaulted on loans or credit facilities, who have logged on at least once within the past month divided by the total number of clients (within the aforementioned meaning). |
This measure provides information about the proportion of active Digital Banking clients in the total number of UBS clients (within the aforementioned meaning) who are serviced by Personal Banking. |
| APM label | Calculation | Information content |
|---|---|---|
| Active Digital Banking clients in Corporate & Institutional Clients (%) – P&C |
Calculated as the number of clients (within the meaning of numbers of unique business relationships or legal entities operated by Corporate & Institutional Clients), excluding clients that do not have an account, mono-product clients and clients that have defaulted on loans or credit facilities, which have logged on at least once within the past month divided by the total number of clients (within the aforementioned meaning). |
This measure provides information about the proportion of active Digital Banking clients in the total number of UBS clients (within the aforementioned meaning) which are serviced by Corporate & Institutional Clients. |
| Mobile Banking log-in share in Personal Banking (%) – P&C |
Calculated as the number of Mobile Banking app log-ins divided by total log-ins via E-Banking and the Mobile Banking app in Personal Banking. |
This measure provides information about the proportion of Mobile Banking app log-ins in the total number of log-ins via E-Banking and the Mobile Bankingappin Personal Banking. |
| Fee-generating assets (USD) – GWM |
Calculated as the sum of discretionary and non- discretionary wealth management portfolios (mandate volume) and assets where generated revenues are predominantly of a recurring nature, i.e., mainly investment and mutual funds, including hedge funds and private markets, where we have a distribution agreement. |
This measure provides information about the volume of invested assets that create a revenue stream, whether as a result of the nature of the contractual relationship with clients or through the fee structure of the asset. An increase in the level of fee-generating assets results in an increase in the associated revenue stream. |
| Net new fee-generating assets (USD) – GWM |
Calculated as the sum of the net amount of fee- generating assets inflows and outflows, including dividend and interest inflows into mandates and outflows from mandate fees paid by clients, during a specific period. |
This measure provides information about the development of fee-generating assets during a specific period as a result of net flows and excludes movements due to market performance and foreign exchange translation. |
| Fee-generating asset margin (bps) – GWM |
Calculated as revenues from fee-generating assets (a portion of which is included in recurring fee income and a portion of which is included in transaction- based income, annualized as applicable) divided by average fee-generating assets for the relevant mandate fee billing period. |
This measure provides information about the revenues from fee-generating assets in relation to their average volume during the relevant mandate fee billing period. |
1 Total book value per share and tangible book value per share in Swiss francs are calculated based on a translation of equity under our US dollar presentation currency.
Abbreviations frequently used in our financial reports
| A | CEM | current exposure method | EPS | earnings per share | |
|---|---|---|---|---|---|
| ABS | asset-backed securities | CEO | Chief Executive Officer | ESG | environmental, social and |
| AEI | automatic exchange of | CET1 | common equity tier 1 | governance | |
| information | CFO | Chief Financial Officer | ETD | exchange-traded derivatives | |
| AGM | Annual General Meeting of | CFTC | US Commodity Futures | ETF | exchange-traded fund |
| shareholders | Trading Commission | EU | European Union | ||
| A-IRB | advanced internal | CHF | Swiss franc | EUR | euro |
| ratings-based | CIC | Corporate & Institutional | Euribor | Euro Interbank Offered Rate | |
| AIV | alternative investment | Clients | EVE | economic value of equity | |
| vehicle | CIO | Chief Investment Office | EY | Ernst & Young (Ltd) | |
| ALCO | Asset and Liability | CLS | Continuous Linked | ||
| Committee | Settlement | F | |||
| AMA | advanced measurement | CMBS | commercial mortgage- | FA | financial advisor |
| approach | backed security | FCA | UK Financial Conduct | ||
| AML | anti-money laundering | C&ORC | Compliance & Operational | Authority | |
| AoA | Articles of Association | Risk Control | FCT | foreign currency translation | |
| APAC | Asia Pacific | CRD IV | EU Capital Requirements | FINMA | Swiss Financial Market |
| APM | alternative performance | Directive of 2013 | Supervisory Authority | ||
| measure | CRM | credit risk mitigation (credit | FMIA | Swiss Financial Market | |
| ARR | alternative reference rate | risk) or comprehensive risk | Infrastructure Act | ||
| ARS | auction rate securities | measure (market risk) | FSB | Financial Stability Board | |
| ASF | available stable funding | CRR | Capital Requirements | FTA | Swiss Federal Tax |
| AT1 | additional tier 1 | Regulation | Administration | ||
| AuM | assets under management | CST | combined stress test | FVA | funding valuation |
| CVA | credit valuation adjustment | adjustment | |||
| B | FVOCI | fair value through other | |||
| BCBS | Basel Committee on | D | comprehensive income | ||
| Banking Supervision | DBO | defined benefit obligation | FVTPL | fair value through profit or | |
| BEAT | base erosion and anti-abuse | DCCP | Deferred Contingent | loss | |
| tax | Capital Plan | FX | foreign exchange | ||
| BIS | Bank for International | DJSI | Dow Jones Sustainability | ||
| Settlements | Indices | G | |||
| BoD | Board of Directors | DM | discount margin | GAAP | generally accepted |
| BVG | Swiss occupational | DOJ | US Department of Justice | accounting principles | |
| pension plan | D-SIB | domestic systemically | GBP | pound sterling | |
| important bank | GDP | gross domestic product | |||
| C | DTA | deferred tax asset | GEB | Group Executive Board | |
| CAO | Capital Adequacy | DVA | debit valuation adjustment | GIA | Group Internal Audit |
| Ordinance | GIIPS | Greece, Italy, Ireland, | |||
| CCAR | Comprehensive Capital | E | Portugal and Spain | ||
| Analysis and Review | EAD | exposure at default | GMD | Group Managing Director | |
| CCF | credit conversion factor | EB | Executive Board | GRI | Global Reporting Initiative |
| CCP | central counterparty | EBA | European Banking Authority | GSE | government sponsored |
| CCR | counterparty credit risk | EC | European Commission | entities | |
| CCRC | Corporate Culture and | ECB | European Central Bank | G-SIB | global systemically |
| Responsibility Committee | ECL | expected credit loss | important bank | ||
| CCyB | countercyclical buffer | EIR | effective interest rate | ||
| CDO | collateralized debt | EL | expected loss | H | |
| obligation | EMEA | Europe, Middle East and | HQLA | high-quality liquid assets | |
| CDS | credit default swap | Africa | HR | human resources | |
| CEA | Commodity Exchange Act | EOP | Equity Ownership Plan | ||
| EPE | expected positive exposure |
Abbreviations frequently used in our financial reports (continued)
| I | NII | net interest income | SAR | stock appreciation right or | |
|---|---|---|---|---|---|
| IAA | internal assessment | NRV | negative replacement value | Special Administrative | |
| approach | NSFR | net stable funding ratio | Region | ||
| IAS | International Accounting | NYSE | New York Stock Exchange | SBC | Swiss Bank Corporation |
| Standards | SDG | Sustainable Development | |||
| IASB | International Accounting | O | Goal | ||
| Standards Board | OCA | own credit adjustment | SE | structured entity | |
| IBOR | Interbank Offered Rate | OCI | other comprehensive | SEC | US Securities and Exchange |
| IFRIC | International Financial | income | Commission | ||
| Reporting Interpretations | OTC | over-the-counter | SEEOP | Senior Executive Equity | |
| Committee | Ownership Plan | ||||
| IFRS | International Financial | P | SFT | securities financing | |
| Reporting Standards | PD | probability of default | transaction | ||
| IHC | intermediate holding | PFE | potential future exposure | SI | sustainable investing |
| company | PIT | point in time | SICR | significant increase in credit | |
| IMA | internal models approach | P&L | profit or loss | risk | |
| IMM | internal model method | POCI | purchased or originated | SIX | SIX Swiss Exchange |
| IRB | internal ratings-based | credit-impaired | SME | small and medium-sized | |
| IRC | incremental risk charge | PRA | UK Prudential Regulation | entity | |
| IRRBB | interest rate risk in the | Authority | SMF | Senior Management | |
| banking book | PRV | positive replacement value | Function | ||
| ISDA | International Swaps and | SNB | Swiss National Bank | ||
| Derivatives Association | Q | SPPI | solely payments of principal | ||
| QCCP | qualifying central | and interest | |||
| K | counterparty | SRB | systemically relevant bank | ||
| KRT | Key Risk Taker | QRRE | qualifying revolving retail | SRM | specific risk measure |
| exposures | SVaR | stressed value-at-risk | |||
| L | |||||
| LAS | liquidity-adjusted stress | R | T | ||
| LCR | liquidity coverage ratio | RBA | role-based allowances | TBTF | too big to fail |
| LGD | loss given default | RBC | risk-based capital | TCJA | US Tax Cuts and Jobs Act |
| LIBOR | London Interbank Offered | RbM | risk-based monitoring | TLAC | total loss-absorbing capacity |
| Rate | RMBS | residential mortgage- | TTC | through-the-cycle | |
| LLC | limited liability company | backed securities | |||
| LRD | leverage ratio denominator | RniV | risks not in VaR | U | |
| LTIP | Long-Term Incentive Plan | RoAE | return on attributed equity | UBS RESI | UBS Real Estate Securities |
| LTV | loan-to-value | RoCET1 | return on CET1 capital | Inc. | |
| RoTE | return on tangible equity | UoM | units of measure | ||
| M | RoU | right-of-use | USD | US dollar | |
| M&A | mergers and acquisitions | RV | replacement value | ||
| MiFID II | Markets in Financial | RW | risk weight | V | |
| Instruments Directive II | RWA | risk-weighted assets | VaR | value-at-risk | |
| MRT | Material Risk Taker | VAT | value added tax | ||
| S | |||||
| N | SA | standardized approach | W | ||
| NAV | net asset value | SA-CCR | standardized approach for | WEKO | Swiss Competition |
| NCL | Non-core and Legacy | counterparty credit risk | Commission | ||
| Portfolio |
This is a general list of the abbreviations frequently used in our financial reporting. Not all of the listed abbreviations may appear in this particular report.
Information sources
Reporting publications
Annual publications
Annual Report (SAP No. 80531): Published in English, this singlevolume report provides descriptions of: our Group strategy and performance; the strategy and performance of the business divisions and Group Functions; risk, treasury and capital management; corporate governance, corporate responsibility and our compensation framework, including information about compensation for the Board of Directors and the Group Executive Board members; and financial information, including the financial statements.
Geschäftsbericht (SAP No. 80531): This publication provides a German translation of selected sections of our Annual Report. Annual Review (SAP No. 80530): This booklet contains key information about our strategy and performance, with a focus on corporate responsibility at UBS. It is published in English, German, French and Italian.
Compensation Report (SAP No. 82307): This report discusses our compensation framework and provides information about compensation for the Board of Directors and the Group Executive Board members. It is available in English and German.
Quarterly publications
The quarterly financial report provides an update on our strategy and performance for the respective quarter. It is available in English.
How to order publications
The annual and quarterly publications are available in .pdf format at ubs.com/investors , under “Financial information,” and printed copies can be requested from UBS free of charge. For annual publications, refer to the “Investor services” section at ubs.com/investors. Alternatively, they can be ordered by quoting the SAP number and the language preference, where applicable, from UBS AG, F4UK–AUL, P.O. Box, CH-8098 Zurich, Switzerland.
Other information
Website
The “Investor Relations” website at ubs.com/investors provides the following information about UBS: news releases; financial information, including results-related filings with the US Securities and Exchange Commission; information for shareholders, including UBS share price charts, as well as data and dividend information, and for bondholders; the UBS corporate calendar; and presentations by management for investors and financial analysts. Information is available online in English, with some information also available in German.
Results presentations
Our quarterly results presentations are webcast live. Recordings of most presentations can be downloaded from ubs.com/presentations .
Messaging service
Email alerts to news about UBS can be subscribed for under “UBS News Alert” at ubs.com/global/en/investor-relations/contact/ investor-services.html . Messages are sent in English, German, French or Italian, with an option to select theme preferences for such alerts.
Form 20-F and other submissions to the US Securities and
Exchange Commission
We file periodic reports and submit other information about UBS to the US Securities and Exchange Commission (the SEC). Principal among these filings is the annual report on Form 20-F, filed pursuant to the US Securities Exchange Act of 1934. The filing of Form 20-F is structured as a wrap-around document. Most sections of the filing can be satisfied by referring to the combined UBS Group AG and UBS AG annual report. However, there is a small amount of additional information in Form 20-F that is not presented elsewhere and is particularly targeted at readers in the US. Readers are encouraged to refer to this additional disclosure. Any document that we file with the SEC is available on the SEC’s website: sec.gov . Refer to ubs.com/investors for more information.
Cautionary Statement Regarding Forward-Looking Statements | This report contains statements that constitute “forward-looking statements,” including but not limited to management’s outlook for UBS’s financial performance, statements relating to the anticipated effect of transactions and strategic initiatives on UBS’s business and future development and goals or intentions to achieve climate, sustainability and other social objectives. While these forward-looking statements represent UBS’s judgments, expectations and objectives concerning the matters described, a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from UBS’s expectations. The outbreak of COVID-19 and the measures taken in response to the pandemic have had and may continue to have a significant adverse effect on global economic activity, and an adverse effect on the credit profile of some of our clients and other market participants, which has resulted in and may continue to increase credit loss expense and credit impairments. In addition, we face heightened operational risks due to remote working arrangements, including risks to supervisory and surveillance controls, as well as increased fraud and data security risks. The unprecedented scale of the measures taken to respond to the pandemic as well as the uncertainty surrounding vaccine supply, distribution, and efficacy against mutated virus strains create significantly greater uncertainty about forward-looking statements. Factors that may affect our performance and ability to achieve our plans, outlook and other objectives also include, but are not limited to: (i) the degree to which UBS is successful in the ongoing execution of its strategic plans, including its cost reduction and efficiency initiatives and its ability to manage its levels of riskweighted assets (RWA) and leverage ratio denominator (LRD), liquidity coverage ratio and other financial resources, including changes in RWA assets and liabilities arising from higher market volatility; (ii) the degree to which UBS is successful in implementing changes to its businesses to meet changing market, regulatory and other conditions; (iii) the continuing low or negative interest rate environment in Switzerland and other jurisdictions; (iv) developments (including as a result of the COVID-19 pandemic) in the macroeconomic climate and in the markets in which UBS operates or to which it is exposed, including movements in securities prices or liquidity, credit spreads, and currency exchange rates, and the effects of economic conditions, market developments, and geopolitical tensions, and changes to national trade policies on the financial position or creditworthiness of UBS’s clients and counterparties as well as on client sentiment and levels of activity; (v) changes in the availability of capital and funding, including any changes in UBS’s credit spreads and ratings, as well as availability and cost of funding to meet requirements for debt eligible for total loss-absorbing capacity (TLAC); (vi) changes in or the implementation of financial legislation and regulation in Switzerland, the US, the UK, the European Union and other financial centers that have imposed, or resulted in, or may do so in the future, more stringent or entity-specific capital, TLAC, leverage ratio, net stable funding ratio, liquidity and funding requirements, heightened operational resilience requirements, incremental tax requirements, additional levies, limitations on permitted activities, constraints on remuneration, constraints on transfers of capital and liquidity and sharing of operational costs across the Group or other measures, and the effect these will or would have on UBS’s business activities; (vii) UBS’s ability to successfully implement resolvability and related regulatory requirements and the potential need to make further changes to the legal structure or booking model of UBS Group in response to legal and regulatory requirements, proposals in Switzerland and other jurisdictions for mandatory structural reform of banks or systemically important institutions or to other external developments; (viii) UBS’s ability to maintain and improve its systems and controls for the detection and prevention of money laundering and compliance with sanctions to meet evolving regulatory requirements and expectations, in particular in the US; (ix) the uncertainty arising from the UK’s exit from the EU; (x) changes in UBS’s competitive position, including whether differences in regulatory capital and other requirements among the major financial centers will adversely affect UBS’s ability to compete in certain lines of business; (xi) changes in the standards of conduct applicable to our businesses that may result from new regulations or new enforcement of existing standards, including measures to impose new and enhanced duties when interacting with customers and in the execution and handling of customer transactions; (xii) the liability to which UBS may be exposed, or possible constraints or sanctions that regulatory authorities might impose on UBS, due to litigation, contractual claims and regulatory investigations, including the potential for disqualification from certain businesses, potentially large fines or monetary penalties, or the loss of licenses or privileges as a result of regulatory or other governmental sanctions, as well as the effect that litigation, regulatory and similar matters have on the operational risk component of our RWA as well as the amount of capital available for return to shareholders; (xiii) the effects on UBS’s cross-border banking business of tax or regulatory developments and of possible changes in UBS’s policies and practices relating to this business; (xiv) UBS’s ability to retain and attract the employees necessary to generate revenues and to manage, support and control its businesses, which may be affected by competitive factors; (xv) changes in accounting or tax standards or policies, and determinations or interpretations affecting the recognition of gain or loss, the valuation of goodwill, the recognition of deferred tax assets and other matters; (xvi) UBS’s ability to implement new technologies and business methods, including digital services and technologies, and ability to successfully compete with both existing and new financial service providers, some of which may not be regulated to the same extent; (xvii) limitations on the effectiveness of UBS’s internal processes for risk management, risk control, measurement and modeling, and of financial models generally; (xviii) the occurrence of operational failures, such as fraud, misconduct, unauthorized trading, financial crime, cyberattacks and systems failures, the risk of which is increased while COVID-19 control measures require large portions of the staff of both UBS and its service providers to work remotely; (xix) restrictions on the ability of UBS Group AG to make payments or distributions, including due to restrictions on the ability of its subsidiaries to make loans or distributions, directly or indirectly, or, in the case of financial difficulties, due to the exercise by FINMA or the regulators of UBS’s operations in other countries of their broad statutory powers in relation to protective measures, restructuring and liquidation proceedings; (xx) the degree to which changes in regulation, capital or legal structure, financial results or other factors may affect UBS’s ability to maintain its stated capital return objective; (xxi) uncertainty over the scope of actions that may be required by UBS, governments and others to achieve goals relating to climate, environmental and social matters as well as the evolving nature of underlying science and industry and governmental standards; and (xxii) the effect that these or other factors or unanticipated events may have on our reputation and the additional consequences that this may have on our business and performance. The sequence in which the factors above are presented is not indicative of their likelihood of occurrence or the potential magnitude of their consequences. Our business and financial performance could be affected by other factors identified in our past and future filings and reports, including those filed with the SEC. More detailed information about those factors is set forth in documents furnished by UBS and filings made by UBS with the SEC, including UBS’s Annual Report on Form 20-F for the year ended 31 December 2020 and UBS’s First Quarter 2021 Report on Form 6K. UBS is not under any obligation to (and expressly disclaims any obligation to) update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.
Rounding | Numbers presented throughout this report may not add up precisely to the totals provided in the tables and text. Percentages and percent changes disclosed in text and tables are calculated on the basis of unrounded figures. Absolute changes between reporting periods disclosed in the text, which can be derived from numbers presented in related tables, are calculated on a rounded basis.
Tables | Within tables, blank fields generally indicate non-applicability or that presentation of any content would not be meaningful, or that information is not available as of the relevant date or for the relevant period. Zero values generally indicate that the respective figure is zero on an actual or rounded basis. Values that are zero on a rounded basis can be either negative or positive on an actual basis.
UBS AG P.O. Box, CH-8098 Zurich P.O. Box, CH-4002 Basel
ubs.com
==> picture [84 x 31] intentionally omitted <==